var docs;if (!docs) docs =[]; docs["29"]={"2900":"<p><b>Title</b> Selective Serotonin Reuptake Inhibitors / BusPIRone</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> BusPIRone may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of BusPIRone. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The combination of a selective serotonin reuptake inhibitor and buspirone should be undertaken with great caution. When combined treatment is clinically indicated, monitor closely for signs of serotonin toxicity/serotonin syndrome (e.g., confusion, delirium, restlessness, tremors, blushing, diaphoresis, hyperpyrexia). Monitor for other toxic effects of buspirone if fluoxetine or fluvoxamine are initiated/dose increased.</p>\n<div>\n <p><b>Selective Serotonin Reuptake Inhibitors Interacting Members</b> Citalopram*, Dapoxetine, Escitalopram, FLUoxetine, FluvoxaMINE*, PARoxetine, Sertraline, Vilazodone, Vortioxetine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A patient developed serotonin syndrome during concomitant therapy with buspirone and citalopram. He was taking doses in excess of those prescribed by his physician (buspirone 10 mg/day and citalopram 40 mg/day).<sup>1</sup> The adverse effects resolved within 5 days of discontinuing both medications. The mechanism of this potential interaction is unknown. It's possible that addition of the individual agent's serotonergic effects caused the problems. Likewise, either agent alone holds the same potential. The dose-dependent nature of the development of these problems is unknown. In addition to serotonergic effects, a small study in normal subjects showed a 2.4-fold increase in buspirone AUC (single 10 mg dose) when administered following 5 days of fluvoxamine therapy (100 mg/day).<sup>2</sup> This pharmacokinetic effect is likely due to the ability of fluvoxamine to inhibit CYP3A4 isoenzymes, thus reducing the metabolism of buspirone. No clinical effects were noted in the study. Fluoxetine also inhibits CYP3A4 isoenzymes. The remaining selective serotonin reuptake inhibitors would probably have a lesser effect on buspirone due to their reduced ability to affect CYP3A4 isoenzymes. Additional reports implicate fluoxetine and buspirone in reducing the therapeutic efficacy of the other agent<sup>3,4</sup> or contributing to the development of a grand mal seizure.<sup>5</sup> The mechanisms of these latter observations are unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Spigset O and Adielsson G, “Combined Serotonin Syndrome and Hyponatremia Caused by a Citalopram-Buspirone Interaction,” <i>Int Clin Psychopharmacol</i>, 1997, 12(1):61-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9179637\">[PubMed 9179637]</a></p>\n<p>2. Lamberg TS, Kivisto KT, Laitila J, et al, “The Effect of Fluvoxamine on the Pharmacokinetics and Pharmacodynamics of Buspirone,” <i>Eur J Clin Pharmacol</i>, 1998, 54(9-10):761-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9923581\">[PubMed 9923581]</a></p>\n<p>3. Bodkin JA and Teicher MH, “Fluoxetine May Antagonize the Anxiolytic Action of Buspirone,” <i>J Clin Psychopharmacol</i>, 1989, 9(2):150. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2786010\">[PubMed 2786010]</a></p>\n<p>4. Tanquary J and Masand P, “Paradoxical Reaction to Buspirone Augmentation of Fluoxetine,” <i>J Clin Psychopharmacol</i>, 1990, 10(5):377. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2258456\">[PubMed 2258456]</a></p>\n<p>5. Grady TA, Pigott TA, L'Heureux F, et al, “Seizure Associated With Fluoxetine and Adjuvant Buspirone Therapy,” <i>J Clin Psychopharmacol</i>, 1992, 12(1):70-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1552045\">[PubMed 1552045]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2902":"<p><b>Title</b> BusPIRone / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of BusPIRone. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased effect of buspirone if combined with grapefruit juice. Patients should avoid consuming large quantities of grapefruit juice.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 10 healthy volunteers, the mean AUC, maximum serum concentration (Cmax), and elimination half-life (T1/2) of buspirone (10 mg single dose given on day 3) increased 4.3-fold (range: 2 to 15.6-fold), 9.2-fold (range: 3 to 20.4-fold), and 1.5-fold, respectively, when coadministered with double-strength grapefruit juice (200 mL 3 times daily).<sup>1</sup> The subjective effect of the buspirone, measured by the visual analog scale (VAS) test, was the only pharmacodynamic alteration noted. The dose of grapefruit juice administered appears to be significantly greater than that which would normally be consumed. Another pharmacokinetic study of 12 healthy subjects administered grapefruit juice (300 mL single dose) and buspirone (10 mg single dose) showed a 2-fold increase in buspirone AUC and negligible difference in peak plasma concentrations.<sup>2</sup><br><br>Buspirone prescribing information states that coadministration of buspirone and grapefruit juice may increase buspirone exposure; patients receiving buspirone should be advised to avoid drinking large amounts of grapefruit juice.<sup>3</sup> <br><br>The mechanism of this interaction is likely due to the ability of certain components of grapefruit juice to inhibit CYP3A4 isoenzymes (primarily in the small intestine), and thus inhibit the metabolism of the buspirone.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lilja JJ, Kivisto KT, Backman JT, Lamberg TS, Neuvonen PJ. Grapefruit juice substantially increases plasma concentrations of buspirone. <i>Clin Pharmacol Ther</i>. 1998:64(6):655-660. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9871430\">[PubMed 9871430]</a></p>\n<p>2. Hanley MJ, Masse G, Harmatz JS, et al. Effect of blueberry juice on clearance of buspirone and flurbiprofen in human volunteers. <i>Br J Clin Pharmacol</i>. 2013;75(4):1041-1052. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22943633\">[PubMed 22943633]</a></p>\n<p>3. Buspar (buspirone) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; November 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2903":"<p><b>Title</b> CarBAMazepine / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of CarBAMazepine. The serum carbamazepine concentration might return to normal within one week of starting cimetidine. <b>Severity</b> Moderate <b>Onset</b> Rapid <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased carbamazepine concentrations and toxicities if cimetidine is initiated or the dose is increased. Initiation or dose increases of cimetidine may transiently increase serum concentrations of carbamazepine during the first few days of treatment.</p> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in 8 healthy volunteers, steady-state serum concentrations of carbamazepine (300 mg twice daily for 42 days) transiently increased by 17% after 2 days of concomitant use with cimetidine (400 mg 3 times daily on days 29 to 35), and returned to pre-cimetidine levels by the seventh day of cimetidine treatment.<sup>1</sup> In 2 pharmacokinetic studies of healthy volunteers, cimetidine (1,000 mg to 1,200 mg per day) increased the carbamazepine (400 mg to 600 mg single dose) AUC 10% to 26%.<sup>2,3</sup> In another analysis, cimetidine (400 mg twice daily) increased carbamazepine (200 mg daily) serum concentrations 33% after 2 weeks of concomitant use.<sup>4</sup> In one case report, an elderly woman receiving carbamazepine (600 mg daily) experienced neurological symptoms and toxic serum concentrations of carbamazepine after initiation of cimetidine (800 mg to 1,000 mg daily).<sup>5</sup><br> <br>In contrast, 2 pharmacokinetic studies of epileptic patients on stable carbamazepine therapy found no change in carbamazepine serum concentrations after the addition of cimetidine (1,000 mg to 1,200 mg per day in 4 divided doses for 7 days).<sup>6,7</sup> <br><br>Carbamazepine prescribing information states that concomitant use of carbamazepine and cimetidine may increase carbamazepine plasma concentrations.<sup>8</sup> Patients should be monitored for increased carbamazepine concentrations and toxicities and carbamazepine dose reductions may be required.<sup>8</sup><br><br>The mechanism of this interaction is likely due to cimetidine-mediated inhibition of CYP3A4, an enzyme involved in carbamazepine metabolism. Carbamazepine auto-induction of CYP3A4 may account for the diminished magnitude of the interaction seen when these drugs are combined for extended periods of time.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dalton MJ, Powell JR, Messenheimer JA Jr, Clark J. Cimetidine and carbamazepine: a complex drug interaction. <i>Epilepsia</i>. 1986;27(5):553-558. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3757941\">[PubMed 3757941]</a></p>\n<p>2. Webster LK, Mihaly GW, Jones DB, Smallwood RA, Phillips JA, Vajda FJ. Effect of cimetidine and ranitidine on carbamazepine and sodium valproate pharmacokinetics. <i>Eur J Clin Pharmacol</i>. 1984;27(3):341-343. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6096154\">[PubMed 6096154]</a></p>\n<p>3. Dalton MJ, Powell JR, Messenheimer JA Jr. The influence of cimetidine on single-dose carbamazepine pharmacokinetics. <i>Epilepsia</i>. 1985;26(2):127-130. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3987645\">[PubMed 3987645]</a></p>\n<p>4. Macphee GJ, Thompson GG, Scobie G, et al. Effects of cimetidine on carbamazepine auto- and hetero-induction in man. <i>Br J Clin Pharmacol</i>. 1984;18(3):411-419. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6487479\">[PubMed 6487479]</a></p>\n<p>5. Telerman-Toppet N, Duret ME, Coers C. Cimetidine interaction with carbamazepine. <i>Ann Intern Med</i>. 1981;94(4 pt 1):544. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7212521\">[PubMed 7212521]</a></p>\n<p>6. Sonne J, Luhdorf K, Larsen NE, Andreasen PB. Lack of interaction between cimetidine and carbamazepine. <i>Acta Neurol Scand</i>. 1983;68(4):253-256. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6659865\">[PubMed 6659865]</a></p>\n<p>7. Levine M, Jones MW, Sheppard I. Differential effect of cimetidine on serum concentrations of carbamazepine and phenytoin. <i>Neurology</i>. 1985;35(4):562-565. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3982643\">[PubMed 3982643]</a></p>\n<p>8. Tegretol (carbamazepine) [prescribing information]. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation; August 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2905":"<p><b>Title</b> CloZAPine / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CarBAMazepine may enhance the myelosuppressive effect of CloZAPine. More specifically, the risk of bone marrow suppression with this combination may be increased due to the independent myelosuppressive effects of the drugs. CarBAMazepine may decrease the serum concentration of CloZAPine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of clozapine with strong CYP3A4 inducers, such as carbamazepine, is not recommended. If such concomitant use is necessary, increased clozapine doses may be necessary. When stopping carbamazepine in patients who had been receiving the combination clozapine dose reductions may be required. Recognize also the possible increased risk of bone marrow suppression with use of this combination. Consider the use of an alternative antiseizure medication (eg, valproic acid) when possible.</p> \n<p><b>Discussion</b> Data from both a small pharmacokinetic study and an analysis of therapeutic drug monitoring data reveal reduced serum clozapine concentrations in patients receiving concomitant carbamazepine therapy. The reductions varied according to the dose of carbamazepine, but averaged approximately 50%.<sup>1,2</sup> The mechanism of this interaction is likely related to the ability of carbamazepine to induce enzymes responsible for clozapine metabolism, including CYP1A2, CYP2C, and CYP3A4.<br><br>Clozapine labeling also cautions that concurrent use with other drugs that are associated with neutropenia may require closer monitoring for neutropenia.<sup>3</sup> Both carbamazepine and clozapine have been independently associated with neutropenia in several reviews and studies.<sup>4,5,6,7</sup> Clozapine induced neutropenia is not necessarily dose dependent,<sup>3</sup> so even if clozapine concentrations are reduced by carbamazepine, the risk of additive neutropenia may still remain. Caution and closer monitoring appears warranted with any such combination. One published case report describes a patient who experienced fatal clozapine-associated agranulocytosis that was described as being potentially influenced by the presence of concurrent carbamazepine, clonazepam, and/or lithium.<sup>8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tiihonen J, Vartiainen H, Hakola P. Carbamazepine-induced changes in plasma levels of neuroleptics. <i>Pharmacopsychiatry</i>. 1995;28(1):26-28. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7746842\">[PubMed 7746842]</a></p>\n<p>2. Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. <i>Ther Drug Monit</i>. 1994;16(4):368-374. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7974626\">[PubMed 7974626]</a></p>\n<p>3. Clozaril (clozapine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2015.</p>\n<p>4. Huber M, Andersohn F, Bronder E, et al. Drug-induced agranulocytosis in the Berlin case-control surveillance study. <i>Eur J Clin Pharmacol</i>. 2014;70(3):339-345. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24297345\">[PubMed 24297345]</a></p>\n<p>5. Demler TL, Trigoboff E. Are clozapine blood dyscrasias associated with concomitant medications? <i>Innov Clin Neurosci</i>. 2011;8(4):35-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21637633\">[PubMed 21637633]</a></p>\n<p>6. Andres E, Maloisel F. Idiosyncratic drug-induced agranulocytosis or acute neutropenia. <i>Curr Opin Hematol</i>. 2008;15(1):15-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18043241\">[PubMed 18043241]</a></p>\n<p>7. Stubner S, Grohmann R, Engel R, et al. Blood dyscrasias induced by psychotropic drugs. <i>Pharmacopsychiatry</i>. 2004;37 Suppl 1:S70-S78. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15052517\">[PubMed 15052517]</a></p>\n<p>8. Gerson SL, Lieberman JA, Friedenberg WR, Lee D, Marx JJ Jr, Meltzer H. Polypharmacy in fatal clozapine-associated agranulocytosis. <i>Lancet</i>. 1991;338(8761):262-263. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1676820\">[PubMed 1676820]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2907":"<p><b>Title</b> CarBAMazepine / Danazol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Danazol may decrease the metabolism of CarBAMazepine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased carbamazepine concentrations and toxicities if danazol is initiated or the dose is increased. A reduction in the dosage of carbamazepine may be needed.</p> \n<p><b>Discussion</b> In a study of 6 female patients administered carbamazepine (1,000 to 2,000 mg per day), therapeutic serum levels increased approximately 2-fold over a period of several days to a few weeks with danazol (400 mg to 600 mg) coadministration.<sup>1</sup> Five patients received acetazolamide (500mg) concurrently, which did not influence carbamazepine serum concentrations. All patients developed adverse effects consistent with elevated carbamazepine levels (eg, behavior changes, impaired motor coordination, lethargy, dizziness) within 7 to 30 days, except 1 patient who experienced reduced seizure frequency.<sup>1</sup> Serum carbamazepine concentrations fell by 63% to 75% and adverse effects resolved after discontinuation of danazol in 4 patients. In the 2 patients that continued danazol therapy, carbamazepine doses were lowered by 12% to 40% (100 mg to 200 mg per day).<sup>1</sup> <br><br>In a pharmacokinetic study of a female patient, danazol co-administration increased the half-life of carbamazepine by 121%, decreased carbamazepine plasma clearance by 60%, and increased the carbamazepine AUC 150%.<sup>2</sup> One case report describes a female patient who experienced toxicities (double vision, nausea, nystagmus, ataxia) and a 2-fold increase in carbamazepine concentrations with danazol initiation that resolved within 3 days of danazol discontinuation.<sup>3</sup> <br><br>Prescribing information for both products states that because danazol may increase carbamazepine levels, patients should be monitored for increased carbamazepine levels and toxicities if these agents are combined.<sup>4,5</sup> <br><br>The mechanism of this interaction is likely due to danazol-mediated inhibition of CYP3A4, an enzyme responsible for carbamazepine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zielinski JJ, Lichten EM, Haidukewych D. Clinically significant danazol-carbamazepine interaction. <i>Ther Drug Monit</i>. 1987;9(1):24-27. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3107168\">[PubMed 3107168]</a></p>\n<p>2. Kramer G, Theisohn M, von Unruh GE, Eichelbaum M. Carbamazepine-danazol drug interaction: its mechanism examined by a stable isotope technique. <i>Ther Drug Monit</i>. 1986;8(4):387-392. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3824425\">[PubMed 3824425]</a></p>\n<p>3. Hayden M, Buchanan N. Danazol-carbamazepine interaction. <i>Med J Aust</i>. 1991;155(11-12):851. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1745195\">[PubMed 1745195]</a></p>\n<p>4. Tegretol (carbamazepine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; September 2015.</p>\n<p>5. Danazol [prescribing information]. North Wales, PA: Teva Pharmaceuticals Inc; October 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2908":"<p><b>Title</b> Doxycycline / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Doxycycline. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of doxycycline if used concurrently with carbamazepine. Consideration might be given to increasing the dose of doxycycline at the initiation of carbamazepine, or use of another tetracycline derivative may be considered to avoid this interaction.</p> \n<p><b>Discussion</b> A comparison of doxycycline half-life in 16 patients on long-term carbamazepine and/or phenytoin therapy revealed a 44-52% shorter half-life compared to controls (mean half-life = 15.1 hours; n=9).<sup>1</sup> For the patients taking carbamazepine specifically, the mean doxycycline half-life was 8.4 hours (n=5), and for those taking both carbamazepine and phenytoin, the mean doxycycline half-life was 7.4 hours (n=4). Duration of carbamazepine and/or phenytoin therapy prior to this study was between 4 months and 10 years.<br><br>The suspected mechanism of this potential interaction is induction of doxycycline metabolism or excretion by carbamazepine. The specific enzyme(s) and/or transporter(s) involved is uncertain, as most inducers like carbamazepine are capable of inducing several metabolic enzymes and transport proteins.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Penttila O, Neuvonen PJ, Aho K, et al, “Interaction Between Doxycycline and Some Antiepileptic Drugs,” <i>Br Med J</i>, 1974, 2(917):470-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4600204\">[PubMed 4600204]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2909":"<p><b>Title</b> Haloperidol / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Haloperidol. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for changes in the therapeutic effects of haloperidol if carbamazepine is initiated/dose is increased or if carbamazepine is discontinued/dose decreased.</p> \n<p><b>Discussion</b> In several pharmacokinetic studies in schizophrenic or psychotic patients on long-term treatment with haloperidol, the addition of carbamazepine decreased plasma haloperidol levels 50% to 60% from baseline.<sup>1,2,3,4</sup> In a trial of schizophrenic patients on long-term haloperidol, haloperidol levels decreased 25%, 61%, and 85% with the addition of carbamazepine at doses of 100 mg/day, 300 mg/day, and 600 mg/day, respectively.<sup>5</sup> Several patients had undetectable haloperidol levels at the 600 mg/day dose and a 50% reduction in the haloperidol level was predicted to occur with carbamazepine doses of 240 mg/day.<sup>5</sup><br> <br>Several retrospective studies of haloperidol-treated patients found that the of use of carbamazepine was associated with haloperidol plasma concentrations that were 37% to 50% lower,<sup>6,7,8</sup> and a haloperidol clearance that was approximately 32% higher,<sup>9</sup> compared with patients not receiving carbamazepine. One study also reported that carbamazepine concentrations were 1.4-fold higher in patients treated with carbamazepine and haloperidol compared with patients who took carbamazepine alone.<sup>10</sup><br><br>The combination of haloperidol and carbamazepine has resulted in a mix of clinical outcomes. Some trials report patients having no changes in symptoms or clinical measurements,<sup>1,2</sup> some report patients becoming more symptomatic as haloperidol levels became undetectable,<sup>3,4,11</sup> and some describe patients who experienced symptomatic improvement as a result of combination therapy.<sup>4,12,13,14</sup><br> <br>One case report describes a patient (with a prior history of successful treatment with haloperidol) treated with carbamazepine who experienced a lack of therapeutic efficacy from haloperidol until carbamazepine was discontinued.<sup>15</sup> Another case report describes the successful use of carbamazepine and haloperidol,<sup>16</sup> while other reports describe patients who experienced neurologic toxicity,<sup>17,18</sup> Stevens-Johnson syndrome,<sup>19</sup> and QT-prolongation with the combination.<sup>20</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kidron R, Averbuch I, Klein E, Belmaker RH. Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia. <i>Biol Psychiatry</i>. 1985;20(2):219-222. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3971003\">[PubMed 3971003]</a></p>\n<p>2. Jann MW, Ereshefsky L, Saklad SR, et al. Effects of carbamazepine on plasma haloperidol levels. <i>J Clin Psychopharmacol</i>. 1985;5(2):106-109. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3988968\">[PubMed 3988968]</a></p>\n<p>3. Arana GW, Goff DC, Friedman H, et al. Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms. <i>Am J Psychiatry</i>. 1986;143(5):650-651. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3963258\">[PubMed 3963258]</a></p>\n<p>4. Kahn EM, Schulz SC, Perel JM, Alexander JE. Change in haloperidol level due to carbamazepine-a complicating factor in combined medication for schizophrenia. <i>J Clin Psychopharmacol</i>. 1990;10(1):54-57. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2106534\">[PubMed 2106534]</a></p>\n<p>5. Yasui-Furukori N, Kondo T, Mihara K, Suzuki A, Inoue Y, Kaneko S. Significant dose effect of carbamazepine on reduction of steady-state plasma concentration of haloperidol in schizophrenic patients. <i>J Clin Psychopharmacol</i>. 2003;23(5):435-440. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14520118\">[PubMed 14520118]</a></p>\n<p>6. Fukuda R. Factors affecting serum haloperidol level assessed by longitudinal therapeutic monitoring. <i>Prog Neuropsychopharmacol Biol Psychiatry</i>. 2000;24(8):1299-1318. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11125855\">[PubMed 11125855]</a></p>\n<p>7. Hirokane G, Someya T, Takahashi S, Morita S, Shimoda K. Interindividual variation of plasma haloperidol concentrations and the impact of concomitant medications: the analysis of therapeutic drug monitoring data. <i>Ther Drug Monit</i>. 1999;21(1):82-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10051058\">[PubMed 10051058]</a></p>\n<p>8. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring databases for postmarketing surveillance of drug-drug interactions: evaluation of a paired approach for psychotropic medication. <i>Ther Drug Monit</i>. 1997;19(1):1-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9029739\">[PubMed 9029739]</a></p>\n<p>9. Yukawa E, Hokazono T, Yukawa M. Population pharmacokinetics of haloperidol using routine clinical pharmacokinetic data in Japanese patients. <i>Clin Pharmacokinet</i>. 2002;41(2):153-159. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11888334\">[PubMed 11888334]</a></p>\n<p>10. Iwahashi K, Miyatake R, Suwaki H, Hosokawa K, Ichikawa Y. The drug-drug interaction effects of haloperidol on plasma carbamazepine levels. <i>Clin Neuropharmacol</i>. 1995;18(3):233-236. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8635181\">[PubMed 8635181]</a></p>\n<p>11. Hesslinger B, Normann C, Langosch JM, Klose P, Berger M, Walden J. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. <i>J Clin Psychopharmacol</i>. 1999;19(4):310-315. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10440457\">[PubMed 10440457]</a></p>\n<p>12. Dose M, Apelt S, Emrich HM. Carbamazepine as an adjunct of antipsychotic therapy. <i>Psychiatry Res</i>. 1987;22(4):303-310. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3324137\">[PubMed 3324137]</a></p>\n<p>13. Moller HJ, Kissling W, Riehl T, Bauml J, Binz U, Wendt G. Doubleblind evaluation of the antimanic properties of carbamazepine as a comedication to haloperidol. <i>Prog Neuropsychopharmacol Biol Psychiatry</i>. 1989;13(1-2):127-136. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2664882\">[PubMed 2664882]</a></p>\n<p>14. Klein E, Bental E, Lerer B, Belmaker RH. Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study. <i>Arch Gen Psychiatry</i>. 1984;41(2):165-170. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6365015\">[PubMed 6365015]</a></p>\n<p>15. Fast DK, Jones BD, Kusalic M, Erickson M. Effect of carbamazepine on neuroleptic plasma levels and efficacy. <i>Am J Psychiatry</i>. 1986;143(1):117-118. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3942266\">[PubMed 3942266]</a></p>\n<p>16. Hejazi M. Temporal lobe epilepsy with schizophrenia. <i>South Med J</i>. 1987;80(8):1043-1045. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3616704\">[PubMed 3616704]</a></p>\n<p>17. Kanter GL, Yerevanian BI, Ciccone JR. Case report of a possible interaction between neuroleptics and carbamazepine. <i>Am J Psychiatry</i>. 1984;141(9):1101-1102. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6147104\">[PubMed 6147104]</a></p>\n<p>18. Brayley J, Yellowlees P. An interaction between haloperidol and carbamazepine in a patient with cerebral palsy. <i>Aust N Z J Psychiatry</i>. 1987;21(4):605-607. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3449054\">[PubMed 3449054]</a></p>\n<p>19. Kumar A, Sarkar S, Praharaj SK, Akhtar S, Diwakar M. Stevens-Johnson syndrome progressing to toxic epidermal necrolysis with haloperidol and carbamazepine combination. <i>Ind Psychiatry J</i>. 2011;20(2):131-133. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23271869\">[PubMed 23271869]</a></p>\n<p>20. Iwahashi K. Significantly higher plasma haloperidol level during cotreatment with carbamazepine may herald cardiac change. <i>Clin Neuropharmacol</i>. 1996;19(3):267-270. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8726546\">[PubMed 8726546]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2910":"<p><b>Title</b> Tricyclic Antidepressants / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Tricyclic Antidepressants. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentration/therapeutic effects of tricyclic antidepressants if carbamazepine is initiated/dose increased, or increased effects if carbamazepine is discontinued/dose decreased.</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline*, Amoxapine, ClomiPRAMINE*, Desipramine*, Dosulepin, Doxepin (Systemic)*, Doxepin (Topical), Imipramine*, Lofepramine, Melitracen [INT], Nortriptyline*, Protriptyline, Trimipramine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a study of 6 healthy volunteers, carbamazepine (300 mg twice daily x 28 days) decreased the desipramine (100 mg single dose) AUC 24%.<sup>1</sup> Additional studies have reported decreases in serum concentrations of nortriptyline (61%),<sup>2</sup> imipramine (31% to 52%),<sup>3,4</sup> amitriptyline (42%),<sup>5</sup> and doxepin (46%)<sup>5</sup> with the addition of carbamazepine therapy. In another study of inpatients, the concentration to dose ratio was 16% lower in patients taking carbamazepine and nortriptyline, and 40% lower in patients taking carbamazepine and amitriptyline compared with that of those taking nortriptyline and amitriptyline alone, respectively.<sup>6</sup> Case reports also describe patients who experienced subtherapeutic concentrations of clomipramine and desipramine with the concomitant use of carbamazepine.<sup>7,8</sup> <br><br>These reductions are likely due to carbamazepine's ability to induce the CYP isoenzymes responsible for metabolism of tricyclic antidepressants. Because many antidepressants have one or more active metabolites, the effect of carbamazepine on their overall therapeutic efficacy is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E. The effect of carbamazepine on the 2-hydroxylation of desipramine. <i>Psychopharmacol (Berl)</i>. 1995;117(4):413-416. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7604141\">[PubMed 7604141]</a></p>\n<p>2. Brosen K, Kragh-Sorensen P. Concomitant intake of nortriptyline and carbamazepine. <i>Ther Drug Monit</i>. 1993;15(3):258-260. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8333008\">[PubMed 8333008]</a></p>\n<p>3. Brown CS, Wells BG, Cold JA, Froemming JH, Self TH, Jabbour JT. Possible influence of carbamazepine on plasma imipramine concentration in children with attention-deficit hyperactivity disorder. <i>J Clin Psychopharmacol</i>. 1990;10(5):359-362. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2258453\">[PubMed 2258453]</a></p>\n<p>4. Szymura-Oleksiak J, Wyska E, Wasieczko A. Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression. <i>Psychopharmacol (Berl)</i>. 2001;154(1):38-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11292004\">[PubMed 11292004]</a></p>\n<p>5. Leinonen E, Lillsunde P, Laukkanen V, Ylitalo P. Effects of carbamazepine on serum antidepressant concentrations in psychiatric patients. <i>J Clin Psychopharmacol</i>. 1991;11(5):313-318. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1765574\">[PubMed 1765574]</a></p>\n<p>6. Jerling M, Bertilsson L, Sjoqvist F. The use of therapeutic drug monitoring data to document kinetic drug interactions: an example of amitriptyline and nortriptyline. <i>Ther Drug Monit</i>. 1994;16(1):1-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7909176\">[PubMed 7909176]</a></p>\n<p>7. Baldessarini RJ, Teicher MH, Cassidy JW, Stein MH. Anticonvulsant cotreatment may increase toxic metabolites of antidepressants and other psychotropic drugs. <i>J Clin Psychopharmacol</i>. 1988;8(5):381-382. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3183079\">[PubMed 3183079]</a></p>\n<p>8. De la Fuente JM, Mendlewicz J. Carbamazepine addition in tricyclic antidepressant-resistant unipolar depression. <i>Biol Psychiatry</i>. 1992;32(4):369-374. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1420651\">[PubMed 1420651]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2911":"<p><b>Title</b> Isoniazid / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CarBAMazepine may enhance the hepatotoxic effect of Isoniazid. Isoniazid may increase the serum concentration of CarBAMazepine. <b>Severity</b> Moderate <b>Onset</b> Rapid (Sequence Important) <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased carbamazepine serum concentrations/toxic effects if combined with isoniazid. Additionally, monitor for increased hepatotoxicity with this combination.</p> \n<p><b>Discussion</b> In a study of 13 patients stabilized on carbamazepine who were initiated on isoniazid (200 mg daily), symptoms of carbamazepine toxicity (eg, disorientation, lethargy, drowsiness) were observed in 10 (77%) patients.<sup>1</sup> Carbamazepine serum concentrations were available for 3 patients, each with therapeutic carbamazepine concentrations prior to isoniazid initiation and supratherapeutic concentrations during isoniazid therapy.<sup>1</sup> Serum concentrations returned to baseline and symptoms resolved after isoniazid discontinuation.<sup>1</sup> Two case reports describe similar elevations in carbamazepine concentrations accompanied by toxicities after the addition of isoniazid.<sup>2,3</sup> Other reports also describe the development of fulminant liver failure with the combination of isoniazid and carbamazepine.<sup>2,4,5</sup><br><br>The mechanism of this interaction is likely related to the ability of isoniazid to inhibit the CYP isoenzymes responsible for metabolizing carbamazepine. Carbamazepine may enhance the hepatotoxicity of isoniazid by accelerating the metabolism of isoniazid, leading to increased production of hepatotoxic metabolites.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Valsalan VC, Cooper GL. Carbamazepine intoxication caused by interaction with isoniazid. <i>Br Med J (Clin Res Ed)</i>. 1982;285(6337):261-262. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6807441\">[PubMed 6807441]</a></p>\n<p>2. Wright JM, Stokes EF, Sweeney VP. Isoniazid-induced carbamazepine toxicity and vice versa: a double drug interaction. <i>N Engl J Med</i>. 1982;307(21):1325-1327. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7133069\">[PubMed 7133069]</a></p>\n<p>3. Block SH. Carbamazepine-isoniazid interaction. <i>Pediatrics</i>. 1982;69(4):494-495. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7070898\">[PubMed 7070898]</a></p>\n<p>4. Campos-Franco J, Gonzalez-Quintela A, Alende-Sixto MR. Isoniazid-induced hyperacute liver failure in a young patient receiving carbamazepine. <i>Eur J Intern Med</i>. 2004;15(6):396-397. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15522577\">[PubMed 15522577]</a></p>\n<p>5. Berkowitz FE, Henderson SL, Fajman N, Schoen B, Naughton M. Acute liver failure caused by isoniazid in a child receiving carbamazepine. <i>Int J Tuberc Lung Dis</i>. 1998;2(7):603-606. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9661830\">[PubMed 9661830]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2912":"<p><b>Title</b> CarBAMazepine / Retinoic Acid Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Retinoic Acid Derivatives may decrease the serum concentration of CarBAMazepine. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of carbamazepine if a retinoic acid derivatives are initiated/dose increased, or increased effects if a retinoic acid derivatives are discontinued/dose decreased.</p>\n<div>\n <p><b>Retinoic Acid Derivatives Interacting Members</b> Acitretin, Alitretinoin (Systemic), Alitretinoin (Topical), Bexarotene (Systemic), ISOtretinoin (Systemic)*, Tretinoin (Systemic)<br><b>Exceptions</b> Adapalene, Bexarotene (Topical), Tretinoin (Topical)</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case report. A patient experienced a 10% decrease in carbamazepine serum concentration within 2 weeks of starting a regimen of isotretinoin (0.5 mg/kg/day).<sup>1</sup> A 24% decrease was observed in the same patient following a 4 week course of a higher dose of isotretinoin (1 mg/kg/day). The mechanism of this interaction is unknown, however, it appears to be effected in a dose-related fashion.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Marsden JR, “Effect of Isotretinoin on Carbamazepine Pharmacokinetics,” <i>Br J Dermatol</i>, 1988, 119(3):403-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2972311\">[PubMed 2972311]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2913":"<p><b>Title</b> CarBAMazepine / LamoTRIgine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> LamoTRIgine may enhance the adverse/toxic effect of CarBAMazepine. CarBAMazepine may increase the metabolism of LamoTRIgine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The manufacturer of lamotrigine has published extensive dosage adjustment guidelines in the approved labeling when the drug is added to an enzyme-inducing antiepileptic drug (AIAED). Please refer to the labeling for additional information. Monitor for reduced effects of lamotrigine if carbamazepine is initiated/dose increased. Monitor for toxic effects of carbamazepine if lamotrigine is initiated or the dose is increased. Note that carbamazepine serum concentrations might not increase, yet toxicity due to increased concentrations of active metabolites or some other undefined mechanism is still possible.</p> \n<p><b>Discussion</b> Carbamazepine-related toxicity, as well as increases in the active metabolite of carbamazepine (carbamazepine-epoxide) has been reported to occur in a number of patients receiving concomitant lamotrigine. One report describes an increase in carbamazepine-epoxide serum concentrations in 3 patients without changes in serum carbamazepine concentrations following the addition of lamotrigine.<sup>1</sup> Another report describes a 47% average increase in serum carbamazepine-epoxide concentrations in 10 patients following the addition of lamotrigine.<sup>2,3</sup> Yet another study failed to show any effect of lamotrigine on carbamazepine-epoxide pharmacokinetics.<sup>4</sup> The predictability of this interaction is a challenge, as is establishing a mechanism for its occurrence. However, it appears possible for clinically important events to occur.<br><br>Of greater importance, the manufacturer of lamotrigine reports that carbamazepine administration can decrease serum lamotrigine concentrations by approximately 40%.<sup>5</sup> Such is likely due to carbamazepine induction of CYP isoenzymes responsible for lamotrigine metabolism. Dosage adjustment guidelines are available in the product labeling.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Graves NM, Ritter FJ, Wagner ML, et al, “Effect of Lamotrigine on Carbamazepine Epoxide Concentrations,” <i>Epilepsia</i>, 1991, 32(Suppl 3):13.</p>\n<p>2. Warner T, Patsalos PN, Prevett M, et al, “Lamotrigine-Induced Carbamazepine Toxicity: A Pharmacokinetic Interaction,” <i>Epilepsia</i>, 1991, 32(Suppl 1):95.</p>\n<p>3. Warner T, Patsalos PN, Prevett M, et al, “Lamotrigine-Induced Carbamazepine Toxicity: An Interaction With Carbamazepine-10,11-Epoxide,” <i>Epilepsy Res</i>, 1992, 11:147-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1618180\">[PubMed 1618180]</a></p>\n<p>4. Pisani F, Xiao B, Fazio A, et al, “Single Dose Pharmacokinetics of Carbamazepine-10,11 Epoxide in Patients on Lamotrigine Monotherapy,” <i>Epilepsy Res</i>, 1994, 19(3):245-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7698101\">[PubMed 7698101]</a></p>\n<p>5. Lamictal [package insert]. Research Triangle Park, NC: Glaxo Wellcome, Inc, 2000.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2914":"<p><b>Title</b> Lithium / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CarBAMazepine may enhance the adverse/toxic effect of Lithium. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for neurotoxic symptoms (eg, ataxia, confusion, dizziness) in patients receiving concomitant lithium and carbamazepine.</p> \n<p><b>Discussion</b> Several reports describe the development of various symptoms of neurotoxicity (eg, ataxia, confusion, dizziness) in patients receiving concomitant lithium and carbamazepine without noted increases in serum concentrations of either agent.<sup>1,2,3,4,5,6</sup> In one report, the symptoms occurred within 3 days of adding carbamazepine to a lithium-treated patient, both initially and upon rechallenge.<sup>2</sup> The symptoms have been observed 3 to 13 days after initiating lithium and carbamazepine therapy.<sup>5</sup> <br><br>The mechanism of this presumed interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ghose K. Interaction between lithium and carbamazepine. <i>Br Med J</i>. 1980;280(6222):1122. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7388439\">[PubMed 7388439]</a></p>\n<p>2. Chaudhry RP, Waters BG. Lithium and carbamazepine interaction: possible neurotoxicity. <i>J Clin Psychiatry</i>. 1983;44(1):30-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6401711\">[PubMed 6401711]</a></p>\n<p>3. Andrus PF. Lithium and carbamazepine. <i>J Clin Psychiatry</i>. 1984;45(12):525. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6501241\">[PubMed 6501241]</a></p>\n<p>4. Shukla S, Godwin CD, Long LE, Miller MG. Lithium-carbamazepine neurotoxicity and risk factors. <i>Am J Psychiatry</i>. 1984;141(12):1604-1606. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6439058\">[PubMed 6439058]</a></p>\n<p>5. Marcoux AW. Carbamazepine-lithium drug interaction. <i>Ann Pharmacother</i>. 1996;30(5):547. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8740344\">[PubMed 8740344]</a></p>\n<p>6. Khaitan AK, Sengupta A, Lata H. Neurotoxicity following lithium and carbamazepine interaction - a case report. <i>Indian J Psychiatry</i>. 1985;27(3):265-266. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21927117\">[PubMed 21927117]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2915":"<p><b>Title</b> Mebendazole / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Mebendazole. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of mebendazole if carbamazepine is initiated/dose increased, especially if mebendazole is being used to treat infections in tissues affected by serum drug concentrations (versus GI tract infections).</p> \n<p><b>Discussion</b> A single report describes decreases in serum mebendazole concentrations presumably due to carbamazepine therapy.<sup>1</sup> It is suggested that this interaction would likely only be of concern when treating infections within tissues, as opposed to GI infections. Mebendazole dose increases might become necessary. The mechanism of this presumed interaction is likely to be carbamazepine-mediated induction of mebendazole metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Luder PJ, Siffert B, Witassek F, et al, “Treatment of Hydatid Disease With High Oral Doses of Mebendazole. Long-Term Follow-Up of Plasma Mebendazole Levels and Drug Interactions,” <i>Eur J Clin Pharmacol</i>, 1986, 31(4):443-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3816925\">[PubMed 3816925]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2916":"<p><b>Title</b> Methadone / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Methadone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects (signs of withdrawal) of methadone if carbamazepine is initiated/dose increased. A methadone dosage adjustment may be needed. Monitor for toxic effects of methadone if carbamazepine is discontinued/dose decreased.</p> \n<p><b>Discussion</b> In an observational study of 8 patients on methadone maintenance therapy, initiation of carbamazepine was associated with an average 60% decrease in serum methadone levels after 7 to 10 days and was associated mild withdrawal symptoms.<sup>1</sup> In one case report, initiation of carbamazepine therapy in a patient on methadone (40 mg per day) resulted in low methadone serum trough concentrations and daily withdrawal symptoms.<sup>2</sup> Another case report describes a 61-year-old woman taking methadone (120 mg per day) and carbamazepine (1,200 mg per day) who experienced methadone-induced respiratory depression 11 days after discontinuing carbamazepine.<sup>3</sup><br><br>The manufacturer of methadone notes that administration of methadone with CYP3A4 inducers (ie, carbamazepine) may result in withdrawal symptoms. They recommend monitoring patients for evidence of withdrawal effects and adjusting methadone doses accordingly.<sup>4</sup><br><br>The mechanism of this interaction is likely due to the ability of carbamazepine to induce the hepatic metabolism of methadone.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kuhn KL, Halikas JA, Kemp KD. Carbamazepine treatment of cocaine dependence in methadone maintenance patients with dual opiate-cocaine addiction. <i>NIDA Res Monogr</i>. 1989;95:316-317. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2640978\">[PubMed 2640978]</a></p>\n<p>2. Bell J, Seres V, Bowron P, Lewis J, Batey R. The use of serum methadone levels in patients receiving methadone maintenance. <i>Clin Pharmacol Ther</i>. 1988;43(6):623-629. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3378383\">[PubMed 3378383]</a></p>\n<p>3. Benitez-Rosario M, Salinas Martin A, Gomez-Ontanon E, Feria M. Methadone-induced respiratory depression after discontinuing carbamazepine administration. <i>J Pain Symptom Manage</i>. 2006;32(2):99-100. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16877171\">[PubMed 16877171]</a></p>\n<p>4. Dolophine (methadone) [prescribing information]. Columbus, OH: Roxane Laboratories Inc; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2917":"<p><b>Title</b> Methylphenidate / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Methylphenidate. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of methylphenidate if carbamazepine is initiated/dose increased, or increased effects if carbamazepine is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Two case reports describe challenges in achieving therapeutic serum concentrations (and clinical efficacy) of methylphenidate in pediatric patients also receiving carbamazepine.<sup> 1,2</sup> In one case, methylphenidate dosing was increased to 30 mg every 4 hours without any benefit, and in the other a doubling of methylphenidate dose (following the addition of carbamazepine) was needed to maintain efficacy. The mechanism of this interaction is unknown. It might be related to increased hepatic metabolism of methylphenidate stimulated by carbamazepine (although CYP enzymes do not contribute significantly to methylphenidate metabolism, and do not contribute at all to the formation of its major metabolite, ritalinic acid). The former case report described finding no trace of either methylphenidate or its metabolites in the patient's serum which might reflect a malabsorption syndrome (the patient also required 1,000 mg of carbamazepine daily to control seizures) as opposed to a metabolic drug interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Behar D, Schaller J, and Spreat S, “Extreme Reduction of Methylphenidate Levels by Carbamazepine,” <i>J Am Acad Child Adolesc Psychiatry</i>, 1998, 37(11):1128-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9808919\">[PubMed 9808919]</a></p>\n<p>2. Schaller JL and Behar D, “Carbamazepine and Methylphenidate in ADHD,” <i>J Am Acad Child Adolesc Psychiatry</i>, 1999, 38(2):112-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9951206\">[PubMed 9951206]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2918":"<p><b>Title</b> Phenytoin / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of CarBAMazepine. CarBAMazepine may increase the serum concentration of Phenytoin. Possibly by competitive inhibition at sites of metabolism. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of carbamazepine or phenytoin if the other agent is initiated/dose increased, or increased serum concentrations/effects of one agent if the other is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Three of 7 patients in one study showed at least a 33% reduction in serum phenytoin concentrations within 4-14 days following the addition of carbamazepine (600 mg/day).<sup>1</sup> Similarly, carbamazepine serum concentrations are reported to be decreased in patients receiving phenytoin<sup>2,3,4</sup> In contrast, several reports of increased serum phenytoin concentrations (35% to 100%) have occurred in apparent response to carbamazepine therapy.<sup>5,6,7</sup> The mechanisms of these presumed interactions are seemingly related to the ability of the agents to affect, and be affected by, CYP isoenzymes. Both agents are known inducers of CYP isoenzymes, and likely stimulate the metabolism of the other agent (and possibly themselves). It's also possible, that acting as substrates for the same enzymes, they might compete against each other for metabolic sites, and thus reduce the metabolism of the other. The extent to which a particular mechanism manifests in a given patient is presently unpredictable, as therefore is the pharmacokinetic and clinical outcomes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hansen JM, Siersboek-Nielsen K, and Skovsted L, “Carbamazepine-Induced Acceleration of Diphenylhydantoin and Warfarin Administration in Man,” <i>Clin Pharmacol Ther</i>, 1971, 12(3):539-43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5567804\">[PubMed 5567804]</a></p>\n<p>2. Cereghino JJ, Block JT, van Meter JC, et al, “The Efficacy of Carbamazepine Combinations in Epilepsy,” <i>Clin Pharmacol Ther</i>, 1975, 18(6):733-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1106934\">[PubMed 1106934]</a></p>\n<p>3. Ramsay RE, McManus DQ, Guterman A, et al, “Carbamazepine Metabolism in Humans: Effect of Concurrent Anticonvulsant Therapy,” <i>Ther Drug Monit</i>, 1990, 12(3):235-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2112276\">[PubMed 2112276]</a></p>\n<p>4. Chapron DJ, LaPierre BA, and Abou-Elkair M, “Unmasking the Significant Enzyme-Inducing Effects of Phenytoin on Serum Carbamazepine Concentrations During Phenytoin Withdrawal,” <i>Ann Pharmacother</i>, 1993, 27(6):708-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8329787\">[PubMed 8329787]</a></p>\n<p>5. Browne TR, Szabo GK, Evans JE, et al, “Carbamazepine Increases Phenytoin Serum Concentration and Reduces Phenytoin Clearance,” <i>Neurology</i>, 1988, 38(7):1146-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3386835\">[PubMed 3386835]</a></p>\n<p>6. Gratz ES, Theodore WH, Newmark ME, et al, “Effect of Carbamazepine on Phenytoin Clearance in Patients With Complex Partial Seizures,” <i>Neurology</i>, 1982, 32:A223.</p>\n<p>7. Zielinski JJ, Haidukewych D, and Leheta BJ, “Carbamazepine-Phenytoin Interaction: Elevation of Plasma Phenytoin Concentrations Due to Carbamazepine Comedication,” <i>Ther Drug Monit</i>, 1985, 7(1):51-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3992622\">[PubMed 3992622]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2920":"<p><b>Title</b> CarBAMazepine / Theophylline Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Theophylline Derivatives. Theophylline Derivatives may decrease the serum concentration of CarBAMazepine. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Seek alternatives to this combination when possible. If these agents are used together, monitor closely for decreased serum concentrations/therapeutic effects of both medications. Decreases in carbamazepine concentration may be seen within the first 1-2 days of theophylline treatment.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline*, Theophylline*<br><b>Exception</b> Dyphylline</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A case report describes an approximate 50% reduction in the half-life of theophylline in an 11-year-old girl within a few days of starting carbamazepine therapy. She had concomitant worsening of her asthma.<sup>1</sup> <br><br>A second case report describes a 10 year old girl with epilepsy effectively managed with carbamazepine (5 mg/kg twice daily) who had a return of seizure activity 8 days after beginning theophylline (14 mg/kg/day).<sup>2</sup> The patient had received theophylline 3 times in the past without incident. Upon rechallenge, carbamazepine trough concentration was observed to decrease by roughly 50% within the first 2 days of theophylline (5 mg/kg every 6 hours). After the seventh dose of theophylline, the child experienced another seizure and theophylline concentration was found to be 142 micromolar. A clinical study of 6 healthy volunteers was later conducted and showed roughly 31% and 46% decreases in carbamazepine (200 mg single oral dose) AUC and maximum concentration, respectively, with concurrent aminophylline (200 mg intravenous three times daily beginning at the time of carbamazepine dosing).<sup>3</sup><br><br>Carbamazepine likely increases clearance of theophylline primarily via induction of its CYP1A2 mediated metabolism. The mechanism by which theophylline could decrease carbamazepine concentrations is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rosenberry KR, Defusco CJ, Mansmann HC, et al, “Reduced Theophylline Half-Life Induced by Carbamazepine Therapy,” <i>J Ped</i>, 1983, 102:472-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6827425\">[PubMed 6827425]</a></p>\n<p>2. Mitchell EA, Dower JC and Green RJ, “Interaction Between Carbamazepine and Theophylline,” <i>N Z Med J</i>, 1986, 99(795):69-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3080715\">[PubMed 3080715]</a></p>\n<p>3. Kulkarni C, Vaz J, David J, et al, “Aminophylline Alters Pharmacokinetics of Carbamazepine but not That of Sodium Valproate--A Single Dose Pharmacokinetic Study in Human Volunteers,” <i>Indian J Physiol Pharmacol</i>, 1995, 39(2):122-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7649598\">[PubMed 7649598]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2921":"<p><b>Title</b> Thyroid Products / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Thyroid Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations and therapeutic effects of thyroid products if carbamazepine is initiated or the dose increased. Conversely, monitor for increased serum concentrations and toxic effects of thyroid products if carbamazepine is discontinued or the dose decreased.</p>\n<div>\n <p><b>Thyroid Products Interacting Members</b> Levothyroxine*, Liothyronine, Liotrix, Thyroid, Desiccated*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 5 children receiving long-term levothyroxine therapy, the addition of carbamazepine (20 mg/kg/day for 2 months) resulted in a mean 41% decrease in total thyroxine (T4) concentrations, a mean 34% decrease in free T4 concentrations, and a mean 300% increase in thyroxine stimulating hormone (TSH) concentrations.<sup>1</sup> Pre-treatment values of the thyroid function tests were restored by increasing the levothyroxine dose in all five patients.<sup>1</sup> In another study of 9 adult patients receiving long-term levothyroxine therapy, the addition of carbamazepine (200 mg once daily for 7 days, then 300 mg once daily for 7 days, then 400 mg once daily for 7 days) led to a 21% and 44% reduction in total T4 and free T4 concentrations, respectively, and a 23% and 35% reduction in total triiodothyronine (T3) and free T3 concentrations, respectively.<sup>2</sup> TSH concentrations were unchanged.<sup>2</sup> In a study of 10 patients on long-term levothyroxine therapy, the addition of carbamazepine (titrated to 450 mg once daily for 7 weeks) significantly reduced total and free T4 concentrations and increased TSH concentrations.<sup>3</sup> Numerous studies also report the development of reduced serum thyroid hormone concentrations, sometimes leading to clinical hypothyroidism, in patients treated with carbamazepine.<sup>4,5,6,7,8,9,10,11,12</sup><br><br>Prescribing information for levothyroxine states that coadministration with carbamazepine may result in hypothyroidism and increased doses of levothyroxine may be required.<sup>13</sup><br><br>The mechanism of this interaction is likely carbamazepine-induced increases in thyroid hormone metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. De Luca F, Arrigo T, Pandullo E, Siracusano MF, Benvenga S, Trimarchi F. Changes in thyroid function tests induced by 2 month carbamazepine treatment in L-thyroxine-substituted hypothyroid children. <i>Eur J Pediatr</i>. 1986;145(1-2):77-79. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3089800\">[PubMed 3089800]</a></p>\n<p>2. Aanderud S, Myking OL, Strandjord RE. The influence of carbamazepine on thyroid hormones and thyroxine binding globulin in hypothyroid patients substituted with thyroxine. <i>Clin Endocrinol (Oxf)</i>. 1981;15(3):247-252. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6796303\">[PubMed 6796303]</a></p>\n<p>3. Simko J, Horacek J. Carbamazepine and risk of hypothyroidism: a prospective study. <i>Acta Neurol Scand</i>. 2007;116(5):317-321. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17850408\">[PubMed 17850408]</a></p>\n<p>4. Yilmaz U, Yilmaz TS, Akinci G, Korkmaz HA, Tekgul H. The effect of antiepileptic drugs on thyroid function in children. <i>Seizure</i>. 2014;23(1):29-35. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24091037\">[PubMed 24091037]</a></p>\n<p>5. Lai EC, Yang YH, Lin SJ, Hsieh CY. Use of antiepileptic drugs and risk of hypothyroidism. <i>Pharmacoepidemiol Drug Saf</i>. 2013;22(10):1071-1079. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23946049\">[PubMed 23946049]</a></p>\n<p>6. Verrotti A, Laus M, Scardapane A, Franzoni E, Chiarelli F. Thyroid hormones in children with epilepsy during long-term administration of carbamazepine and valproate. <i>Eur J Endocrinol</i>. 2009;160(1):81-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18984773\">[PubMed 18984773]</a></p>\n<p>7. Isojarvi JI, Turkka J, Pakarinen AJ, Kotila M, Rattya J, Myllyla VV. Thyroid function in men taking carbamazepine, oxcarbazepine, or valproate for epilepsy. <i>Epilepsia</i>. 2001;42(7):930-934. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11488894\">[PubMed 11488894]</a></p>\n<p>8. Verrotti A, Basciani F, Morresi S, Morgese G, Chiarelli F. Thyroid hormones in epileptic children receiving carbamazepine and valproic acid. <i>Pediatr Neurol</i>. 2001;25(1):43-46. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11483395\">[PubMed 11483395]</a></p>\n<p>9. Eiris-Punal J, Del Rio-Garma M, Del Rio-Garma MC, Lojo-Rocamonde S, Novo-Rodriguez I, Castro-Gago M. Long-term treatment of children with epilepsy with valproate or carbamazepine may cause subclinical hypothyroidism. <i>Epilepsia</i>. 1999;40(12):1761-1766. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10612341\">[PubMed 10612341]</a></p>\n<p>10. Tiihonen M, Liewendahl K, Waltimo O, Ojala M, Valimaki M. Thyroid status of patients receiving long-term anticonvulsant therapy assessed by peripheral parameters: a placebo-controlled thyroxine therapy trial. <i>Epilepsia</i>. 1995;36(11):1118-1125. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7588456\">[PubMed 7588456]</a></p>\n<p>11. Isojarvi JI, Airaksinen KE, Repo M, Pakarinen AJ, Salmela P, Myllyla VV. Carbamazepine, serum thyroid hormones and myocardial function in epileptic patients. <i>J Neurol Neurosurg Psychiatry</i>. 1993;56(6):710-712. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8509792\">[PubMed 8509792]</a></p>\n<p>12. Yuksel A, Yalcin E, Cenani A. Influence of long-term carbamazepine treatment on thyroid function. <i>Acta Paediatr Jpn</i>. 1993;35(3):229-232. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8351990\">[PubMed 8351990]</a></p>\n<p>13. Synthroid (levothyroxine) [prescribing information]. North Chicago, IL: Abbott Laboratories; July 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2923":"<p><b>Title</b> Vitamin K Antagonists / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Vitamin K Antagonists. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased INR and effects of vitamin K antagonists if carbamazepine is initiated/dose increased, or increased INR and effects if carbamazepine is discontinued/dose decreased. Warfarin dose adjustments will likely be required.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a retrospective cohort study of 166 patients, warfarin doses and INRs were compared before and after the initiation of carbamazepine therapy.<sup>1</sup> After 4 weeks of coadministration, the mean INR decreased from 2.26 to 1.78 and 79% of patients experienced a subtherapeutic INR.<sup>1</sup> By weeks 10 to 13 of coadministration, warfarin doses were 49% higher. Despite these warfarin dose increases, INRs did not return to baseline until weeks 18 to 20 of coadministration.<sup>1</sup><br><br>In another analysis of stable warfarin-treated patients, those taking carbamazepine (n = 5) required doses of warfarin that were 2.3-fold higher than those not taking carbamazepine or any other interacting medication (n = 54).<sup>2</sup> The S-warfarin and R-warfarin clearance was 2.2-fold and 1.8-fold higher, respectively, in carbamazepine-treated patients compared with those not taking carbamazepine.<sup>2</sup><br> <br>A retrospective cross-sectional analysis of the Swedish Prescribed Drug Register found that even after statistical adjustment, carbamazepine use was associated with a 37% increase in warfarin dose dispensed compared with the warfarin dose dispensed to patients who received warfarin alone.<sup>3</sup> In a study of 3 patients, the mean half-life of warfarin was decreased approximately 45% after 3 weeks of carbamazepine therapy (200 mg daily x 7 days, 400 mg daily x 7 days, 600 mg daily x 7 days).<sup>4</sup><br><br>In support of these analyses, several case reports describe warfarin-treated patients who experienced decreases in INR with carbamazepine initiation<sup>5,6,7</sup> or elevations in INR and/or bleeding when carbamazepine was discontinued.<sup>5,8,9</sup><br><br>The mechanism of this interaction has not been fully investigated, but carbamazepine induction of enzymes responsible for warfarin metabolism (eg, CYP1A2, CYP3A4, CYP2C9), likely plays a role.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mannheimer B, Andersson ML, Pettersson HJ, Lindh JD. The effect of carbamazepine on warfarin anticoagulation: a register-based nationwide cohort study involving the Swedish population [published online January 21, 2016]. <i>J Thromb Haemost</i>. doi: 10.1111/jth.13268. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26792124\">[PubMed 26792124]</a> </p>\n<p>2. Herman D, Locatelli I, Grabnar I, et al. The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose. <i>Eur J Clin Pharmacol</i>. 2006;62(4):291-296. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16552506\">[PubMed 16552506]</a></p>\n<p>3. Andersson ML, Lindh JD, Mannheimer B. The impact of interacting drugs on dispensed doses of warfarin in the Swedish population: a novel use of population based drug registers. <i>J Clin Pharmacol</i>. 2013;53(12):1322-1327. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24038065\">[PubMed 24038065]</a></p>\n<p>4. Hansen JM, Siersboek-Nielsen K, Skovsted L. Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man. <i>Clin Pharmacol Ther</i>. 1971;12(3):539-543. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5567804\">[PubMed 5567804]</a></p>\n<p>5. Parrish RH, Pazdur DE, O'donnell PJ. Effect of carbamazepine initiation and discontinuation on antithrombotic control in a patient receiving warfarin: case report and review of the literature. <i>Pharmacotherapy</i>. 2006;26(11):1650-1653. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17064211\">[PubMed 17064211]</a></p>\n<p>6. Massey EW. Effect of carbamazepine on Coumadin metabolism. <i>Ann Neurol</i>. 1983;13(6):691-692. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6881938\">[PubMed 6881938]</a></p>\n<p>7. Kendall AG, Boivin M. Warfarin-carbamazepine interaction. <i>Ann Intern Med</i>. 1981;94(2):280. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7469228\">[PubMed 7469228]</a></p>\n<p>8. Denbow CE, Fraser HS. Clinically significant hemorrhage due to warfarin-carbamazepine interaction. <i>South Med J</i>. 1990;83(8):981. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2382161\">[PubMed 2382161]</a></p>\n<p>9. Ross JR, Beeley L. Interaction between carbamazepine and warfarin. <i>Br Med J</i>. 1980;280(6229):1415-1416. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7427137\">[PubMed 7427137]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2924":"<p><b>Title</b> Methotrexate / Penicillins</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Penicillins may increase the serum concentration of Methotrexate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for toxic effects of methotrexate if a penicillin antibiotic is initiated or the dose is increased. Lower (e.g., antirheumatic) doses of methotrexate would likely carry less risk than higher (e.g., antineoplastic) doses.</p>\n<div>\n <p><b>Penicillins Interacting Members</b> Amdinocillin, Amoxicillin*, Ampicillin, Bacampicillin, Cloxacillin, Dicloxacillin*, Flucloxacillin, Nafcillin, Oxacillin, Penicillin G (Parenteral/Aqueous)*, Penicillin G Benzathine*, Penicillin G Procaine*, Penicillin V Benzathine, Penicillin V Potassium*, Piperacillin*, Temocillin, Ticarcillin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Several case reports describe increased serum methotrexate concentrations, with accompanying signs and symptoms of toxicity, when coadministered with a variety of penicillin antibiotics.<sup>1,2,3,4,5,6,7</sup> Clinical effects of this interaction have manifested within a few days of starting the antibiotic. In a clinical study of 10 patients with rheumatoid arthritis, the AUC of methotrexate (5-15 mg weekly dose) increased by only 8% following pretreatment with floxacillin (500 mg 4 times daily for 8 doses).<sup>8</sup> <br><br>The mechanism of this interaction is uncertain. There is some in vitro evidence that penicillins could compete with methotrexate for excretion sites in the renal tubules.<sup>9</sup> This could in turn reduce methotrexate elimination and increase the likelihood of significant toxicity. The significance of this interaction is expected to increase with increasing doses of penicillin or methotrexate.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bloom EJ, Ignoffo RJ, Reis CA, et al, “Delayed Clearance (CL) of Methotrexate (MTX) Associated With Antibiotics and Anti-Inflammatory Agents,” <i>Clin Res</i>, 1986, 34:560A. </p>\n<p>2. Ronchera CL, Hernandez T, Peris JE, et al, “Pharmacokinetic Interaction Between High Dose Methotrexate and Amoxycillin,” <i>Ther Drug Monit</i>, 1993, 15:375-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8249043\">[PubMed 8249043]</a></p>\n<p>3. Gibson DL, Bleyer AW, and Savitch JL, “Carbenicillin Potentiation of Methotrexate Plasma Concentration During High Dose Methotrexate Therapy,” <i>Am Soc Hosp Pharm,</i> Mid Year Clinical Meeting Abstracts, New Orleans, Dec 6-10, 1989, 111.</p>\n<p>4. Dean R, Nachman J, and Lorenzana AN, “Possible Methotrexate-Mezlocillin Interaction,” <i>Am J Pediatr Hematol Oncol</i>, 1992, 14:88-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1550270\">[PubMed 1550270]</a></p>\n<p>5. Nierenberg DW and Mamelok RD, “Toxic Reaction to Methotrexate in a Patient Receiving Penicillin and Furosemide: A Possible Interaction,” <i>Arch Dermatol</i>, 1983, 119:449-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6859880\">[PubMed 6859880]</a></p>\n<p>6. Zarychanski R, Wlodarczyk K, Ariano R, et al, “Pharmacokinetic Interaction Between Methotrexate and Piperacillin/Tazobactam Resulting in Prolonged Toxic Concentrations of Methotrexate,” <i>J Antimicrob Chemother</i>, 2006, 58(1):228-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16717053\">[PubMed 16717053]</a></p>\n<p>7. Yamamoto K, Sawada Y, Matsushita Y, et al, “Delayed Elimination of Methotrexate Associated With Piperacillin Administration,” <i>Ann Pharmacother</i>, 1997, 31(10):1261-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9337457\">[PubMed 9337457]</a></p>\n<p>8. Herrick AL, Grennan DM, Griffen K, et al, “Lack of Interaction Between Flucloxacillin and Methotrexate in Patients with Rheumatoid Arthritis,” <i>Br J Clin Pharmacol</i>, 1996, 41(3):223-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8866922\">[PubMed 8866922]</a></p>\n<p>9. Takeda M, Khamdang S, Narikawa S, et al, “Characterization of Methotrexate Transport and its Drug Interactions With Human Organic Anion Transporters,” <i>J Pharmacol Exp Ther</i>, 2002, 302(2):666-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12130730\">[PubMed 12130730]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2925":"<p><b>Title</b> CARBOplatin / Aminoglycosides</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased ototoxic effects of concurrently administered aminoglycosides and carboplatin (especially if used in high doses).</p>\n<div>\n <p><b>Aminoglycosides Interacting Members</b> Amikacin, Arbekacin, Gentamicin (Systemic), Isepamicin, Kanamycin, Neomycin, Streptomycin, Tobramycin (Systemic)</p>\n</div> \n<p><b>Discussion</b> A carboplatin dose-escalation study in refractory adult leukemia patients revealed a higher incidence of significant ototoxicity in those patients who had recently received, or were currently receiving, aminoglycosides.<sup>1</sup> Both agents are known to potentially cause ototoxicity. The mechanism of this interaction might simply be the result of adding their individual toxicities together.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lee EJ, Egorin MJ, Van Echo DA, et al, “Phase I and Pharmacokinetic Trial of Carboplatin in Refractory Adult Leukemia,” <i>J Natl Cancer Inst</i>, 1988, 80:131-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3278122\">[PubMed 3278122]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2927":"<p><b>Title</b> Beta-Blockers / Selective Serotonin Reuptake Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Beta-Blockers. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased effects of beta-blockers if certain selective serotonin reuptake inhibitors (SSRIs) are initiated/dose increased, or decreased effects if these SSRIs are discontinued/dose decreased. Ophthalmic beta blockers may be less likely to exhibit systemic toxicity with this interaction.</p>\n<div>\n <p><b>Beta-Blockers Interacting Members</b> Arotinolol, Carvedilol*, Celiprolol, Metoprolol*, Nebivolol*, Oxprenolol, Pindolol*, Propranolol*, Timolol (Ophthalmic), Timolol (Systemic)<br><b>Exceptions</b> Acebutolol, Atenolol, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Carteolol (Ophthalmic), Esmolol, Labetalol, Levobunolol, Metipranolol, Nadolol, Penbutolol, Sotalol</p>\n <p><b>Selective Serotonin Reuptake Inhibitors Interacting Members</b> Dapoxetine, FLUoxetine*, PARoxetine, Sertraline, Vilazodone, Vortioxetine<br><b>Exceptions</b> Citalopram, Escitalopram, FluvoxaMINE</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Clinical studies describe increased exposure (up to 5-6 fold increases in AUC) to certain beta-blockers (propranolol, metoprolol, pindolol, carvedilol, nebivolol) when given concomitantly with the selective serotonin reuptake inhibitors (SSRIs) paroxetine and fluoxetine.<sup>1,2,3,4,5,6,7</sup> While these pharmacokinetic changes have generally not been associated with toxicity in clinical studies, case reports suggest some potential for clinically important effects such as atrioventricular block, bradycardia, syncope, and lethargy.<sup>8,9,10</sup><br><br>The likely primary mechanism of interaction between these groups of agents is SSRI inhibition of CYP2D6 mediated beta-blocker metabolism. Beta-blockers that are not known major CYP2D6 substrates and SSRIs that are not clinically significant inhibitors of this enzyme are therefore considered “exceptions” to this interaction until clinical data establish otherwise. <br><br>In addition to this pharmacokinetic interaction, pindolol has been investigated for possible potentiation of serotonergic responses to SSRIs based on 5-HT1A partial agonist/antagonist properties, although clinical study findings have been variable.<sup>11,12,13,14,15,16,17,18</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Goldberg MJ, Bergstrom RF, Cerimele BJ, et al, “Fluoxetine Effects on Pindolol Pharmacokinetics,” <i>Clin Pharmacol Ther</i>, 1997, 61(2):178.</p>\n<p>2. Lindamood C, Ortiz S, Shaw A, et al, “Effects of Commonly Administered Agents and Genetics on Nebivolol Pharmacokinetics: Drug-Drug Interaction Studies,” <i>J Clin Pharmacol</i>, 2011, 51(4):575-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20489028\">[PubMed 20489028]</a></p>\n<p>3. Stout SM, Nielsen J, Bleske BE, et al, “The Impact of Paroxetine Coadministration on Stereospecific Carvedilol Pharmacokinetics,” <i>J Cardiovasc Pharmacol Ther</i>, 2010, 15(4):373-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20705902\">[PubMed 20705902]</a></p>\n<p>4. Goryachkina K, Burbello A, Boldueva S, et al, “Inhibition of Metoprolol Metabolism and Potentiation of its Effects by Paroxetine in Routinely Treated Patients with Acute Myocardial Infarction (AMI),” <i>Eur J Clin Pharmacol</i>, 2008, 64(3):275-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18043911\">[PubMed 18043911]</a></p>\n<p>5. Stout SM, Nielsen J, Welage LS, et al, “Influence of Metoprolol Dosage Release Formulation on the Pharmacokinetic Drug Interaction With Paroxetine,” <i>J Clin Pharmacol</i>, 2011, 51(3):389-96. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20400652\">[PubMed 20400652]</a></p>\n<p>6. Hemeryck A, Lefebvre RA, De Vriendt C, “Paroxetine Affects Metoprolol Pharmacokinetics and Pharmacodynamics in Healthy Volunteers,” <i>Clin Pharmacol Ther</i>, 2000, 67(3):283-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10741632\">[PubMed 10741632]</a></p>\n<p>7. Graff DW, Williamson KM, Pieper JA, et al, “Effect of Fluoxetine on Carvedilol Pharmacokinetics, CYP2D6 Activity, and Autonomic Balance in Heart Failure Patients,” <i>J Clin Pharmacol</i>, 2001, 41(1):97-106. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11225566\">[PubMed 11225566]</a></p>\n<p>8. Drake WM and Gordon GD, “Heart Block in a Patient on Propranolol and Fluoxetine,” <i>Lancet</i>, 1994, 343(8894):425. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7905586\">[PubMed 7905586]</a></p>\n<p>9. Walley T, Pirmohamed M, Proudlove C, et al, “Interaction of Metoprolol and Fluoxetine,” <i>Lancet</i>, 1993, 341(8850):967-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8096308\">[PubMed 8096308]</a></p>\n<p>10. Onalan O, Cumurcu B, Bekar L, et al, “Complete Atrioventricular Block Associated With Concomitant Use of Metoprolol and Paroxetine,” <i>Mayo Clin Proc</i>, 2008;83(5):595-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18452693\">[PubMed 18452693]</a></p>\n<p>11. Bordet R, Thomas P and Dupuis B, “Effect of Pindolol on Onset of Action of Paroxetine in the Treatment of Major Depression: Intermediate Analysis of a Double-Blind, Placebo-Controlled Trial. Reseau de Recherche et d'Experimentation Psychopharmacologique,” <i>Am J Psychiatry</i>, 1998, 155(10):1346-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9766765\">[PubMed 9766765]</a></p>\n<p>12. Berman RM, Anand A, Cappiello A, et al, “The Use of Pindolol With Fluoxetine in the Treatment of Major Depression: Final Results From a Double-Blind, Placebo-Controlled Trial,” <i>Biol Psychiatry</i>, 1999, 45(9):1170-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10331109\">[PubMed 10331109]</a></p>\n<p>13. Stein MB, Sareen J, Hami S, et al, “Pindolol Potentiation of Paroxetine for Generalized Social Phobia: A Double-Blind, Placebo-Controlled, Crossover Study,” <i>Am J Psychiatry</i>, 2001, 158(10):1725-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11579011\">[PubMed 11579011]</a></p>\n<p>14. Perry EB, Berman RM, Sanacora G, et al, “Pindolol Augmentation in Depressed Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Double-Blind, Randomized, Controlled Trial,” <i>J Clin Psychiatry</i>, 2004, 65(2):238-43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15003079\">[PubMed 15003079]</a></p>\n<p>15. Sokolski KN, Conney JC, Brown BJ, et al, “Once-Daily High-Dose Pindolol for SSRI-Refractory Depression,” <i>Psychiatry Res</i>, 2004, 125(2):81-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15006431\">[PubMed 15006431]</a></p>\n<p>16. Segrave R, Croft RJ, Illic S, et al, “Pindolol Does Not Augment Central Serotonin Function Increases to Citalopram in Humans: An Auditory Evoked Potential Investigation,” <i>Pharmacol Biochem Behav</i>, 2006, 85(1):82-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16904172\">[PubMed 16904172]</a></p>\n<p>17. Geretsegger C, Bitterlich W, Stelzig R, et al, “Paroxetine With Pindolol Augmentation: A Double-Blind, Randomized, Placebo-Controlled Study in Depressed In-Patients,” <i>Eur Neuropsychopharmacol</i>, 2008, 18(2):141-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18054209\">[PubMed 18054209]</a></p>\n<p>18. Portella MJ, de Diego-Adelino J, Ballesteros J, et al, “Can We Really Accelerate and Enhance the Selective Serotonin Reuptake Inhibitor Antidepressant Effect? A Randomized Clinical Trial and a Meta-Analysis of Pindolol in Nonresistant Depression,” <i>J Clin Psychiatry</i>, 2010, Oct 19. Epub ahead of print. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21034693\">[PubMed 21034693]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2928":"<p><b>Title</b> Chloramphenicol (Systemic) / Barbiturates</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Chloramphenicol (Systemic) may decrease the metabolism of Barbiturates. Barbiturates may increase the metabolism of Chloramphenicol (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of chloramphenicol if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. In addition, monitor for increased effects of barbiturates if chloramphenicol is initiated/dose increased, or decreased effects if chloramphenicol is discontinued/dose decreased.</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital, Butabarbital, Butalbital, Methohexital, PENTobarbital, PHENobarbital*, Primidone, Secobarbital, Thiopental</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Chloramphenicol serum peak and trough concentrations were noted to be decreased by 34% and 44%, respectively, in a group of children receiving concomitant phenobarbital therapy compared with a group who were not.<sup>1</sup> Two other pediatric patients appeared to have had their chloramphenicol serum concentrations suppressed during concomitant phenobarbital therapy.<sup>2</sup> This interaction is presumably due to phenobarbital's ability to induce the CYP isoenzymes responsible for chloramphenicol metabolism. In addition to these effects, a case report describes a patient who experienced a significant decrease in phenobarbital serum concentrations following discontinuation of chloramphenicol (such even in the face of increased dosage of the phenobarbital).<sup>3</sup> The mechanism of this latter interaction is likely related to a reduction in phenobarbital metabolism induced by chloramphenicol.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Krasinski K, Kusmiesz H, and Nelson JD, “Pharmacological Interactions Among Chloramphenicol, Phenytoin, and Phenobarbital,” <i>Pediatr Infect Dis</i>, 1990, 12(Suppl 3):S327-33.</p>\n<p>2. Bloxham RA, Durbin GM, Johnson T, et al, “Chloramphenicol and Phenobarbitone - A Drug Interaction,” <i>Arch Dis Child</i>, 1979, 54:76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=311186\">[PubMed 311186]</a></p>\n<p>3. Koup JR, Gibaldi M, McNamara P, et al, “Interaction of Chloramphenicol With Phenytoin and Phenobarbital. Case Report,” <i>Clin Pharmacol Ther</i>, 1978, 24:571. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=699481\">[PubMed 699481]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2930":"<p><b>Title</b> Chloramphenicol (Systemic) / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> RifAMPin may increase the metabolism of Chloramphenicol (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of chloramphenicol if rifampin is initiated/dose increased, or increased serum concentrations/toxic effects if rifampin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Four case reports describe an 80% (average) decrease in serum chloramphenicol concentrations in pediatric patients within 3-4 days of initiating rifampin therapy.<sup>1,2</sup> The extent of this interaction is presumably sufficient to reduce the therapeutic efficacy of the chloramphenicol. The mechanism of this interaction is likely related to the ability of rifampin to induce the CYP isoenzymes responsible for chloramphenicol metabolism (possibly CYP2B glucuronidation).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prober CG, “Effect of Rifampin on Chloramphenicol Levels,” <i>N Engl J Med</i>, 1985, 312:788-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3974656\">[PubMed 3974656]</a></p>\n<p>2. Kelly HW, Couch RC, Davis RL, et al, “Interaction of Chloramphenicol and Rifampin,” <i>J Pediatr</i>, 1988, 112:817-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3258909\">[PubMed 3258909]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2931":"<p><b>Title</b> Antipsychotic Agents (Phenothiazines) / Antimalarial Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antimalarial Agents may increase the serum concentration of Antipsychotic Agents (Phenothiazines). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for toxic effects of phenothiazines if antimalarial agents are initiated/dose increased, or decreased effects if antimalarial agents are discontinued/dose decreased.</p>\n<div>\n <p><b>Antimalarial Agents Interacting Members</b> Amodiaquine, Artemether, Artenimol, Artesunate, Chloroquine, Halofantrine, Hydroxychloroquine, Lumefantrine, Mefloquine, Piperaquine, Primaquine, Proguanil, Pyrimethamine*, QuiNINE</p>\n <p><b>Antipsychotic Agents (Phenothiazines) Interacting Members</b> ChlorproMAZINE*, FluPHENAZine, Methotrimeprazine, Periciazine, Perphenazine, Pipotiazine, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Serum chlorpromazine concentrations, measured 3 hours after an oral dose, were found to be increased in 15 patients who received 1 of 3 different antimalarial agents (chloroquine 400 mg, amodiaquine 600 mg, or a combination of sulfadoxine 1500 mg plus pyrimethamine 75 mg).<sup>1</sup> The chlorpromazine concentrations were increased three- to fourfold over preantimalarial concentrations. Subjective evaluations revealed heavier sedation in patients following administration of the antimalarial agents. The mechanism of these interactions is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Makanjuola RO, Dixon PA, and Oforah E, “Effects of Antimalarial Agents on Plasma Levels of Chlorpromazine and Its Metabolites in Schizophrenic Patients,” <i>Trop Geogr Med</i>, 1988, 40:31-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3381314\">[PubMed 3381314]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2933":"<p><b>Title</b> Methotrexate / Aminoquinolines (Antimalarial)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Aminoquinolines (Antimalarial) may decrease the serum concentration of Methotrexate. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of methotrexate if aminoquinoline antimalarials are initiated/dose increased, or toxic effects if aminoquinoline antimalarials are discontinued/dose decreased.</p>\n<div>\n <p><b>Aminoquinolines (Antimalarial) Interacting Members</b> Chloroquine*, Hydroxychloroquine, Primaquine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of methotrexate in 11 patients receiving 15 mg/week was decreased an average of 28% when the dose was administered concurrent with chloroquine 250 mg.<sup>1</sup> The effects of multiple doses of chloroquine on methotrexate disposition are unknown, but could reach clinically important levels. The mechanism of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Seideman P, Albertioni F, Beck O, et al, “Chloroquine Reduces the Bioavailability of Methotrexate in Patients With Rheumatoid Arthritis. A Possible Mechanism of Reduced Hepatotoxicity,” <i>Arthritis Rheum</i>, 1994, 37(6):830-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8003056\">[PubMed 8003056]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2934":"<p><b>Title</b> Anthelmintics / Aminoquinolines (Antimalarial)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Aminoquinolines (Antimalarial) may decrease the serum concentration of Anthelmintics. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of anthelmintics if aminoquinoline antimalarials are initiated/dose increased.</p>\n<div>\n <p><b>Aminoquinolines (Antimalarial) Interacting Members</b> Chloroquine*, Hydroxychloroquine, Primaquine</p>\n <p><b>Anthelmintics Interacting Members</b> Albendazole, Mebendazole, Praziquantel*, Pyrantel Pamoate, Thiabendazole<br><b>Exception</b> Niclosamide</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC and peak serum concentrations of a single dose of praziquantel (40 mg/kg) were reduced 65% and 59%, respectively, in 8 normal subjects when administered 2 hours after a single dose of chloroquine (600 mg).<sup>1</sup> These changes, if sustained, could decrease the efficacy of praziquantel. The mechanism of this interaction is unknown. The effect of other antimalarials or anthelmintics is also unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Masimirembwa CM, Naik YS, and Hasler JA, “The Effect of Chloroquine on the Pharmacokinetics and Metabolism of Praziquantel in Rats and Humans,” <i>Biopharm Drug Dispoa</i>, 1994, 15:33-43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8161714\">[PubMed 8161714]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2935":"<p><b>Title</b> Antipsychotic Agents (Phenothiazines) / Alpha-/Beta-Agonists</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Alpha-/Beta-Agonists may enhance the arrhythmogenic effect of Antipsychotic Agents (Phenothiazines). Thioridazine is of most concern. <b>Severity</b> Major <b>Onset</b> Immediate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Though only a single case report exists, the fatal outcome warrants consideration in avoiding the use of alpha-/beta-agonists and/or antihistamines in patients receiving phenothiazines (especially thioridazine in combination with an anticholinergic agent). The alpha-/beta-agonist is more likely than the antihistamine to be the problem-causing agent. Monitor for evidence of ventricular arrhythmias during concomitant use. In addition, monitor for muted pressor effects of the alpha-/beta-agonists in patients receiving phenothiazines. The use of epinephrine in local anesthetics should pose no clinical concern.</p>\n<div>\n <p><b>Alpha-/Beta-Agonists Interacting Members</b> Amezinium, DOPamine, Ephedra, EPHEDrine (Nasal), EPHEDrine (Systemic), EPINEPHrine (Nasal), EPINEPHrine (Oral Inhalation), EPINEPHrine (Systemic), Isometheptene, Levonordefrin, Metaraminol, Norepinephrine, Pseudoephedrine</p>\n <p><b>Antipsychotic Agents (Phenothiazines) Interacting Members</b> ChlorproMAZINE*, FluPHENAZine, Methotrimeprazine, Periciazine, Perphenazine, Pipotiazine, Prochlorperazine, Promazine, Thioridazine*, Trifluoperazine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case report. Patient receiving chronic thioridazine (100 mg/day) and procyclidine (5 mg/day) died within 2 hours of receiving a single dose of phenylpropanolamine (50 mg) plus chlorpheniramine (4 mg).<sup>1</sup> Thioridazine has been reported to cause ventricular arrhythmias/sudden death.<sup>2</sup> The contribution of either the alpha-/beta-agonist or the antihistamine, in combination with the anticholinergic effects of procyclidine, to the fatality in this case is unknown. The widespread use of these agents would suggest that the incidence of any such interaction is very low. The temporal relationship of dose administration, along with the severity of outcome, warrants caution. In addition, some (not all) data has indicated that the pressor effects of agents such as epinephrine may be diminished (even paradoxically reversed) in patients receiving agents such as chlorpromazine.<sup>3,4</sup> The phenothiazine may block the peripheral alpha effects of the alpha-/beta-agonists, leaving the beta (vasodilating) effects unopposed.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Chouinard G, Ghadirian AM, and Jones BD, “Death Attributed to Ventricular Arrhythmia Induced by Thioridazine in Combination With a Single <i>Contac C</i> Capsule,” <i>Can Med Assoc J</i>, 1978, 119(7):729. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=709472\">[PubMed 709472]</a></p>\n<p>2. Giles TD and Modlin RK, “Death Associated With Ventricular Arrhythmia and Thioridazine Hydrochloride,” <i>JAMA</i>, 1968, 205:108-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5694867\">[PubMed 5694867]</a></p>\n<p>3. Foster CA, “Chlorpromazine: A Study of Its Action on the Circulation in Man,” <i>Lancet</i>, 1954, 2:614-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13202451\">[PubMed 13202451]</a></p>\n<p>4. Yagiela JA, Duffin SR, and Hunt LM, “Drug Interaction and Vasoconstrictors Used in Local Anesthetic Solutions,” <i>Oral Surg Oral Med Oral Pathol</i>, 1985, 59:565. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3892411\">[PubMed 3892411]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2938":"<p><b>Title</b> Beta-Blockers / Antipsychotic Agents (Phenothiazines)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antipsychotic Agents (Phenothiazines) may enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased therapeutic or toxic effects of both phenothiazines and beta-blockers if these agents are used concomitantly. It is possible that the use of renally-eliminated beta-blockers (eg, atenolol, and nadolol) may minimize this interaction. Ophthalmic beta-blockers are not likely of concern. Beta-blockers are commonly used to treat antipsychotic-induced akathisia.</p>\n<div>\n <p><b>Antipsychotic Agents (Phenothiazines) Interacting Members</b> ChlorproMAZINE*, FluPHENAZine, Methotrimeprazine, Periciazine, Perphenazine, Pipotiazine, Prochlorperazine, Promazine, Thioridazine*, Trifluoperazine</p>\n <p><b>Beta-Blockers Interacting Members</b> Acebutolol, Arotinolol, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Esmolol, Labetalol, Metoprolol, Nebivolol, Oxprenolol, Penbutolol, Pindolol, Propranolol*, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)<br><b>Exceptions</b> Atenolol, Levobunolol, Metipranolol, Nadolol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Mean steady state serum propranolol concentrations increased an average of 70% in 5 subjects following the addition of chlorpromazine (50 mg) to their regimens.<sup>1</sup> A severe case of orthostatic hypotension was described in the same report.<sup>1</sup> Thioridazine has been reported to increase serum pindolol concentrations.<sup>2</sup> Conversely, serum chlorpromazine concentrations were increased two- to sixfold in 7 patients following the addition of propranolol.<sup>3</sup> Another report describes increases in both chlorpromazine and thiothixene serum concentrations, with concomitant delirium and grand mal seizures, in a patient following the addition of propranolol.<sup>4</sup> Thioridazine serum concentrations increased four- to fivefold in 2 patients within 4-6 weeks of initiating propranolol.<sup>5</sup> It is likely that each of these agent groups inhibits the metabolism of the other. Beta-blockers that are renally excreted may thus be less likely to be affected by phenothiazines. It is also likely that the hypotension noted with concomitant use is simply an outcome of the additive hypotensive effects of the individual agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Vestal RE, Kornhauser DM, Hollifield JW, et al, “Inhibition of Propranolol Metabolism by Chlorpromazine,” <i>Clin Pharmacol Ther</i>, 1979, 25:19. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=758241\">[PubMed 758241]</a></p>\n<p>2. Greendyke RM and Gulya A, “Effect of Pindolol Administration on Serum Levels of Thioridazine, Haloperidol, and Phenobarbital,” <i>J Clin Psychiatry</i>, 1988, 49:105-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3346197\">[PubMed 3346197]</a></p>\n<p>3. Peet M, Middlemiss DN, and Yates RA, “Pharmacokinetic Interaction Between Propranolol and Chlorpromazine in Schizophrenic Patients,” <i>Lancet</i>, 1980, ii:978. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6107617\">[PubMed 6107617]</a></p>\n<p>4. Miller FA and Rampling D, “Adverse Effects of Combined Propranolol and Chlorpromazine Therapy,” <i>Am J Psychiatry</i>, 1982, 139:1198-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6810714\">[PubMed 6810714]</a></p>\n<p>5. Silver JM, Yudofsky SC, Kogan M, et al, “Elevation of Thioridazine Plasma Levels by Propranolol,” <i>Am J Psychiatry</i>, 1986, 143:1290-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3766793\">[PubMed 3766793]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2939":"<p><b>Title</b> Serotonin Reuptake Inhibitor/Antagonists / Antipsychotic Agents (Phenothiazines)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Serotonin Reuptake Inhibitor/Antagonists. Specifically, this may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. Serotonin Reuptake Inhibitor/Antagonists may enhance the hypotensive effect of Antipsychotic Agents (Phenothiazines). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use caution with concurrent use of any serotonin modulator (e.g., trazodone, nefazodone, etc.) with an antipsychotic. Monitor patients extra closely for evidence of serotonin toxicity (e.g., mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (e.g., hyperthermia, muscle rigidity, autonomic dysfunction). Additionally, monitor patients closely for signs and symptoms of hypotension for at least 2 weeks following the start of concomitant therapy with phenothiazines and a serotonin reuptake inhibitor/antagonist such as nefazodone or trazodone. This risk for orthostatic hypotension may be less significant with nefazodone than with trazodone.</p>\n<div>\n <p><b>Serotonin Reuptake Inhibitor/Antagonists Interacting Members</b> Nefazodone, TraZODone*</p>\n <p><b>Antipsychotic Agents (Phenothiazines) Interacting Members</b> ChlorproMAZINE*, FluPHENAZine, Methotrimeprazine, Periciazine, Perphenazine, Pipotiazine, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Several published case reports describe symptoms consistent with serotonin syndrome in patients receiving an antipsychotic agent together with a serotonin modulator (most involved serotonergic antidepressants).<sup>1,2,3,4,5,6,7</sup> In another report, 17 cases of apparent olanzapine-related neuroleptic malignant syndrome (NMS) were analyzed to determine the degree of overlapping symptoms with serotonin syndrome, and according to this report, most of the NMS cases possessed several characteristics of serotonin syndrome, suggesting a possible association between these conditions.<sup>8</sup> Consistent with this, several case reports describe apparent NMS attributed to concurrent use of an antipsychotic agent with a serotonergic antidepressant.<sup>9,10,11,12,13</sup> The prescribing information for many of the relevant drugs also warn that concurrent use could increase the risk for serotonin syndrome or NMS. <br><br>The specific mechanism for any apparent interaction is unclear, though one hypothesis for potential NMS-related symptoms focuses on the ability of serotonin to decrease dopamine release, exacerbating the dopamine blockade caused by many antipsychotics.<sup>14</sup><br><br>In addition, two case reports describe signs and symptoms of hypotension in patients taking phenothiazines (chlorpromazine, trifluoperazine) that developed within 2-14 days of starting trazodone (100 mg/day).<sup>15</sup> The blood pressure returned to normal within 1-2 days of discontinuing the trazodone in each case. The mechanism for this potential interactions is unknown, but may be related to additive/synergistic blood pressure-lowering effects of the individual agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Verre M, Bossio F, Mammone A, et al, “Serotonin Syndrome Caused by Olanzapine and Clomipramine,” <i>Minerva Anestesiol</i>, 2008, 74(1-2):41-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18004234\">[PubMed 18004234]</a></p>\n<p>2. Kohen I, Gordon ML, Manu P, “Serotonin Syndrome in Elderly Patients Treated for Psychotic Depression with Atypical Antipsychotics and Antidepressants: Two Case Reports,” <i>CNS Spectr</i>, 2007, 12(8):596-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17667887\">[PubMed 17667887]</a></p>\n<p>3. Kaufman KR, Levitt MJ, Schiltz JF, et al, “Neuroleptic Malignant Syndrome and Serotonin Syndrome in the Critical Care Setting: Case Analysis,” <i>Ann Clin Psychiatry</i>, 2006, 18(3):201-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16923659\">[PubMed 16923659]</a></p>\n<p>4. Marlowe K, Schirgel D, “Quetiapine and Citalopram: Aetiological Significances in Serotonin Syndrome,” <i>N Z Med J</i>, 2006, 119(1237):U2058. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16862204\">[PubMed 16862204]</a></p>\n<p>5. Chopra P, Ng C, Schweitzer I, “Serotonin Syndrome Associated with Fluoxetine and Olanzapine,” <i>World J Biol Psychiatry</i>, 2004, 5(2):114-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15179671\">[PubMed 15179671]</a></p>\n<p>6. Karki SD, Masood GR, “Combination Risperidone and SSRI-Induced Serotonin Syndrome,” <i>Ann Pharmacother</i>, 2003, 37(3):388-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12639169\">[PubMed 12639169]</a></p>\n<p>7. Fisher AA, Davis MW, “Serotonin Syndrome Caused by Selective Serotonin Reuptake-Inhibitors-Metoclopramide Interaction,” <i>Ann Pharmacother</i>, 2002, 36(1):67-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11816261\">[PubMed 11816261]</a></p>\n<p>8. Kontaxakis VP, Havaki-Kontaxaki BJ, Christodoulou NG, et al, “Olanzapine-Associated Neuroleptic Malignant Syndrome: Is there an Overlap with the Serotonin Syndrome?” <i>Ann Gen Hosp Psychiatry</i>, 2003, 2(1):10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14613516\">[PubMed 14613516]</a></p>\n<p>9. Kim JM, Lee ST, Song EC, et al, “Neurotoxic Syndrome Developed After Taking Sertraline and Risperidone,” <i>J Clin Neurol</i>, 2007, 3(3):165-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19513287\">[PubMed 19513287]</a></p>\n<p>10. Gambassi G, Capurso S, Tarsitani P, et al, “Fatal Neuroleptic Malignant Syndrome in a Previously Long-Term User of Clozapine Following its Reintroduction in Combination with Paroxetine,” <i>Aging Clin Exp Res</i>, 2006, 18(3):266-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16804375\">[PubMed 16804375]</a></p>\n<p>11. Matsumoto R, Kitabayashi Y, Nakatomi Y, et al, “Neuroleptic Malignant Syndrome Induced by Quetiapine and Fluvoxamine,” <i>Am J Psychiatry</i>, 2005, 162(4):812. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15800166\">[PubMed 15800166]</a></p>\n<p>12. Duggal HS, Kithas J, “Possible Neuroleptic Malignant Syndrome with Aripiprazole and Fluoxetine,” <i>Am J Psychiatry</i>, 2005, 162(2):397-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15677611\">[PubMed 15677611]</a></p>\n<p>13. Kontaxakis VP, Havaki-Kontaxaki BJ, Pappa DA, et al, “Neuroleptic Malignant Syndrome After Addition of Paroxetine to Olanzapine,” <i>J Clin Psychopharmacol</i>, 2003, 23(6):671-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14624202\">[PubMed 14624202]</a></p>\n<p>14. Stevens DL, “Association between Selective Serotonin-Reuptake Inhibitors, Second-Generation Antipsychotics, and Neuroleptic Malignant Syndrome,” <i>Ann Pharmacother</i>, 2008, 42(9):1290-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18628446\">[PubMed 18628446]</a></p>\n<p>15. Asayesh K, “Combination of Trazodone and Phenothiazines: A Possible Additive Hypotensive Effect,” <i>Can J Psychiatry</i>, 1986, 31:857-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3802006\">[PubMed 3802006]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2940":"<p><b>Title</b> Nonsteroidal Anti-Inflammatory Agents / Bile Acid Sequestrants</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Bile Acid Sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. Ibuprofen appears to be minimally affected, particularly when administered with colestipol. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.</p>\n<div>\n <p><b>Bile Acid Sequestrants Interacting Members</b> Cholestyramine Resin*, Colesevelam, Colestipol*</p>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen*, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic)*, Piroxicam (Topical), Propyphenazone, Sulindac*, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of diclofenac was reduced by 62% in 6 normal subjects when coadministered with cholestyramine.<sup>1</sup> Colestipol reduced diclofenac AUC by 33% in the same study.<sup>1</sup> Cholestyramine reduced the AUC of sulindac in 6 normal subjects by 78% when coadministered, and by 44% when the sulindac was administered 3 hours prior to the cholestyramine.<sup>2</sup> Ibuprofen appears to be affected less by cholestyramine and not at all by colestipol.<sup>3</sup> The clearance of oral piroxicam was increase by 52% in 8 normal subjects when they also received cholestyramine (4 g 3 times/day). The mechanism of these interactions is likely twofold. Initial absorption of the nonsteroidal anti-inflammatory agent (NSAID) is probably decreased due to binding with the bile acid sequestrant in the GI tract when the agents administered concurrently. In addition, enterohepatic circulation is likely disrupted when the NSAID is excreted into the bile, offering another opportunity for binding to the bile acid sequestrant. As such, separating doses of the agents would not be likely to completely eliminate the risk of the interaction. The clinical effects of reduced NSAID serum concentrations will vary widely. The effect of colesevelam is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Al-Balla SR, El-Sayed YM, Al-Meshal MA, et al, “The Effects of Cholestyramine and Colestipol on the Absorption of Diclofenac in Man,” <i>Int J Clin Pharmacol Ther</i>, 1994, 32:441-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7981930\">[PubMed 7981930]</a></p>\n<p>2. Malloy MJ, Ravis WR, Pennell AT, et al, “Influence of Cholestyramine Resin Administration on Single Dose Sulindac Pharmacokinetics,” <i>Int J Clin Pharmacol Ther</i>, 1994, 32:286-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7921528\">[PubMed 7921528]</a></p>\n<p>3. Al-Meshal MA, El-Sayed YM, Al-Balla SR, et al, “The Effect of Colestipol and Cholestyramine on Ibuprofen Bioavailability in Man,” <i>Biopharm Drug Dispoa</i>, 1994, 15:463-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7993984\">[PubMed 7993984]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2941":"<p><b>Title</b> Cardiac Glycosides / Bile Acid Sequestrants</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of cardiac glycosides are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Bile Acid Sequestrants may decrease the absorption of Cardiac Glycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of cardiac glycosides if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. Colestipol may be less likely to interact than cholestyramine.</p>\n<div>\n <p><b>Bile Acid Sequestrants Interacting Members</b> Cholestyramine Resin*, Colestipol*<br><b>Exception</b> Colesevelam</p>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin*, Digoxin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of digoxin was decreased by 32% in normal subjects when coadministered with cholestyramine (8 g/day).<sup>1</sup> Other reports describe similar changes in digoxin or digitoxin serum concentrations or markers thereof (eg, reduced urinary recovery of digoxin).<sup>2,3,4,5,6,7</sup> In contrast, a 1-year, 10-patient study showed no significant changes in digoxin or digitoxin serum concentrations while the patients were receiving 12 g of cholestyramine 1.5 hours after glycoside administration.<sup>8</sup> In addition, a single dose study failed to demonstrate appreciable changes in digoxin concentrations when administered with colestipol (10 g).<sup>9</sup> The mechanism of these interactions is likely related to the binding of the cardiac glycosides to the bile acid sequestrant in the GI tract, thus inhibiting absorption and interrupting enterohepatic circulation. The effect of colestipol appears minimal, and the effect of cholestyramine is variable. Colesevelam does not significantly affect the bioavailability of digoxin.<sup>10</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Brown DD, Schmidt J, Long RA, et al, “A Steady-State Evaluation of the Effects of Propantheline Bromide and Cholestyramine of the Bioavailability of Digoxin When Administered as Tablets or Capsules,” <i>J Clin Pharmacol</i>, 1985, 25:360-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4031112\">[PubMed 4031112]</a></p>\n<p>2. Brown DD, Juhl RP, and Warner SL, “Decreased Bioavailability of Digoxin Produced by Dietary Fibre and Cholestyramine,” <i>Am J Cardiol</i>, 1977, 39:297.</p>\n<p>3. Hall WH, Shappell SD, and Doherty JE, “Effect of Cholestyramine on Digoxin Absorption and Excretion in Man,” <i> Am J Cardiol</i>, 1977, 39:213. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=835478\">[PubMed 835478]</a></p>\n<p>4. Caldwell JH and Greenberger NJ, “Cholestyramine Enhances Digitalis Excretion and Protects Against Lethal Intoxication,” <i>Clin Invest Med</i>, 1970, 49:16a.</p>\n<p>5. Caldwell JH, Bush CA, and Greenberger NJ, “Interruption of the Enterohepatic Circulation of Digitoxin by Cholestyramine,” <i>J Clin Invest</i>, 1971, 50:2638. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5129315\">[PubMed 5129315]</a></p>\n<p>6. Carruthers SG and Dujovne CA, “Cholestyramine and Spironolactone and Their Combination in Digitoxin Elimination,” <i>Clin Pharmacol Ther</i>, 1980, 27:184. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7353337\">[PubMed 7353337]</a></p>\n<p>7. Brown DD, Juhl RP, and Warner SL, “Decreased Bioavailability of Digoxin Due to Hypocholesterolemic Interventions,” <i>Circulation</i>, 1978, 58:164. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=647881\">[PubMed 647881]</a></p>\n<p>8. Bazzano G and Bazzano GS, “Effects of Digitalis Binding Resins on Cardiac Glycoside Plasma Levels,” <i>Clin Res</i>, 1972, 20:24.</p>\n<p>9. Neuvonen PJ, Kivisto K, Hirvisalo EL, et al, “Effects of Resins and Activated Charcoal on the Absorption of Digoxin, Carbamazepine and Furosemide,” <i>Br J Clin Pharmacol</i>, 1988, 25:229-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3358884\">[PubMed 3358884]</a></p>\n<p>10. Prescribing information. Welchol (colesevelam). Parsippany, NJ: Daiichi Sankyo, Inc, 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2942":"<p><b>Title</b> Loop Diuretics / Bile Acid Sequestrants</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of loop diuretics are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Bile Acid Sequestrants may decrease the absorption of Loop Diuretics. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of loop diuretics if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.</p>\n<div>\n <p><b>Bile Acid Sequestrants Interacting Members</b> Cholestyramine Resin*, Colesevelam, Colestipol*</p>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide*, Torsemide</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Six normal subjects received furosemide (40 mg oral) with and without a bile acid sequestrant (cholestyramine 8 mg; colestipol 10 g). When received with a bile acid sequestrant, the AUC and diuretic response to furosemide was significantly reduced (95% and 77%, respectively by cholestyramine; 80% and 58%, respectively by colestipol).<sup>1</sup> The bile acid sequestrant likely binds to the furosemide in the GI tract, thus reducing its absorption. The effect on other loop diuretics is unknown. The effect of colesevelam is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Neuvonen PJ, Kivisto K, and Hirvisalo EL, “Effects of Resins and Activated Charcoal on the Absorption of Digoxin, Carbamazepine, and Furosemide,” <i>Br J Clin Pharmacol</i>, 1988, 25(2):229-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3358884\">[PubMed 3358884]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2943":"<p><b>Title</b> Corticosteroids (Oral) / Bile Acid Sequestrants</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Bile Acid Sequestrants may decrease the absorption of Corticosteroids (Oral). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of oral corticosteroids if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.</p>\n<div>\n <p><b>Bile Acid Sequestrants Interacting Members</b> Cholestyramine Resin*, Colesevelam, Colestipol*</p>\n <p><b>Corticosteroids (Oral) Interacting Members</b> Budesonide (Systemic), Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone, PrednisoLONE (Systemic), PredniSONE</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of an oral dose of hydrocortisone was decreased approximately 43% in ten normal subjects when coadministered with cholestyramine (4 g).<sup>1</sup> The decrease was greater with 8 g doses administered to some of these same subjects. A case report describes the development of symptoms of hypopituitarism in a hydrocortisone-stable patient within 4 days of starting colestipol (15 g 3 times/day).<sup>2</sup> Intragut binding of the bile acid sequestrant and the corticosteroid are the likely mechanism of this interaction. The effect of colesevelam is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Johansson C, Adamsson U, Stierner U, et al, “Interaction of Cholestyramine on the Uptake of Hydrocortisone in the Gastrointestinal Tract,” <i>Acta Med Scand</i>, 1978, 204:509-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=735882\">[PubMed 735882]</a></p>\n<p>2. Nekl KE and Aron DC, “Hydrocortisone-Colestipol Interaction,” <i>Ann Pharmacother</i>, 1993, 27:980-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8364291\">[PubMed 8364291]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2944":"<p><b>Title</b> Methotrexate / Bile Acid Sequestrants</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Bile Acid Sequestrants may decrease the absorption of Methotrexate. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of methotrexate if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.</p>\n<div>\n <p><b>Bile Acid Sequestrants Interacting Members</b> Cholestyramine Resin*, Colesevelam, Colestipol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Cholestyramine has been successfully used to treat methotrexate toxicity (whether oral or IV).<sup>1,2</sup> Serum methotrexate concentrations have been reduced by 50% within 24 hours of cholestyramine administration compared to noncholestyramine therapy cycles.<sup>1</sup> Cholestyramine apparently binds to methotrexate in the GI tract, thus inhibiting absorption and interrupting the enterohepatic circulation of the agent. The effect of other bile acid sequestrants is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Erttmann R and Landbeck G, “Effect of Oral Cholestyramine on the Elimination of High-Dose Methotrexate,” <i>J Cancer Res Clin Oncol</i>, 1985, 110:48. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4019569\">[PubMed 4019569]</a></p>\n<p>2. Ellman MH, Telfer MC, and Turner AF, “Benefit of G-CSF for Methotrexate-Induced Neutropenia in Rheumatoid Arthritis,” <i>Am J Med</i>, 1992, 92:337-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1372153\">[PubMed 1372153]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2945":"<p><b>Title</b> Thyroid Products / Bile Acid Sequestrants</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): This interaction has only been demonstrated with orally administered thyroid products.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Bile Acid Sequestrants may decrease the serum concentration of Thyroid Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Administer oral thyroid products at least 4 hours prior to colesevelam and at least 1 hour before or 4-6 hours after cholestyramine. Specific recommendations for colestipol are not available. Monitor for decreased serum concentrations and clinical effects of oral thyroid products if coadministered with any bile acid sequestrant.</p>\n<div>\n <p><b>Bile Acid Sequestrants Interacting Members</b> Cholestyramine Resin*, Colesevelam*, Colestipol</p>\n <p><b>Thyroid Products Interacting Members</b> Levothyroxine*, Liothyronine, Liotrix, Thyroid, Desiccated*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Coadministration of colesevelam with oral levothyroxine has led to decreases in levothyroxine exposure in several clinical investigations in healthy volunteers: simultaneous colesevelam (3.75-4 g) dosing decreased levothyroxine (0.6-1 mg) average maximum concentration (Cmax) by 73% (one study only) and AUC by 68-94%, adjusted for baseline levothyroxine concentrations (uncorrected/absolute decreases were 33% and 22%, respectively, in one study);<sup>1,2,3</sup> colesevelam (4 g) dosing 1 hour after levothyroxine (0.6 mg) decreased levothyroxine Cmax by 7% and AUC by 20% (uncorrected/absolute decreases 2% and 6%, respectively);<sup>1,2</sup> and colesevelam (4 g) dosing 4 hours after levothyroxine (0.6 mg) was associated with slight increases in levothyroxine Cmax with no change in AUC.<sup>1,2</sup> Two case reports describe an approximate doubling in fecal recovery of orally administered levothyroxine when given to patients receiving cholestyramine (4 g four times/day),<sup>4</sup> and several published case reports describe changes (laboratory and clinical) consistent with reduced concentrations and/or effects of exogenous levothyroxine during cholestyramine treatment.<sup>5,6,7,8,9</sup><br><br>Bile acid sequestrants likely bind thyroid products in the gastrointestinal tract, thereby decreasing absorption and possibly interrupting enterohepatic circulation. Bile acid sequestrants may facilitate excretion of endogenous thyroid hormones in patients with hyperthyroidism or thyrotoxicosis, based on a number of case reports and clinical studies identifying a potential adjunctive role for bile acid sequestrants in these settings.<sup>10,11,12,13,14,15</sup> However, no studies to date have identified such effects in other populations. One clinical study noted that colestipol (30 g/day) in combination with niacin (3-6 g/day) was associated with declines in thyroxine binding globulin as well as total and free thyroxine concentrations in euthyroid patients,<sup>16</sup> but colestipol alone was not associated with such changes in another clinical study.<sup>17</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Welchol (colesevelam). Parsippany, NJ: Daiichi Sankyo, Inc., 6/2012.</p>\n<p>2. Brown KS, Armstrong IC, Wang A, et al, “Effect of the Bile Acid Sequestrant Colesevelam on the Pharmacokinetics of Pioglitazone, Repaglinide, Estrogen Estradiol, Norethindrone, Levothyroxine, and Glyburide,” <i>J Clin Pharmacol</i>, 2010, 50(5):554-65. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19789374\">[PubMed 19789374]</a></p>\n<p>3. Weitzman SP, Ginsburg KC and Carlson HE, “Colesevelam Hydrochloride and Lanthanum Carbonate Interfere With the Absorption of Levothyroxine,” <i>Thyroid</i>, 2009, 19(1):77-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19119983\">[PubMed 19119983]</a></p>\n<p>4. Northcutt RC, Stiel JN, Hollifield JW, et al, “The Influence of Cholestyramine on Thyroxine Absorption,” <i>JAMA</i>, 1969, 208:1857. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5818830\">[PubMed 5818830]</a></p>\n<p>5. Harmon SM and Seifert CF, “Levothyroxine-Cholestyramine Interaction Re-emphasized,” <i>Ann Intern Med</i>, 1991, 115:658-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1892339\">[PubMed 1892339]</a></p>\n<p>6. Shakir KM, Michaels RD, Hays JH, et al, “The Use of Bile Acid Sequestrants to Lower Serum Thyroid Hormones in Iatrogenic Hyperthyroidism,” <i>Ann Intern Med</i>, 1993, 15;118(2):112-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8416306\">[PubMed 8416306]</a></p>\n<p>7. de Luis DA, Duenas A, Martin J, et al, “Light Symptoms Following a High-Dose Intentional L-Thyroxine Ingestion Treated With Cholestyramine,” <i>Horm Res</i>, 2002, 57(1-2):61-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12006723\">[PubMed 12006723]</a></p>\n<p>8. Rosenberg R, “Malabsorption of Thyroid Hormone With Cholestyramine Administration,” <i>Conn Med</i>, 1994, 58(2):109. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8004946\">[PubMed 8004946]</a></p>\n<p>9. Lehrner LM and Weir MR, “Acute Ingestions of Thyroid Hormones,” <i>Pediatrics</i>, 1984, 73(3):313-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6701055\">[PubMed 6701055]</a></p>\n<p>10. Solomon BL, Wartofsky L and Burman KD, “Adjunctive Cholestyramine Therapy for Thyrotoxicosis,” <i>Clin Endocrinol (Oxf)</i>, 1993, 38(1):39-43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8435884\">[PubMed 8435884]</a></p>\n<p>11. Sebastian-Ochoa A, Quesada-Charneco M, Fernandez-Garcia D, et al, “Dramatic Response to Cholestyramine in a Patient With Graves' Disease Resistant to Conventional Therapy,” <i>Thyroid</i>, 2008, 18(10):1115-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18816181\">[PubMed 18816181]</a></p>\n<p>12. Tsai WC, Pei D, Wang TF, et al, “The Effect of Combination Therapy With Propylthiouracil and Cholestyramine in the Treatment of Graves' Hyperthyroidism,” <i>Clin Endocrinol (Oxf)</i>, 2005, 62(5):521-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15853819\">[PubMed 15853819]</a></p>\n<p>13. Mercado M, Mendoza-Zubieta V, Bautista-Osorio R, et al, “Treatment of Hyperthyroidism With a Combination of Methimazole and Cholestyramine,” <i>J Clin Endocrinol Metab</i>, 1996, 81(9):3191-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8784067\">[PubMed 8784067]</a></p>\n<p>14. Kaykhaei MA, Shams M, Sadegholvad A, et al, “Low Doses of Cholestyramine in the Treatment of Hyperthyroidism,” <i>Endocrine</i>, 2008, 34(1-3):52-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18946743\">[PubMed 18946743]</a></p>\n<p>15. Hagag P, Nissenbaum H and Weiss M, “Role of Colestipol in the Treatment of Hyperthyroidism,” <i>J Endocrinol Invest</i>, 1998, 21(11):725-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9972670\">[PubMed 9972670]</a></p>\n<p>16. Cashin-Hemphill L, Spencer CA, Nicoloff JT, et al, “Alterations in Serum Thyroid Hormonal Indices With Colestipol-Niacin Therapy,” <i>Ann Intern Med</i>, 1987, 107(3):324-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3113309\">[PubMed 3113309]</a></p>\n<p>17. Witztum JL, Jacobs LS and Schonfeld G, “Thyroid Hormone and Thyrotropin Levels in Patients Placed on Colestipol Hydrochloride,” <i>J Clin Endocrinol Metab</i>, 1978, 46(5):838-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=262768\">[PubMed 262768]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2946":"<p><b>Title</b> Vitamin K Antagonists / Bile Acid Sequestrants</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Bile Acid Sequestrants may decrease the absorption of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of oral coumarin derivatives if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction.</p>\n<div>\n <p><b>Bile Acid Sequestrants Interacting Members</b> Cholestyramine Resin*, Colesevelam*, Colestipol</p>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Concomitant administration of warfarin and cholestyramine (8 g 3 times/day with one dose administered 30 minutes after warfarin) decreased peak serum warfarin concentrations by more than 50% and decreased the prothrombin time by more than 25%.<sup>1</sup> When the cholestyramine was administered 6 hours after the warfarin, the serum concentration and prothrombin time changes were reduced 16% and 0%, respectively. Similar results have been reported elsewhere.<sup>2</sup> Another study showed that total warfarin clearance was increased with cholestyramine administration, even when the warfarin was administered IV.<sup>3</sup> The mechanism of this interaction is possibly related to the ability of cholestyramine to bind warfarin in the GI tract both upon initial presentation and during the course of enterohepatic cycling. Colesevelam does not significantly affect the bioavailability of warfarin,<sup>4</sup> but post-marketing reports have described INR reductions associated with the initiation of colesevelam in patients previously stabilized on warfarin.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kuentzel WP and Brunk SF, “Cholestyramine-Warfarin Interaction,” <i>Clin Res</i>, 1970, 18:594.</p>\n<p>2. Robinson DA, Benjamin DM, and McCormack JJ, “Interaction of Warfarin and Nonsystemic Gastrointestinal Drugs,” <i>Clin Pharmacol Ther</i>, 1971, 12:491. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5567801\">[PubMed 5567801]</a></p>\n<p>3. Jahnchen E, Meinertz T, Gilfrich HJ, et al, “Enhanced Elimination of Warfarin During Treatment With Cholestyramine,” <i>Br J Clin Pharmacol</i>, 1978, 5(5):437-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=656283\">[PubMed 656283]</a></p>\n<p>4. Prescribing information. Welchol (colesevelam). Parsippany, NJ: Daiichi Sankyo, Inc, 1/2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2947":"<p><b>Title</b> Cisapride / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Cisapride. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider alternatives to cimetidine due to a potential for increased cisapride concentrations/toxicity (e.g. cardiac arrhythmias). If this combination cannot be avoided, monitor for toxic effects of cisapride following cimetidine initiation/dose increase, or decreased efficacy following cimetidine discontinuation/dose decrease.</p> \n<p><b>Discussion</b> In a clinical study of 8 healthy volunteers, the AUC of cisapride (10 mg 3 times/day) was increased by 45% by coadministration of cimetidine (400 mg 3 times/day for 1 week).<sup>1</sup> <br><br>The likely primary mechanism of this interaction is cimetidine to inhibition of CYP3A4 mediated cisapride metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kirch W, Janisch HD, Ohnhaus EE, et al, “Cisapride-Cimetidine Interaction: Enhanced Cisapride Bioavailability and Accelerated Cimetidine Absorption,” <i>Ther Drug Monit</i>, 1989, 11(4):411-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2741189\">[PubMed 2741189]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2948":"<p><b>Title</b> Selective Serotonin Reuptake Inhibitors / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cimetidine may decrease the metabolism of Selective Serotonin Reuptake Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider using an alternative H<sub>2</sub>-antagonist to avoid the risk of selective serotonin reuptake inhibitor (SSRI) toxicity. Monitor for increased therapeutic or toxic effects of SSRI if cimetidine is initiated/dose increased, or decreased effects if cimetidine is discontinued/dose decreased.</p>\n<div>\n <p><b>Selective Serotonin Reuptake Inhibitors Interacting Members</b> Citalopram*, Dapoxetine, Escitalopram, FLUoxetine, FluvoxaMINE, PARoxetine*, Sertraline, Vilazodone, Vortioxetine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of citalopram (40 mg/day) was increased by 43% in healthy subjects when coadministered with cimetidine (400 mg twice daily) for 7 days.<sup>1</sup> A study in 16 healthy subjects administered cimetidine (400 mg twice daily) for 4 days and escitalopram (20 mg) found an increase of 72% in AUC of escitalopram and a small, statistically insignificant increase in maximum plasma concentration.<sup>2</sup> Similar 7-day studies using femoxetine and paroxetine showed a 140% increase in serum trough concentrations of femoxetine and 51% increases in paroxetine AUC.<sup>3,4</sup> No effects on clinical outcome were reported in these studies. The mechanism of these interactions is likely related to the ability of cimetidine to inhibit CYP isoenzymes involved in metabolizing SSRIs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Priskorn M, Larsen F, Segonzac A, et al, “Pharmacokinetic Interaction Study of Citalopram and Cimetidine in Healthy Subjects,” <i>Eur J Clin Pharmacol</i>, 1997, 52:241-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9218934\">[PubMed 9218934]</a></p>\n<p>2. Mailing D, Poulsen MN, Sogaard B, “The Effect of Cimetidine or Omeprazole on the Pharmacokinetics of Escitalopram in Healthy Subjects,” <i>Br J Clin Pharmacol</i>, 2005, 60(3):287-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16120067\">[PubMed 16120067]</a></p>\n<p>3. Schmidt J, Sorensen AS, Gjerris A, et al, “Femoxetine and Cimetidine: Interaction in Healthy Volunteers,” <i>Eur J Clin Pharmacol</i>, 1986, 31:299-302. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3792427\">[PubMed 3792427]</a></p>\n<p>4. Bannister SJ, Houser VP, Hulse JD, et al, “Evaluation of the Potential for Interactions of Paroxetine With Diazepam, Cimetidine, Warfarin, and Digoxin,” <i>Acta Psychiatr Scand</i>, 1989, 80(Suppl 350):102-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2530759\">[PubMed 2530759]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2949":"<p><b>Title</b> Bisphosphonate Derivatives / Calcium Salts</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of calcium salts and bisphosphonate derivatives are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.</p>\n<div>\n <p><b>Bisphosphonate Derivatives Interacting Members</b> Alendronate, Clodronate, Etidronate, Ibandronate, Risedronate, Tiludronate<br><b>Exceptions</b> Pamidronate, Zoledronic Acid</p>\n <p><b>Calcium Salts Interacting Members</b> Calcium Acetate, Calcium Carbonate, Calcium Chloride, Calcium Citrate, Calcium Glubionate, Calcium Gluconate, Calcium Lactate, Polycarbophil</p>\n</div> \n<p><b>Discussion</b> The manufacturers of all oral bisphosphonate derivatives caution that absorption may be impaired by concomitant oral intake of calcium supplements.<sup>1,2,3,4,5,6</sup> The likely primary mechanism of this interaction is binding of the bisphosphonate derivative to calcium ions to form a nonabsorbable (or very poorly absorbable) chelate.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Skelid (tiludronate disodium) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; March 2010.</p>\n<p>2. Actonel (risedronate sodium) [prescribing information]. North Norwich, NY: Norwich Pharmaceuticals Inc; April 2015.</p>\n<p>3. Fosamax (alendronate sodium) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; February 2015.</p>\n<p>4. Bonefos (clodronate disodium) [product monograph]. Toronto, Ontario, Canada: Bayer Inc; September 2011.</p>\n<p>5. Didronel (etidronate disodium) [prescribing information]. North Norwich, NY: Norwich Pharmaceuticals Inc; April 2015.</p>\n<p>6. Boniva (ibandronate sodium) [prescribing information]. South San Francisco, CA: Genentech USA Inc; April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2950":"<p><b>Title</b> CloZAPine / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of CloZAPine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider use of an alternative H2 antagonist. Monitor for increased toxic effects of clozapine if cimetidine is initiated/dose increased, or decreased effects if cimetidine is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The average serum clozapine (900 mg/day) concentration increased by approximately 60% in a patient following the addition of oral cimetidine (800 mg/day).<sup>1</sup> No clinical problems accompanied this concentration change. Approximately 3 months later, the cimetidine dose was increased to 1200 mg. Within 3 days, the patient exhibited symptoms of clozapine toxicity (e.g. diaphoresis, dizziness, vomiting, weakness). The symptoms resolved following discontinuation of the cimetidine and a reduction in the dose of clozapine. The clozapine dose was subsequently returned to 900 mg daily, and the patient received ranitidine (300 mg/day) without incident. <br><br>The mechanism of this presumed interaction is likely related to the ability of cimetidine to inhibit the CYP isoenzymes (e.g. CYP 1A2) that metabolize clozapine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Szymanski S, Lieberman JA, Picou D, et al. A case report of cimetidine-induced clozapine toxicity. <i>J Clin Psychiatry</i>. 1991;52:21-22. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1988413\">[PubMed 1988413]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2951":"<p><b>Title</b> Tricyclic Antidepressants / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cimetidine may decrease the metabolism of Tricyclic Antidepressants. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for toxic effects of tricyclic antidepressants if cimetidine is initiated/dose increased, or decreased effects if cimetidine is discontinued/dose decreased. Consider the use of an alternative H<sub>2</sub>-antagonist to avoid this interaction.</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline*, Amoxapine, ClomiPRAMINE, Desipramine*, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine*, Lofepramine, Melitracen [INT], Nortriptyline*, Protriptyline, Trimipramine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The peak serum concentrations, steady state serum concentrations, and AUC of tricyclic antidepressants are increased by coadministration of cimetidine.<sup>1,2,3,4,5,6</sup> Case reports describe increases in the normally tolerable side effects of tricyclic antidepressants following the addition of cimetidine.<sup>7,8,9,10</sup> One report suggests that increases in desipramine serum concentrations may only take place to a significant extent in rapid hydroxylators.<sup>11</sup> Ranitidine does not appear to negatively affect tricyclics.<sup>12,13</sup> The mechanism of these interactions is likely related to the ability of cimetidine to inhibit the CYP isoenzymes that may metabolize the tricyclic antidepressants.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Curry SH, De Vane CL, and Wolfe MM, “Cimetidine Interaction With Amitriptyline,” <i>Eur J Clin Pharmacol</i>, 1985, 29:429-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3912187\">[PubMed 3912187]</a></p>\n<p>2. Amsterdam JD, Brunswick DJ, Potter L, et al, “Cimetidine-Induced Alterations in Desipramine Plasma Concentrations,” <i>Psychopharmacology</i>, 1984, 83:373-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6436867\">[PubMed 6436867]</a></p>\n<p>3. Abernethy DR and Todd EL, “Doxepin-Cimetidine Interaction: Increased Bioavailability During Cimetidine Treatment,” <i>J Clin Psychopharmacol</i>, 1986, 6:8-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3950073\">[PubMed 3950073]</a></p>\n<p>4. Sutherland DL, Remillard AJ, Haight KR, et al, “The Influence of Cimetidine Versus Ranitidine on Doxepin Pharmacokinetics,” <i>Eur J Clin Pharmacol</i>, 1987, 32:159-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3582480\">[PubMed 3582480]</a></p>\n<p>5. Wells BG, Pieper JA, Self TH, et al, “The Effect of Ranitidine and Cimetidine on Imipramine Disposition,” <i>Eur J Clin Pharmacol</i>, 1986, 31:285-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=379426\">[PubMed 379426]</a></p>\n<p>6. Henauer SA and Hollister LE, “Cimetidine Interaction With Imipramine and Nortriptyline,” <i>Clin Pharmacol Ther</i>, 1984, 35:183-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6692646\">[PubMed 6692646]</a></p>\n<p>7. Brown MA, Haight KR, and McKay G, “Cimetidine-Doxepin Interaction,” <i>J Clin Psychopharmacol</i>, 1985, 5:245-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4019813\">[PubMed 4019813]</a></p>\n<p>8. Shapiro PA, “Cimetidine-Imipramine Interaction: Case Report and Comments,” <i>Am J Psychiatry</i>, 1984, 141:152. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6691449\">[PubMed 6691449]</a></p>\n<p>9. Miller DD and Macklin M, “Cimetidine-Imipramine Interaction: A Case Report,” <i>Am J Psychiatry</i>, 1983, 140:351. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6829810\">[PubMed 6829810]</a></p>\n<p>10. Miller DD, Sawyer JB, and Duffy JP, “Cimetidine’s Effect on Steady-State Serum Nortriptyline Concentrations,” <i>Drug Intell Clin Pharm</i>, 1983, 17(12):904-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6653407\">[PubMed 6653407]</a></p>\n<p>11. Steiner E and Spina E, “Differences in the Inhibitory Effect of Cimetidine on Desipramine Metabolism Between Rapid and Slow Debrisoquin Hydroxylators,” <i>Clin Pharmacol Ther</i>, 1987, 42:278-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3621787\">[PubMed 3621787]</a></p>\n<p>12. Curry SH, DeVane CL, and Wolfe MM, “Lack of Interaction of Ranitidine With Amitriptyline,” <i>Eur J Clin Pharmacol</i>, 1987, 32:317-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3595705\">[PubMed 3595705]</a></p>\n<p>13. Wells BG, Pieper JA, Self TH, et al, “The Effect of Ranitidine and Cimetidine on Imipramine Disposition,” <i>Eur J Clin Pharmacol</i>, 1986, 31:285-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3792426\">[PubMed 3792426]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2952":"<p><b>Title</b> Calcium Channel Blockers / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Calcium Channel Blockers. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider alternatives to cimetidine in patients receiving the calcium channel blockers included in this monograph. If no suitable alternative to cimetidine exists, monitor for increased effects of these calcium channel blockers following cimetidine initiation/dose increase, or decreased effects following cimetidine discontinuation/dose decrease.</p>\n<div>\n <p><b>Calcium Channel Blockers Interacting Members</b> Barnidipine, Benidipine, Bepridil, Cilnidipine, DilTIAZem*, Efonidipine, Felodipine*, Isradipine, Lacidipine, Lercanidipine, Manidipine, NIFEdipine*, Nilvadipine, NiMODipine*, Nisoldipine*, Nitrendipine, Verapamil<br><b>Exceptions</b> AmLODIPine, Clevidipine, NiCARdipine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUCs of calcium channel blockers are frequently increased in patients who also receive cimetidine. The following increases have been seen in clinical studies: diltiazem (50%),<sup>1</sup> felodipine (56%),<sup>2</sup> nifedipine (31-100%),<sup>3,4,5,6,7,8</sup> nisoldipine (50%);<sup>9</sup> and nimodipine (82%).<sup>10</sup> AUCs of nitrendipine (0-154%)<sup>11,12</sup> and verapamil (0-28%)<sup>13,14,15,16,17</sup> may or may not be affected by cimetidine coadministration, as these effects have been variable in clinical studies to date. Studies have shown no impact of cimetidine on amlodipine and nicardipine pharmacokinetics.<sup>18,19</sup><br><br>Most of the pharmacokinetic changes described above resulted in little or no change in measured clinical effects of the calcium channel blockers. However, most of these studies were conducted using single calcium channel blocker doses in healthy volunteers, and effects could theoretically be greater with multiple dosing in patients eligible for calcium channel blocker treatment. The likely primary mechanism of interaction between cimetidine and most calcium channel blockers is cimetidine inhibition of CYP3A4 mediated calcium channel blocker metabolism Elevated gastric pH could also cause minor increases in bioavailability of some calcium channel blockers.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Winship LC, McKenney JM, Wright JT, et al, “The Effect of Ranitidine and Cimetidine on Single-Dose Diltiazem Pharmacokinetics,” <i>Pharmacotherapy</i>, 1985, 5(1):16-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3982974\">[PubMed 3982974]</a></p>\n<p>2. Janzon K, Edgar B, Lundborg P, et al, “The Influence of Cimetidine and Spironolactone on the Pharmacokinetics and Haemodynamic Effects of Felodipine in Healthy Subjects,” <i>Acta Pharmacol Toxicol</i>, 1986, 59(Suppl 4):98.</p>\n<p>3. Kirch W, Ramsch K, Janisch HD, et al, “The Influence of Two Histamine H2-Receptor Antagonists, Cimetidine, and Ranitidine on the Plasma Levels and Clinical Effect of Nifedipine and Metoprolol,” <i>Arch Toxicol Suppl</i>, 1984, 7:256-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6151387\">[PubMed 6151387]</a></p>\n<p>4. Khan A, Langley SJ, Mullins FG, et al, “The Pharmacokinetics and Pharmacodynamics of Nifedipine at Steady State During Concomitant Administration of Cimetidine or High Dose Ranitidine,” <i>Br J Clin Pharmacol</i>, 1991, 32(4):519-22. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1958451\">[PubMed 1958451]</a></p>\n<p>5. Schellens JH, van der Wart JH, Brugman M, et al, “Influence of Enzyme Induction and Inhibition on the Oxidation of Nifedipine, Sparteine, Mephenytoin and Antipyrine in Humans as Assessed by a ”Cocktail“ Study Design,” <i>J Pharmacol Exp Ther</i>, 1989, 249(2):638-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2724144\">[PubMed 2724144]</a></p>\n<p>6. Schwartz JB, Upton RA, Lin ET, et al, “Effect of Cimetidine or Ranitidine Administration on Nifedipine Pharmacokinetics and Pharmacodynamics,” <i>Clin Pharmacol Ther</i>, 1988, 43(6):673-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3378388\">[PubMed 3378388]</a></p>\n<p>7. Smith SR, Kendall MJ, Lobo J, et al, “Ranitidine and Cimetidine; Drug Interactions With Single Dose and Steady-State Nifedipine Administration,” <i>Br J Clin Pharmacol</i>, 1987, 23(3):311-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3567045\">[PubMed 3567045]</a></p>\n<p>8. Renwick AG, Le Vie J, Challenor VF, et al, “Factors Affecting the Pharmacokinetics of Nifedipine,” <i>Eur J Clin Pharmacol</i>, 1987, 32(4):351-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3609112\">[PubMed 3609112]</a></p>\n<p>9. van Harten J, van Brummelen P, Lodewijks MT, et al, “Pharmacokinetics and Hemodynamic Effects of Nisoldipine and its Interaction With Cimetidine,” <i>Clin Pharmacol Ther</i>, 1988, 43(3):332-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3345623\">[PubMed 3345623]</a></p>\n<p>10. Muck W, Wingender W, Seiberling M, et al, “Influence of the H2-Receptor Antagonists Cimetidine and Ranitidine on the Pharmacokinetics of Nimodipine in Healthy Volunteers,” <i>Eur J Clin Pharmacol</i>, 1992, 42:325-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1577052\">[PubMed 1577052]</a></p>\n<p>11. Soons PA, Vogels BA, Roosemalen MC, et al, “Grapefruit Juice and Cimetidine Inhibit Stereoselective Metabolism of Nitrendipine in Humans,” <i>Clin Pharmacol Ther</i>, 1991, 50(4):394-403. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1914375\">[PubMed 1914375]</a></p>\n<p>12. Kirch W, Hutt HJ, Heidemann H, et al, “Drug Interactions With Nitrendipine,” <i>J Cardiovasc Pharmacol</i>, 1984, 6 Suppl 7:S982-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6085389\">[PubMed 6085389]</a></p>\n<p>13. Mikus G, Eichelbaum M, Fischer C, et al, “Interaction of Verapamil and Cimetidine: Stereochemical Aspects of Drug Metabolism, Drug Disposition and Drug Action,” <i>J Pharmacol Exp Ther</i>, 1990, 1042-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2359015\">[PubMed 2359015]</a></p>\n<p>14. Abernethy DR, Schwartz JB and Todd EL, “Lack of Interaction Between Verapamil and Cimetidine,” <i>Clin Pharmacol Ther</i>, 1985, 38(3):342-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4028631\">[PubMed 4028631]</a></p>\n<p>15. Loi CM, Rollins DE, Dukes GE, et al, “Effect of Cimetidine on Verapamil Disposition,” <i>Clin Pharmacol Ther</i>, 1985, 37(6):654-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4006365\">[PubMed 4006365]</a></p>\n<p>16. Wing LM, Miners JO and Lillywhite KJ, “Verapamil Disposition--Effects of Sulphinpyrazone and Cimetidine,” <i>Br J Clin Pharmacol</i>, 1985, 19(3):385-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3986090\">[PubMed 3986090]</a></p>\n<p>17. Smith MS, Benyunes MC, Bjornsson TD, et al, “Influence of Cimetidine on Verapamil Kinetics and Dynamics,” <i>Clin Pharmacol Ther</i>, 1984, 36(4):551-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6478741\">[PubMed 6478741]</a></p>\n<p>18. Quoted as Unpublished Data, Pfizer Central Research by Abernethy DR, “Amlodipine: Pharmacokinetic Profile of a Low-Clearance Calcium Antagonist,” <i>J Cardiovasc Pharmacol</i>, 1991, 17(Suppl 1):S4-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16296697\">[PubMed 16296697]</a></p>\n<p>19. Loi CM, McEntegart CM, Maher KE, et al, “The Effects of IV Cimetidine on the Pharmacokinetics and Pharmacodynamics of IV Nicardipine in Man,” <i>Pharm Res</i>, 1994, 11(Suppl 10):S-386.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2953":"<p><b>Title</b> Dofetilide / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Dofetilide. This is likely via inhibition of dofetilide renal tubular secretion (primarily) and inhibition of dofetilide metabolism. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Dofetilide prescribing information lists the combination of cimetidine and dofetilide as contraindicated. Consider using an alternative H2-antagonist to avoid the potential toxic effects of dofetilide. Monitor for increased toxic effects (eg, QTc prolongation) of dofetilide if cimetidine is initiated/dose increased, or decreased effects if cimetidine is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Dofetilide concentrations were an average of 58% higher with concurrent administration of cimetidine 400 mg twice daily, according to the dofetilide prescribing information.<sup>1</sup> With a lower cimetidine dose of 100 mg twice daily the dofetilide concentration was 13% higher.<sup>1</sup> The AUC of single doses of dofetilide (500 mcg) were increased up to 48% in 20 healthy subjects when administered following 4 days of cimetidine (400 mg twice daily).<sup>2</sup> Lower cimetidine doses (100 mg twice daily) had reduced pharmacokinetic changes. Both renal and nonrenal clearance was affected. The QTc effect of dofetilide was significantly increased with both doses of cimetidine. Cimetidine likely affects these changes due to its ability to a) inhibit the hepatic metabolism of dofetilide (CYP3A4); and b) inhibit the renal clearance of dofetilide (inhibition of renal cation secretion mediated by MATE1 and/or OCTs).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tikosyn (dofetilide) [prescribing information]. New York, NY: Pfizer Inc; March 2016.</p>\n<p>2. Abel S, Nichols DJ, Brearley CJ, Eve MD. Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide. <i>Br J Clin Pharmacol</i>. 2000;49(1):64-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10606839\">[PubMed 10606839]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2954":"<p><b>Title</b> MetFORMIN / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of MetFORMIN. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Consider alternatives to cimetidine in patients receiving metformin due to a potential for increased metformin concentrations and toxicity (including lactic acidosis).</p> \n<p><b>Discussion</b> The AUC of metformin (250 mg/day) was increased 50% in 7 healthy volunteers following concomitant administration with cimetidine (400 mg twice daily) for 5 days.<sup>1</sup> In a second study of 15 healthy volunteers, cimetidine administration decreased metformin renal tubular clearance by 18.7% to 48.2%, depending on the individual's organic cation transporter 2 (OCT2) genotype.<sup>2</sup> Participants carrying the OCT2 808G&gt;T polymorphism had lower baseline tubular clearance of metformin and a correspondingly lower magnitude of interaction with cimetidine.<sup>2</sup><br><br>In addition to these clinical studies, 3 case reports describe patients receiving stable metformin therapy who developed metabolic acidosis after initiating cimetidine.<sup>3,4,5</sup><br><br>The presumed primary mechanism of this interaction is cimetidine inhibition of OCTs, particularly OCT2, resulting in reduced renal tubular secretion of metformin.<sup>1,2,6,7,8</sup> Based on in vitro data, gastric pH elevations induced by cimetidine or cimetidine inhibition of human multidrug and toxin extrusion 1 (hMATE1/SLC47A1) and hMATE2-K (SLC47A2)-mediated metformin transport may also contribute.<sup>7,9</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. Reduction of metformin renal tubular secretion by cimetidine in man. <i>Br J Clin Pharmacol</i>. 1987;23(5):545-551. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3593625\">[PubMed 3593625]</a></p>\n<p>2. Wang ZJ, Yin OQ, Tomlinson B, Chow MS. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. <i>Pharmacogenet Genomics</i>. 2008;18(7):637-645. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18551044\">[PubMed 18551044]</a></p>\n<p>3. Dawson D, Conlon C. Case study: metformin-associated lactic acidosis: could orlistat be relevant? <i>Diabetes Care</i>. 2003;26(8):2471-2472. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12882884\">[PubMed 12882884]</a></p>\n<p>4. Boehm KM, Gunaga S. Cimetidine-induced lactic acidosis and acute pancreatitis. <i>South Med J</i>. 2010;103(8):849. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20622719\">[PubMed 20622719]</a></p>\n<p>5. Seo JH, Lee da Y, Hong CW, Lee IH, Ahn KS, Kang GW. Severe lactic acidosis and acute pancreatitis associated with cimetidine in a patient with type 2 diabetes mellitus taking metformin. <i>Intern Med</i>. 2013;52(19):2245-2248. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24088760\">[PubMed 24088760]</a></p>\n<p>6. Glucophage (metformin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2009.</p>\n<p>7. Umehara KI, Iwatsubo T, Noguchi K, Usui T, Kamimura H. Effect of cationic drugs on the transporting activity of human and rat OCT/Oct 1-3 in vitro and implications for drug-drug interactions. <i>Xenobiotica</i>. 2008;38(9):1203-1218. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18686197\">[PubMed 18686197]</a></p>\n<p>8. Tsuda M, Terada T, Ueba M, et al. Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. <i>J Pharmacol Exp Ther</i>. 2009;329(1):185-191. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19164462\">[PubMed 19164462]</a></p>\n<p>9. Sultana N, Arayne MS, Ahmed N. In vitro availability of metformin in presence of h(2) receptor antagonists. <i>Pak J Pharm Sci</i>. 2006;19(1):28-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16632449\">[PubMed 16632449]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2955":"<p><b>Title</b> Adenosine / Nicotine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nicotine may enhance the AV-blocking effect of Adenosine. Nicotine may enhance the tachycardic effect of Adenosine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased therapeutic/toxic effects of adenosine if nicotine is initiated/dose increased, or decreased effects if nicotine is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Use of nicotine chewing gum (2 mg) concomitant with administration of adenosine caused an increase in heart rate, enhanced AV blocking activity, and increased the severity of chest pain when compared with adenosine alone.<sup>1,2</sup> <br><br>The mechanism of this presumed interaction is unclear. Both nicotine and adenosine can increase heart rate. The clinical significance of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Smits P, Eijsbouts A, and Thien T, “Nicotine Enhances the Circulatory Effects of Adenosine in Human Beings,” <i>Clin Pharmacol Ther</i>, 1989, 46:272-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2673620\">[PubMed 2673620]</a></p>\n<p>2. Sylven C, Beermann B, Kaijser L, et al, “Nicotine Enhances Angina Pectoris-Like Chest Pain and Atrioventricular Blockade Provoked by Intravenous Bolus of Adenosine in Healthy Volunteers,” <i>J Cardiovasc Pharmacol</i>, 1990, 16:962-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1704990\">[PubMed 1704990]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2956":"<p><b>Title</b> Nicotine / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Nicotine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased physiological effects of nicotine if cimetidine is initiated/dose increased, or decreased effects if cimetidine is discontinued/dose decreased.</p> \n<p><b>Discussion</b> In a clinical study of 6 healthy volunteers, the clearance of nicotine (1 mcg/kg/min intravenous for 30 minutes) decreased an average of 30% when administered following a 2-day course of cimetidine (600 mg orally twice daily).<sup>1</sup> <br><br>The primary mechanism of this interaction is likely cimetidine inhibition CYP1A2 mediated metabolism of nicotine. Cimetidine inhibition of nicotine metabolism via other CYP enzymes (e.g. 2C9, 2C19, 2D6, 2E1, 3A4) and / or competition with nicotine for renal excretion may also play a role. In the cited study, ranitidine had a minimal effect on nicotine disposition.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bendayan R, Sullivan JR, Shaw C, et al, “Effect of Cimetidine and Ranitidine on the Hepatic and Renal Elimination of Nicotine in Humans,” <i>Eur J Clin Pharmacol</i>, 1990, 38:165-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2338114\">[PubMed 2338114]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2958":"<p><b>Title</b> Praziquantel / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Praziquantel. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for signs/symptoms of praziquantel toxicity if cimetidine is initiated/dose increased, or decreased effects if cimetidine is discontinued/dose decreased. This interaction may be intentionally employed to enhance the effectiveness of praziquantel.</p> \n<p><b>Discussion</b> Two different case reports describe patients with neurocysticercosis resistant to prior praziquantel treatment that was successfully treated with the addition of cimetidine.<sup>1,2</sup> In one case, higher dose praziquantel (100 mg/kg/day) plus cimetidine (800 mg/day) was employed,<sup>1</sup> and in the other case, cimetidine (1600 mg/day) was added to ongoing praziquantel (50 mg/kg/day) therapy.<sup>2</sup> Pharmacokinetic data from the second case showed that the maximum serum concentration, half-life, and AUC were all substantially increased (by approximately 136%, 94%, and 300%, respectively) than with concurrent cimetidine.<sup>2</sup><br><br>Similarly, serum concentrations and AUC of praziquantel (25 mg/kg orally every 2 hours for 3 doses) were increased by approximately 100% in healthy subjects (n=8) when the subjects received cimetidine (400 mg).<sup>3</sup><br><br>The mechanism of this interaction is likely related to the ability of cimetidine to inhibit the cytochrome P450 enzyme(s) involved in the metabolism of praziquantel.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Yee T, Barakos JA, Knight RT, “High-Dose Praziquantel with Cimetidine for Refractory Neurocysticercosis: A Case Report with Clinical and MRI Follow-up,” <i>West J Med</i>, 1999, 170(2):112-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10063399\">[PubMed 10063399]</a></p>\n<p>2. Dachman WD, Adubofour KO, Bikin DS, et al, “Cimetidine-Induced Rise in Praziquantel Levels in a Patient with Neurocysticercosis Being Treated with Anticonvulsants,” <i>J Infect Dis</i>, 1994, 169(3):689-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8158054\">[PubMed 8158054]</a></p>\n<p>3. Jung H, Medina R, Castro N, et al, “Pharmacokinetic Study of Praziquantel Administered Alone and in Combination With Cimetidine in a Single-Day Therapeutic Regimen,” <i>Antimicrob Agents Chemother</i>, 1997, 41:1256-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9174180\">[PubMed 9174180]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2959":"<p><b>Title</b> Propafenone / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Propafenone. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for toxic effects of propafenone if cimetidine is initiated/dose increased, or decreased effects if cimetidine is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Propafenone (225 mg every 8 hours) maximum serum concentration (Cmax) increased by an average of 24% following 5 days of concomitant therapy with cimetidine (400 mg every 8 hours) in a study of 12 healthy volunteers.<sup>1</sup> One-third of the subjects experienced decreased serum concentrations (9%) and the other two-thirds experienced an average increase of 54%. QRS intervals were increased in some subjects, but the study investigators concluded that the observed pharmacodynamic and pharmacokinetic changes were unlikely to be of clinical significance.<br><br>The mechanism of this interaction is uncertain, but it is likely related to cimetidine inhibition of propafenone metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pritchett EL, Smith WM, and Kirsten EB, “Pharmacokinetic and Pharmacodynamic Interactions of Propafenone and Cimetidine,” <i>J Clin Pharmacol</i>, 1988, 28:619-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3063727\">[PubMed 3063727]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2960":"<p><b>Title</b> QuiNIDine / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of QuiNIDine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider alternatives to cimetidine in patients receiving quinidine. If the combination cannot be avoided, monitor for increased quinidine concentrations/toxicity with cimetidine initiation/dose increase, or decreased concentrations/effects with cimetidine discontinuation/dose decrease.</p> \n<p><b>Discussion</b> The half-life of quinidine was increased by 54% in 4 healthy volunteers when concomitantly administered with cimetidine (1200 mg/day) for 5 days.<sup>1</sup> Several case reports and small studies have confirmed this effect, showing increased quinidine concentrations, decreased clearance, or both with cimetidine coadministration.<sup>2,3,4,5,6</sup> Increases in quinidine AUC, when reported, have generally been small (less than 20%).<br><br>The likely primary mechanism of interaction between these drugs is cimetidine inhibition of CYP3A4 mediated quinidine metabolism. Additionally, based on a trend toward decreased renal clearance of quinidine seen in one study, cimetidine inhibition of quinidine renal clearance may also contribute.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. MacKichan JJ, Boudoulas H, and Schall SF, “Effect of Cimetidine on Quinidine Bioavailability,” <i>Biopharm Drug Dispoa</i>, 1989, 10(1):121-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2923957\">[PubMed 2923957]</a></p>\n<p>2. Hardy BG, Zador IT, Golden L, et al, “Effect of Cimetidine on the Pharmacokinetics and Pharmacodynamics of Quinidine,” <i>Am J Cardiol</i>, 1983, 52(1):172-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6858908\">[PubMed 6858908]</a></p>\n<p>3. Kolb KW, Garnett WR, Small RE, et al, “Effect of Cimetidine on Quinidine Clearance,” <i>Ther Drug Monit</i>, 1984, 6(3):306-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6506138\">[PubMed 6506138]</a></p>\n<p>4. Farringer JA, McWay-Hess K, and Clementi WA, “Cimetidine-Quinidine Interaction,” <i>Clin Pharm</i>, 1984, 3(1):81-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6697678\">[PubMed 6697678]</a></p>\n<p>5. Polish LB, Branch RA and Fitzgerald GA, “Digitoxin-Quinidine Interaction: Potentiation During Administration of Cimetidine,” <i>South Med J</i>, 1981, 74(5):633-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7244727\">[PubMed 7244727]</a></p>\n<p>6. Hardy BG and Schentag JJ, “Lack of Effect of Cimetidine on the Metabolism of Quinidine: Effect on Renal Clearance,” <i>Int J Clin Pharmacol Ther Toxicol</i>, 1988, 26(8):388-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3220613\">[PubMed 3220613]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2961":"<p><b>Title</b> Theophylline Derivatives / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cimetidine may decrease the metabolism of Theophylline Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for toxic effects of theophylline derivatives if cimetidine is initiated/dose increased, or decreased effects if cimetidine is discontinued/dose decreased. Consider using an alternative H<sub>2</sub>-antagonist. Consider a priori reduction in the dosage of theophylline if cimetidine is to be added to the patient's regimen.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Theophylline*<br><b>Exception</b> Dyphylline</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The half-life and serum concentrations of theophylline are increased in the presence of cimetidine to the extent that theophylline toxicity becomes evident in some patients.<sup>1,2,3,4,5,6,7,8,9</sup> The changes in serum concentrations vary widely, but likely increase 50% to 100% in many patients. The impact of tobacco smoking on the extent of this interaction is unclear. In contrast, theophylline clearance (from a continuous infusion of aminophylline, 10.8 mg/hr) was unaffected by a concurrent continuous infusion of cimetidine (50 mg/hr) for 48 hours.<sup>10</sup> The mechanism of this interaction is related to the ability of cimetidine to inhibit the CYP isoenzymes involved in metabolizing theophylline. Other H<sub>2</sub>-antagonists are not likely to affect theophylline disposition.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Weinberger MM, Smith G, Milavetz G, et al, “Decreased Clearance of Theophylline Due to Cimetidine,” <i>N Engl J Med</i>, 1981, 304(11):672. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7453750\">[PubMed 7453750]</a></p>\n<p>2. Campbell MA, Plachetka JR, Jackson JE, et al, “Cimetidine Decreases Theophylline Clearance,” <i>Ann Intern Med</i>, 1981, 95(1):68-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7247131\">[PubMed 7247131]</a></p>\n<p>3. Lofgren RP and Gilbertson RA, “Cimetidine and Theophylline,” <i>Ann Intern Med</i>, 1982, 96(3):378. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6800293\">[PubMed 6800293]</a></p>\n<p>4. Bauman JH, Kimelblatt BJ, Carracio TR, et al, “Cimetidine-Theophylline Interaction. Report of Four Patients,” <i>Ann Allergy</i>, 1982, 48(2):100-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6121526\">[PubMed 6121526]</a></p>\n<p>5. Powell JR, Rogers JF, Wargin WA, et al, “The Influence of Cimetidine vs Ranitidine on Theophylline Pharmacokinetics,” <i>Clin Pharmacol Ther</i>, 1982, 31:261.</p>\n<p>6. Vestal RE, Thummel KE, Musser B, et al, “Cimetidine Inhibits Theophylline Clearance in Patients With Chronic Obstructive Pulmonary Disease. A Study Using Stable Isotope Methodology During Multiple Oral Dose Administration,” <i>Br J Clin Pharmacol</i>, 1983, 15(4):411-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6849776\">[PubMed 6849776]</a></p>\n<p>7. Powell JR, Rogers JF, Wargin WA, et al, “Inhibition of Theophylline Clearance by Cimetidine But Not Ranitidine,” <i>Arch Intern Med</i>, 1984, 144(3):484-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6322709\">[PubMed 6322709]</a></p>\n<p>8. Cohen IA, Johnson CE, Berardi RR, et al, “Cimetidine-Theophylline Interactions: Effects of Age and Cimetidine Dose,” <i>Ther Drug Monit</i>, 1985, 7(4):426-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4082242\">[PubMed 4082242]</a></p>\n<p>9. Mulkey PM, Murphy JE, and Shleifer NH, “Steady-State Theophylline Pharmacokinetics During and After Short-Term Cimetidine Administration,” <i>Clin Pharm</i>, 1983, 2(5):439-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6627870\">[PubMed 6627870]</a></p>\n<p>10. Mojtahedzadeh M, Sadray S, Hadjibabaie M, et al, “Determination of Theophylline Clearance After Cimetidine Infusion in Critically Ill Patients,” <i>J Infus Nurs</i>, 2003, 26(4):234-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12869856\">[PubMed 12869856]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2962":"<p><b>Title</b> Quinolones / Didanosine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction is only expected with buffered didanosine preparations.</p></li>\n <li><p><b>Route</b> (oral): Only oral preparations of quinolone antibiotics are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Quinolones may decrease the serum concentration of Didanosine. Didanosine may decrease the serum concentration of Quinolones. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Administer oral quinolone antibiotics at least 2 hours before, or 6 hours after, didanosine. Monitor for decreased therapeutic effects of the quinolone, particularly if doses cannot be separated as recommended. This interaction is likely of much less clinical significance with the enteric coated didanosine capsule product.</p>\n<div>\n <p><b>Quinolones Interacting Members</b> Ciprofloxacin (Systemic)*, Delafloxacin, Gemifloxacin, LevoFLOXacin (Systemic), Lomefloxacin, Moxifloxacin (Systemic), Nalidixic Acid, Norfloxacin, Ofloxacin (Systemic), Pefloxacin, Pipemidic Acid, Sparfloxacin<br><b>Exception</b> LevoFLOXacin (Oral Inhalation)</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of ciprofloxacin (750 mg orally) was decreased by 98% in 12 healthy subjects when coadministered with 2 didanosine placebo tablets (containing all normal excipients/buffers but not didanosine).<sup>1</sup> Other studies have showed that giving the ciprofloxacin 2 hours before didanosine yielded smaller (up to 26%) decreases in absorption and acceptable serum ciprofloxacin concentrations.<sup>2,3,4</sup><br><br>The likely mechanism of this interaction is formation of an insoluble chelate of ciprofloxacin with aluminum and magnesium ions that are used as buffers in the didanosine formulation. Enteric coated didanosine capsules do not contain buffering agents and do not appear to affect the pharmacokinetic profile of ciprofloxacin to the same magnitude as the prior buffered formulation,<sup>4,5</sup> but the pediatric powder for oral solution is to be mixed with an antacid prior to administration and would be expected to have a higher risk for such chelation-type interactions.<sup>6</sup><br><br>Of note, the didanosine AUC and maximum serum concentration (Cmax) were an average of 18% and 28% lower, respectively, in a study of subjects (n=8) who received ciprofloxacin (750 mg every 12 hours for 3 days) given two hours prior to didanosine (200 mg every 12 hours for 3 days).<sup>4</sup> The clinical significance of this change is uncertain, and the mechanism for the interaction is similarly unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sahai J, Gallicano K, Oliveras L, et al, “Cations in the Didanosine Tablet Reduce Ciprofloxacin Bioavailability,” <i>Clin Pharmacol Ther</i>, 1993, 53:292-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8453847\">[PubMed 8453847]</a></p>\n<p>2. Sahai J, “Avoiding the Ciprofloxacin-Didanosine Interaction,” <i>Ann Intern Med</i>, 1995, 123:394-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7625637\">[PubMed 7625637]</a></p>\n<p>3. Knupp CA and Barbhaiya RH, “A Multiple-Dose Pharmacokinetic Interaction Study Between Didanosine (Videx) and Ciprofloxacin in Male Subjects Seropositive for HIV but Asymptomatic,” <i>Biopharm Drug Dispoa</i>, 1997, 18:65-77. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9008270\">[PubMed 9008270]</a></p>\n<p>4. Prescribing information. Videx EC (didanosine). Princeton, NJ: Bristol-Myers Squibb Company, December 2012.</p>\n<p>5. Damle BD, Mummaneni V, Kaul S, et al, “Lack of Effect of Simultaneously Administered Didanosine Encapsulated Enteric Bead Formulation (Videx EC) on Oral Absorption of Indinavir, Ketoconazole, or Ciprofloxacin,” <i>Antimicrob Agents Chemother</i>, 2002, 46(2):385-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11796346\">[PubMed 11796346]</a></p>\n<p>6. Prescribing information. Videx (didanosine) Pediatric Powder for Oral Solution. Princeton, NJ: Bristol-Myers Squibb Company, December 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2963":"<p><b>Title</b> Quinolones / Iron Salts</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): This interaction is only expected with the use of oral iron salts and oral quinolone antibiotics. Intravenous preparations are not expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Iron Salts may decrease the serum concentration of Quinolones. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Administer oral quinolones at least several hours before (4 h for moxifloxacin and sparfloxacin, 2 h for others) or after (8 h for moxifloxacin, 6 h for ciprofloxacin and delafloxacin, 4 h for lomefloxacin, 3 h for gemifloxacin, 2 h for levofloxacin, norfloxacin, ofloxacin, pefloxacin, or nalidixic acid) oral iron salts. Monitor for diminished effects of the quinolone if this duration of dose separation cannot be achieved.</p>\n<div>\n <p><b>Iron Salts Interacting Members</b> Ferric Citrate, Ferrous Fumarate, Ferrous Gluconate*, Ferrous Sulfate*, Iron Acetyltransferrin, Polysaccharide-Iron Complex, Sodium Feredetate<br><b>Exceptions</b> Ferric Carboxymaltose, Ferric Gluconate, Ferric Hydroxide Polymaltose Complex, Ferric Pyrophosphate Citrate, Ferumoxytol, Iron Dextran Complex, Iron Isomaltoside, Iron Sucrose</p>\n <p><b>Quinolones Interacting Members</b> Ciprofloxacin (Systemic), Delafloxacin, Gemifloxacin, LevoFLOXacin (Systemic), Lomefloxacin*, Moxifloxacin (Systemic), Nalidixic Acid, Norfloxacin*, Ofloxacin (Systemic), Pefloxacin, Pipemidic Acid, Sparfloxacin*<br><b>Exception</b> LevoFLOXacin (Oral Inhalation)</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The ability of iron salts to reduce the absorption of oral quinolones is well established and has been demonstrated in numerous pharmacokinetic studies.<sup>1,2,3,4,5,6,7,8,9,10</sup> Various oral iron salts have been reported to reduce quinolone AUCs by the following percentages: ciprofloxacin (33% to 70%), levofloxacin (19%), lomefloxacin (14%), moxifloxacin (61%), norfloxacin (51% to 73%), ofloxacin (25%), and sparfloxacin (28%).<sup>1,2,3,4,5,6,7,8</sup> The maximum serum concentrations of oral quinolones were reduced by the following percentages: ciprofloxacin (46% to 75%), levofloxacin (45%), lomefloxacin (28%), moxifloxacin (41%), norfloxacin (75% to 82%), ofloxacin (36%), and sparfloxacin (46%).<sup>1,2,3,4,5,6,7,8</sup> Case reports of ciprofloxacin treatment failure when combined with iron salts support these pharmacokinetic study findings.<sup>11,12</sup> <br><br>The effect of dose separation was evaluated in one study.<sup>13</sup> The gemifloxacin (320 mg single oral dose) AUC was unchanged when ferrous sulfate (325 mg single oral dose) was given 2 hours after and was reduced 11% (thought to be a clinically insignificant reduction) when ferrous sulfate was given 3 hours prior to gemifloxacin administration.<sup>13</sup> Specific dose separation recommendations aimed at minimizing these interactions are offered by the manufacturers of oral quinolone products.<sup>14,15,16,17,18,19,20,21,22,23,24</sup><br><br>The suspected primary mechanisms of these interactions are formation of an insoluble complex between the quinolone antibiotic and the iron salt that is not readily absorbed from the GI tract.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stass H, Kubitza D. Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans. <i>Clin Pharmacokinet</i>. 2001;40(suppl 1):57-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11352443\">[PubMed 11352443]</a></p>\n<p>2. Lehto P, Kivisto KT. Different effects of products containing metal ions on the absorption of lomefloxacin. <i>Clin Pharmacol Ther</i>. 1994;56(5):477-482. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7955811\">[PubMed 7955811]</a></p>\n<p>3. Lehto P, Kivisto KT, Neuvonen PJ. The effect of ferrous sulphate on the absorption of norfloxacin, ciprofloxacin and ofloxacin. <i>Br J Clin Pharmacol</i>. 1994;37(1):82-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8148225\">[PubMed 8148225]</a></p>\n<p>4. Kara M, Hasinoff BB, McKay DW, Campbell NR. Clinical and chemical interactions between iron preparations and ciprofloxacin. <i>Br J Clin Pharmacol</i>. 1991;31(3):257-261. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2054264\">[PubMed 2054264]</a></p>\n<p>5. Polk RE, Healy DP, Sahai J, Drwal L, Racht E. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. <i>Antimicrob Agents Chemother</i>. 1989;33(11):1841-1844. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2610494\">[PubMed 2610494]</a></p>\n<p>6. Kanemitsu K, Hori S, Yanagawa A, Shimada J. Effect of ferrous sulfate on the absorption of sparfloxacin in healthy volunteers and rats. <i>Drugs</i>. 1995;49(suppl 2):352-356. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8549359\">[PubMed 8549359]</a></p>\n<p>7. Shiba K, Sakai O, Shimada J, Okazaki O, Aoki H, Hakusui H. Effects of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans. <i>Antimicrob Agents Chemother</i>. 1992;36(10):2270-2274. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1444308\">[PubMed 1444308]</a></p>\n<p>8. Brouwers JR, Van der Kam HJ, Sijtsma J, Proost JH. Decreased ciprofloxacin absorption with concomitant administration of ferrous fumarate. <i>Pharm Weekbl Sci</i>. 1990;12(5):182-183. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2255585\">[PubMed 2255585]</a></p>\n<p>9. Martinez Cabarga M, Sanchez Navarro A, Colino Gandarillas CI, Dominguez-Gil A. Effects of two cations on gastrointestinal absorption of ofloxacin. <i>Antimicrob Agents Chemother</i>. 1991;35(10):2102-2105. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1759833\">[PubMed 1759833]</a></p>\n<p>10. Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW. Norfloxacin interaction with antacids and minerals. <i>Br J Clin Pharmacol</i>. 1992;33(1):115-116. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1540482\">[PubMed 1540482]</a></p>\n<p>11. LePennec MP, Kitzis MD, Terdjman M, Foubard S, Garbarz E, Hanania G. Possible interaction of ciprofloxacin with ferrous sulphate. <i>J Antimicrob Chemother</i>. 1990;25(1):184-185. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2318752\">[PubMed 2318752]</a></p>\n<p>12. Suda KJ, Garey KW, Danziger LH. Treatment failures secondary to drug interactions with divalent cations and fluoroquinolone. <i>Pharm World Sci</i>. 2005;27(2):81-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15999916\">[PubMed 15999916]</a></p>\n<p>13. Allen A, Bygate E, Faessel H, Isaac L, Lewis A. The effect of ferrous sulphate and sucralfate on the bioavailability of oral gemifloxacin in healthy volunteers. <i>Int J Antimicrob Agents</i>. 2000;15(4):283-289. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10929878\">[PubMed 10929878]</a></p>\n<p>14. Cipro (ciprofloxacin) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; February 2015.</p>\n<p>15. Factive (gemifloxacin) [prescribing information]. Toronto, Ontario, Canada: Merus Labs; August 2013. </p>\n<p>16. Levaquin (levofloxacin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; May 2014.</p>\n<p>17. Maxaquin (lomefloxacin) [prescribing information]. New York, NY: Pfizer Inc; March 2005.</p>\n<p>18. Avelox (moxifloxacin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2014.</p>\n<p>19. Neggram (nalidixic acid) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2012.</p>\n<p>20. Noroxin (norfloxacin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; August 2013.</p>\n<p>21. Floxin (ofloxacin) [prescribing information]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals Inc; February 2011.</p>\n<p>22. Zagam (sparfloxacin) [prescribing information]. Research Triangle Park, NC: Bertek Pharmaceuticals Inc; April 2003.</p>\n<p>23. Baxdela (delafloxacin) [prescribing information]. Lincolnshire, IL: Melinta Therapeutics Inc; June 2017.</p>\n<p>24. Pefloxacin tablet [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199101448 Accessed October 26, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2964":"<p><b>Title</b> Quinolones / Sucralfate</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction appears limited to orally administered quinolone antibiotics.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Sucralfate may decrease the serum concentration of Quinolones. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Interactions can be minimized by administering oral quinolones at least 2 hours before or 6 hours after the dose of sucralfate. Greater separation of the two drugs appears to lessen the risk for a significant interaction even further. If the products must be administered closer together than desired, monitor for decreased therapeutic effect of oral quinolone.</p>\n<div>\n <p><b>Quinolones Interacting Members</b> Ciprofloxacin (Systemic), Delafloxacin, Gemifloxacin, LevoFLOXacin (Systemic), Lomefloxacin*, Moxifloxacin (Systemic), Nalidixic Acid, Norfloxacin*, Ofloxacin (Systemic), Pefloxacin, Pipemidic Acid, Sparfloxacin*<br><b>Exception</b> LevoFLOXacin (Oral Inhalation)</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A case report describes a patient with prostatitis in whom the therapeutic failure of ciprofloxacin was attributed to concurrent use of sucralfate.<sup>1</sup> The relative bioavailability and/or AUC of several quinolone antibacterials has been reduced by 24% to more than 90% when given with or within several hours sucralfate.<sup>2,3,4,5,6,7,8,9,10,11,12,13,14</sup> This interaction has been reported with numerous individual quinolones, including (but not necessarily limited to) ciprofloxacin,<sup>2,3,4,5</sup> norfloxacin,<sup>6,7</sup> fleroxacin,<sup>8</sup> ofloxacin,<sup>7,9</sup> sparfloxacin,<sup>10,11</sup> gemifloxacin,<sup>12</sup> moxifloxacin,<sup>13</sup>, and lomefloxacin.<sup>14</sup> The magnitude of this interaction appears to depend on several factors, including specific quinolone involved, timing of quinolone administration, route of quinolone administration, and fasting vs. fed state of the patient. Of the quinolones with available data regarding this interaction, fleroxacin appears to be least affected, with only a 24% reduction in relative bioavailability with concurrent use (vs. at least a 44% with other quinolones).<sup>8</sup> Timing is also of critical importance, with a lessening interaction magnitude with administration as soon as 2 hours after sucralfate (30-43% reductions vs. at least 90% reduction with concurrent administration for ciprofloxacin and norfloxacin).<sup>2,4,6</sup> When the quinolone is administered at least 2 hours before a sucralfate dose, the interaction has been shown to be statistically and/or clinically insignificant.<sup>4,7,11,12,15</sup> Also of note, studies examining both fecal ciprofloxacin concentrations and impact on fecal Enterobacteriacea following the use of intravenous ciprofloxacin have concluded that concurrent sucralfate does not significantly impact the ability of intravenous ciprofloxacin to attain meaningful concentrations in the colon.<sup>16,17</sup> For at least some quinolones, administration with food may lessen the magnitude of the sucralfate interaction, with one study reporting a 61% reduction in ofloxacin AUC with concurrent sucralfate in fasting volunteers, but only a 31% reduction in the same volunteers when fed.<sup>9</sup><br><br>The mechanism of these interactions appears related to the formation of an insoluble complex between the quinolone and the aluminum component of sucralfate, reducing the absorbability of the antibiotic. Subtherapeutic serum concentrations can result.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Spivey JM, Cummings DM, Pierson NR, “Failure of Prostatitis Treatment Secondary to Probable Ciprofloxacin-Sucralfate Drug Interaction,” <i>Pharmacotherapy</i>, 1996, 16(2):314-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8820479\">[PubMed 8820479]</a></p>\n<p>2. Nix DE, Watson WA, Handy L, et al, “The Effect of Sucralfate Pretreatment on the Pharmacokinetics of Ciprofloxacin,” <i>Pharmacotherapy</i>, 1989, 9(6):377-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2616352\">[PubMed 2616352]</a></p>\n<p>3. Garrelts JC, Godley PJ, Peterie JD, et al, “Sucralfate Significantly Reduces Ciprofloxacin Concentrations in Serum,” <i>Antimicrob Agents Chemother</i>, 1990, 34:931-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2360833\">[PubMed 2360833]</a></p>\n<p>4. Van Slooten AD, Nix DE, Wilton JH, et al, “Combined Use of Ciprofloxacin and Sucralfate,” <i>DICP</i>, 1991, 25:578-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1877263\">[PubMed 1877263]</a></p>\n<p>5. Yuk JH, Nightingale CN, and Quintiliani R, “Ciprofloxacin Levels When Receiving Sucralfate,” <i>JAMA</i>, 1989, 262:901. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2754785\">[PubMed 2754785]</a></p>\n<p>6. Parpia SH, Nix DE, Hejmanowski LG, et al, “Sucralfate Reduces the Gastrointestinal Absorption of Norfloxacin,” <i>Antimicrob Agents Chemother</i>, 1989, 33(1):99-102. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2712548\">[PubMed 2712548]</a></p>\n<p>7. Lehto P and Kivisto KT, “Effect of Sucralfate on Absorption of Norfloxacin and Ofloxacin,” <i>Antimicrob Agents Chemother</i>, 1994, 38:248-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8192452\">[PubMed 8192452]</a></p>\n<p>8. Lubowski TJ, Nightingale CH, Sweeney K, et al, “Effect of Sucralfate on Pharmacokinetics of Fleroxacin in Healthy Volunteers,” <i>Antimicrob Agents Chemother</i>, 1992, 36:2785-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14824145\">[PubMed 14824145]</a></p>\n<p>9. Kawakami J, Matsuse T, Kotaki H, et al, “The Effect of Food on the Interaction of Ofloxacin with Sucralfate in Healthy Volunteers,” <i>Eur J Clin Pharmacol</i>, 1994, 47(1):67-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7988627\">[PubMed 7988627]</a></p>\n<p>10. Zix JA, “Pharmacokinetics of Sparfloxacin and Interaction With Cisapride and Sucralfate,” <i>Antimicrob Agents Chemother</i>, 1997, 41:1668-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9257738\">[PubMed 9257738]</a></p>\n<p>11. Kamberi M, Nakashima H, Ogawa K, et al, “The Effect of Staggered Dosing of Sucralfate on Oral Bioavailability of Sparfloxacin,” <i>Br J Clin Pharmacol</i>, 2000, 49(2):98-103. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10671902\">[PubMed 10671902]</a></p>\n<p>12. Allen A, Bygate E, Faessel H, et al, “The Effect of Ferrous Sulphate and Sucralfate on the Bioavailability of Oral Gemifloxacin in Healthy Volunteers,” <i>Int J Antimicrob Agents</i>, 2000, 15(4):283-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10929878\">[PubMed 10929878]</a></p>\n<p>13. Stass H, Schuhly U, Moller JG, et al, “Effects of Sucralfate on the Oral Bioavailability of Moxifloxacin, A Novel 8-methoxyfluoroquinolone, in Healthy Volunteers,” <i>Clin Pharmacokinet</i>, 2001, 40(Suppl 1):49-55. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11352442\">[PubMed 11352442]</a></p>\n<p>14. Lehto PL and Kivisto KT, “Different Effects of Products Containing Metal Ions on the Absorption of Lomefloxacin,” <i>Clin Pharmacol Ther</i>, 1994, 56:477-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7955811\">[PubMed 7955811]</a></p>\n<p>15. Lee LJ, Hafkin B, Lee ID, et al, “Effects of Food and Sucralfate on a Single Oral Dose of 500 Milligrams of Levofloxacin in Healthy Subjects,” <i>Antimicrob Agents Chemother</i>, 1997, 41(10):2196-200. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9333047\">[PubMed 9333047]</a></p>\n<p>16. Krueger WA, Ruckdeschel G, Unertl K, “Influence of Intravenously Administered Ciprofloxacin on Aerobic Intestinal Microflora and Fecal Drug Levels when Administered Simultaneously with Sucralfate,” <i>Antimicrob Agents Chemother</i>, 1997, 41(8):1725-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9257749\">[PubMed 9257749]</a></p>\n<p>17. Krueger WA, Ruckdeschel G, Unertl K, “Elimination of Fecal Enterobacteriaceae by Intravenous Ciprofloxacin is Not Inhibited by Concomitant Sucralfate--A Microbiological and Pharmacokinetic Study in Patients,” <i>Infection</i>, 1999, 27(6):335-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10624593\">[PubMed 10624593]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2965":"<p><b>Title</b> Theophylline Derivatives / Quinolones</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Quinolones may decrease the metabolism of Theophylline Derivatives. Ciprofloxacin and enoxacin are of greatest concern. Theophylline/quinolone therapy might augment the seizure-producing potential of each of the individual agents. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Consider an empiric reduction in the dosage of theophylline (25% to 50%) if ciprofloxacin or enoxacin is to be initiated to minimize the risk of theophylline toxicity. Consider using quinolones other than ciprofloxacin or enoxacin to reduce the risk of interaction. Monitor for toxic effects of theophylline preparations if a quinolone antibiotic is initiated/dose increased, or decreased effects if a quinolone antibiotic is discontinued/dose decreased.</p>\n<div>\n <p><b>Quinolones Interacting Members</b> Ciprofloxacin (Systemic), LevoFLOXacin (Oral Inhalation), Norfloxacin*, Ofloxacin (Systemic), Pipemidic Acid<br><b>Exceptions</b> Delafloxacin, Gemifloxacin, LevoFLOXacin (Systemic), Lomefloxacin, Moxifloxacin (Systemic), Nalidixic Acid, Pefloxacin, Sparfloxacin</p>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Theophylline*<br><b>Exception</b> Dyphylline</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Several data demonstrate two- to threefold increases in serum theophylline concentrations following a few days (2-3) of concurrent therapy with ciprofloxacin or enoxacin.<sup>1,2,3,4,5,6,7,8,9,10</sup> Theophylline toxicity resulting in seizures, and even death, has been associated with these reports. Other quinolones (eg, clinafloxacin, grepafloxacin, norfloxacin, ofloxacin, perfloxacin) appear to similarly affect theophylline but to a lesser extent than ciprofloxacin or enoxacin.<sup>11,12,13,14,15,16</sup> A case report describes a 60% decrease in theophylline clearance (associated with signs and symptoms of toxicity) in a patient following the addition of both clarithromycin and levofloxacin.<sup>17</sup> Theophylline clearance returned to preantibiotic values following the discontinuation of levofloxacin (while clarithromycin was continued). A separate report on the effects of levofloxacin fails to confirm this finding.<sup>18</sup> Fleroxacin, moxifloxacin, nalidixic acid, sparfloxacin, and trovafloxacin do not appear to interact with theophylline.<sup>19,20,21,22,23,24,25,26,27,28</sup> The mechanism of these interactions is likely related to quinolone inhibition of CYP1A2 and/or CYP3A4 isoenzymes, thus limiting the metabolism of theophylline. In addition, it has been suggested that combined theophylline/quinolone therapy might augment the seizure-producing potential of each of the individual agents.<sup>29</sup> Lomefloxacin does not appear to significantly affect theophylline disposition.<sup>30</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Raoof S, Wollschlager C, and Khan FA, “Ciprofloxacin Increases Serum Levels of Theophylline,” <i>Am J Med</i>, 1987, 82(Suppl 4A):115-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3578320\">[PubMed 3578320]</a></p>\n<p>2. Nix DE, DeVito JM, Whitbread MA, et al, “Effect of Multiple Dose Oral Ciprofloxacin on the Pharmacokinetics of Theophylline and Indocyanine Green,” <i>J Antimicrob Chemother</i>, 1987, 19(2):263-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3571046\">[PubMed 3571046]</a></p>\n<p>3. Bem JL and Mann RD, “Danger of Interaction Between Ciprofloxacin and Theophylline,” <i>Br Med J</i>, 1988, 296:1131. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3132238\">[PubMed 3132238]</a></p>\n<p>4. Paidipaty B and Erickson S, “Ciprofloxacin-Theophylline Drug Interaction,” <i>Crit Care Med</i>, 1990, 18:685-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2344769\">[PubMed 2344769]</a></p>\n<p>5. Bader MB, “Role of Ciprofloxacin in Fatal Seizures,” <i>Chest</i>, 1992, 101:883-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1541177\">[PubMed 1541177]</a></p>\n<p>6. Wijnands WJ, van Herwaarden CL, and Vree TB, “Enoxacin Raises Plasma Theophylline Concentrations,” <i>Lancet</i>, 1984, ii:108. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6145999\">[PubMed 6145999]</a></p>\n<p>7. Davies BI, Maesen FP, and Teengs JP, “Serum and Sputum Concentrations of Enoxacin After Oral Single Dosing in a Clinical and Bacteriological Study,” <i>J Antimicrob Chemother</i>, 1984, 14(Suppl C):83-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6594325\">[PubMed 6594325]</a></p>\n<p>8. Sano M, Kawakatsu K, Ohkita C, et al, “Effects of Enoxacin, Ofloxacin and Norfloxacin on Theophylline Disposition in Humans,” <i>Eur J Clin Pharmacol</i>, 1988, 35:161-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3191935\">[PubMed 3191935]</a></p>\n<p>9. Takagi K, Hasegawa T, Ogura Y, et al, “Comparative Studies on Interaction Between Theophylline and Quinolones,” <i>J Asthma</i>, 1988, 25:63-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3182580\">[PubMed 3182580]</a></p>\n<p>10. Koup JR, Toothaker RG, Posvar E, et al, “Theophylline Dosage Adjustment During Enoxacin Administration,” <i>Antimicrob Agents Chemother</i>, 1990, 34:803-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2360819\">[PubMed 2360819]</a></p>\n<p>11. Matuschka PR and Vissing RS, “Clinafloxacin-Theophylline Drug Interaction,” <i>Ann Pharmacother</i>, 1995, 29:378-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7633015\">[PubMed 7633015]</a></p>\n<p>12. Niki Y, Hashiguchi K, Okimoto N, et al, “Quinolone Antimicrobial Agents and Theophylline,” <i>Chest</i>, 1992, 101:881. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1541174\">[PubMed 1541174]</a></p>\n<p>13. Tierney MG, Ho G, and Dales RE, “Effect of Norfloxacin on Theophylline Pharmacokinetics,” <i>Clin Pharmacol Ther</i>, 1988, 43:156.</p>\n<p>14. Gregoire SL, Grasela TH, Freer JP, et al, “Inhibition of Theophylline Clearance by Coadministered Ofloxacin Without Alteration of Theophylline Effects,” <i>Antimicrob Agents Chemother</i>, 1987, 31:375-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3472488\">[PubMed 3472488]</a></p>\n<p>15. Wijnands WJ, Verr TB, and van Herwaarden CL, “The Influence of Quinolone Derivatives on Theophylline Clearance,” <i>Br J Clin Pharmacol</i>, 1986, 22:677-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3567014\">[PubMed 3567014]</a></p>\n<p>16. Al-Turk WA, Shaheen OM, Othman S, et al, “Effect of Ofloxacin on the Pharmacokinetics of a Single Intravenous Theophylline Dose,” <i>Ther Drug Monit</i>, 1988, 10:160-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3164150\">[PubMed 3164150]</a></p>\n<p>17. Nakamura H, Ohtsuka T, Enomoto H, et al, “Effect of Levofloxacin on Theophylline Clearance During Theophylline and Clarithromycin Combination Therapy,” <i>Ann Pharmacother</i>, 2001, 35(6):691-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11408986\">[PubMed 11408986]</a></p>\n<p>18. Gisclon LG, Curtin CR, Fowler CL, et al, “Absence of a Pharmacokinetic Interaction Between Intravenous Theophylline and Orally Administered Levofloxacin,” <i>Intersci Conf Antimicrob Ag Chemother</i>, 1995, 35:A39.</p>\n<p>19. Niki Y, Tasaka Y, Kishimoto T, et al, “Effect of Fleroxacin on Serum Concentrations of Theophylline,” <i>Chemotherapy</i>, 1990, 38:364-71.</p>\n<p>20. Seelmann R, Mahr G, Gottschalk B, et al, “Influence of Fleroxacin on the Pharmacokinetics of Theophylline,” <i>Rev Infect Dis</i>, 1989, II(Suppl 5):S1100.</p>\n<p>21. Grasela TH and Dreis MW, “An Evaluation of the Quinolone-Theophylline Interaction Using the Food and Drug Administration Spontaneous Reporting System,” <i>Arch Intern Med</i>, 1992, 152:617-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1312320\">[PubMed 1312320]</a></p>\n<p>22. Takagi K, Yamaki K, Nadai M, et al, “Effect of New Quinolone, Sparfloxacin, on the Pharmacokinetics of Theophylline in Asthmatic Patients,” <i>Antimicrob Agents Chemother</i>, 1991, 35:1137-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1929255\">[PubMed 1929255]</a></p>\n<p>23. Yamaki K, Miyatake H, Taki F, et al, “Studies on Sparfloxacin (SPFX) Against Respiratory Tract Infections and its Effect on Theophylline Pharmacokinetics,” <i>Chemotherapy</i>, 1991, 39:280-5.</p>\n<p>24. Dickens GR, Wermeling D, and Vincent J, “Phase I Pilot Study of the Effects of Trovafloxacin (CP-99, 219) on the Pharmacokinetics of Theophylline in Healthy Men,” <i>J Clin Pharmacol</i>, 1997, 37:248-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9089427\">[PubMed 9089427]</a></p>\n<p>25. Vincent J, Teng R, Dogolo LC, et al, “Effect of Trovafloxacin, a New Fluoroquinolone Antibiotic, on the Steady-State Pharmacokinetics of Theophylline in Healthy Volunteers,” <i>J Antimicrob Chemother</i>, 1997, 39(Suppl B):81-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9222075\">[PubMed 9222075]</a></p>\n<p>26. Stass H and Kubitza D, “Lack of Pharmacokinetic Interaction Between Moxifloxacin, a Novel 8-methoxyfluoroquinolone, and Theophylline,” <i>Clin Pharmacokinet</i>, 2001, 40(Suppl 1):63-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11352444\">[PubMed 11352444]</a></p>\n<p>27. Chyrek-Borowska S, Siergiejko Z, Michalska I, et al, “Effect of Ofloxacin, Ciprofloxacin and Nalidixic Acid on Serum Theophylline Level in Patients Treated With Methylxanthine Preparations,” <i>Pneumonol Alergol Pol</i>, 1992, 60(1-2):36-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1290977\">[PubMed 1290977]</a></p>\n<p>28. Prince RA, Casabar E, Adair CG, et al, “Effect of Quinolone Antimicrobials on Theophylline Pharmacokinetics,” <i>J Clin Pharmacol</i>, 1989, 29(7):650-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2760258\">[PubMed 2760258]</a></p>\n<p>29. Segev S, Rehavi M, and Rubenstein E, “Quinolones, Theophylline and Diclofenac Interactions With Gamma-Aminobutyric Acid Receptor,” <i>Antimicrob Agents Chemother</i>, 1988, 32:1624-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2855295\">[PubMed 2855295]</a></p>\n<p>30. Maxaquin [package insert]. Chicago, IL: GD Searle LLC, 2003.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2966":"<p><b>Title</b> Vitamin K Antagonists / Quinolones</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Quinolones may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased INR/prothrombin time (PT) and/or toxic effects of warfarin or acenocoumarol if a quinolone antibiotic is initiated (especially during the first few days of concomitant therapy) or the dose is increased, or for decreased effects if a quinolone antibiotic is discontinued or its dose is decreased.</p>\n<div>\n <p><b>Quinolones Interacting Members</b> Ciprofloxacin (Systemic), Delafloxacin, Gemifloxacin, LevoFLOXacin (Oral Inhalation), LevoFLOXacin (Systemic), Lomefloxacin, Moxifloxacin (Systemic), Nalidixic Acid*, Norfloxacin*, Ofloxacin (Systemic), Pefloxacin, Pipemidic Acid, Sparfloxacin</p>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The risk of bleeding was significantly increased for warfarin-treated patients who were also treated with a fluoroquinolone, according to the results of four separate cohort or case-control/case-crossover studies.<sup>1,2,3,4</sup> The magnitude of the risk varied somewhat (adjusted OR or HR = 1.30 to 2.84) among studies and according to specific fluoroquinolone and time since exposure. A significant increase in risk or odds has been reported for ciprofloxacin, levofloxacin, and gatifloxacin. In contrast, one large case-control study of older patients concluded there was no significant increase in the odds for a gastrointestinal bleed with norfloxacin.<sup>1</sup><br><br>Several studies have reported increases in INR associated with ciprofloxacin,<sup>5,6,7</sup> levofloxacin,<sup>6,8,9,10,11</sup> moxifloxacin,<sup>6</sup> and gatifloxacin.<sup>9</sup> The magnitude of the reported change in INR varied considerably among individual studies, and even among studies of the same specific fluoroquinolone. One study of 18 warfarin-treated subjects who received levofloxacin for treatment of a variety of types of infections reported no significant change in INR.<sup>12</sup> Similarly, some of the studies that did report an increased INR with concurrent levofloxacin, described increases that were likely of questionable or only minor clinical significance.<sup>9,11</sup><br><br>In contrast to most of these studies, many studies of healthy volunteers or warfarin-treated but non-infected subjects have reported no change in INR or PT ratio with concurrent ciprofloxacin,<sup>13,14,15</sup> levofloxacin,<sup>16</sup> gemifloxacin,<sup>17</sup> grepafloxacin,<sup>18</sup> enoxacin,<sup>19</sup> or norfloxacin.<sup>20</sup><br><br>The precise mechanism(s) for any fluoroquinolone/vitamin K antagonist interaction is/are uncertain. At least some of the fluorquinolones are potential inhibitors of the metabolism of the less potent R-warfarin enantiomer, but available data show that levofloxacin and ciprofloxacin have little or no significant impact on warfarin pharmacokinetics.<sup>13,14,16</sup> Protein binding displacement is another proposed mechanism,<sup>21</sup> but the extent to which other fluoroquinolones displace vitamin K antagonist protein binding and the clinical significance of any such displacement are unknown. Antibacterial interference with enteric flora-mediated vitamin K2 production is another possible explanation, though much remains uncertain regarding the potential clinical significance of any such effect. An additional consideration is the impact of the underlying infection on vitamin K antagonist therapy.<sup>22</sup> Infections can result in increases in circulating concentrations of cytokines, glucocorticoids, and tumor necrosis factor. It is currently believed that substances released during inflammation and infection elicit a downregulation of some metabolic enzymes, possibly leading to an interaction with vitamin K antagonists and an increased risk of bleeding. While the contribution of any such factors is not known, this could explain at least a portion of the observed discrepancy between studies of healthy or non-infected subjects from those of individual receiving a fluorquinolone for treatment of an active infection.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Fischer HD, Juurlink DN, Mamdani MM, Kopp A, Laupacis A. Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study. <i>Arch Intern Med</i>. 2010;170(7):617-621. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20386005\">[PubMed 20386005]</a></p>\n<p>2. Lane MA, Zeringue A, McDonald JR. Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans. <i>Am J Med</i>. 2014;127(7):657-663.e2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24657899\">[PubMed 24657899]</a></p>\n<p>3. Baillargeon J, Holmes HM, Lin YL, Raji MA, Sharma G, Kuo YF. Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults. <i>Am J Med</i>. 2012;125(2):183-189. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22269622\">[PubMed 22269622]</a></p>\n<p>4. Schelleman H, Bilker WB, Brensinger CM, Han X, Kimmel SE, Hennessy S. Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. <i>Clin Pharmacol Ther</i>. 2008;84(5):581-588. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18685566\">[PubMed 18685566]</a></p>\n<p>5. Saum LM, Balmat RP. Ceftriaxone potentiates warfarin activity greater than other antibiotics in the treatment of urinary tract infections. <i>J Pharm Pract</i>. 2016;29(2):121-124. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25092605\">[PubMed 25092605]</a></p>\n<p>6. Ghaswalla PK, Harpe SE, Tassone D, Slattum PW. Warfarin-antibiotic interactions in older adults of an outpatient anticoagulation clinic. <i>Am J Geriatr Pharmacother</i>. 2012;10(6):352-360. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23089199\">[PubMed 23089199]</a></p>\n<p>7. Moffett BS, Ung M, Bomgaars L. Risk factors for elevated INR values during warfarin therapy in hospitalized pediatric patients. <i>Pediatr Blood Cancer</i>. 2012;58(6):941-944. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22069087\">[PubMed 22069087]</a></p>\n<p>8. Mercadal Orfila G, Gracia Garcia B, Leiva Badosa E, Perayre Badia M, Reynaldo Martinez C, Jodar Masanes R. Retrospective assessment of potential interaction between levofloxacin and warfarin. <i>Pharm World Sci</i>. 2009;31(2):224-229. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19067226\">[PubMed 19067226]</a></p>\n<p>9. Mathews S, Cole J, Ryono RA. Anticoagulation-related outcomes in patients receiving warfarin after starting levofloxacin or gatifloxacin. <i>Pharmacotherapy</i>. 2006;26(10):1446-1452. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16999655\">[PubMed 16999655]</a></p>\n<p>10. Glasheen JJ, Fugit RV, Prochazka AV. The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens. <i>J Gen Intern Med</i>. 2005;20(7):653-656. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16050864\">[PubMed 16050864]</a></p>\n<p>11. McCall KL, Scott JC, Anderson HG. Retrospective evaluation of a possible interaction between warfarin and levofloxacin. <i>Pharmacotherapy</i>. 2005;25(1):67-73. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15767222\">[PubMed 15767222]</a></p>\n<p>12. Yamreudeewong W, Lower DL, Kilpatrick DM, Enlow AM, Burrows MM, Greenwood MC. Effect of levofloxacin coadministration on the international normalized ratios during warfarin therapy. <i>Pharmacotherapy</i>. 2003;23(3):333-338. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12627932\">[PubMed 12627932]</a></p>\n<p>13. Washington C, Hou SY, Hughes NC, Campanella C, Berner B. Ciprofloxacin prolonged-release tablets do not affect warfarin pharmacokinetics and pharmacodynamics. <i>J Clin Pharmacol</i>. 2007;47(10):1320-1326. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17724088\">[PubMed 17724088]</a></p>\n<p>14. Israel DS, Stotka J, Rock W, et al. Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin. <i>Clin Infect Dis</i>. 1996;22(2):251-256. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8838180\">[PubMed 8838180]</a></p>\n<p>15. Bianco TM, Bussey HI, Farnett LE, Linn WD, Roush MK, Wong YW. Potential warfarin-ciprofloxacin interaction in patients receiving long-term anticoagulation. <i>Pharmacotherapy</i>. 1992;12(6):435-439. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1492006\">[PubMed 1492006]</a></p>\n<p>16. Liao S, Palmer M, Fowler C, Nayak RK. Absence of an effect of levofloxacin on warfarin pharmacokinetics and anticoagulation in male volunteers. <i>J Clin Pharmacol</i>. 1996;36(11):1072-1077. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8973996\">[PubMed 8973996]</a></p>\n<p>17. Davy M, Bird N, Rost KL, Fuder H. Lack of effect of gemifloxacin on the steady-state pharmacodynamics of warfarin in healthy volunteers. <i>Chemotherapy</i>. 1999;45(6):491-495. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10567780\">[PubMed 10567780]</a></p>\n<p>18. Efthymiopoulos C, Bramer SL, Maroli A, Blum B. Theophylline and warfarin interaction studies with grepafloxacin. <i>Clin Pharmacokinet</i>. 1997;33 suppl 1:39-46. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9433655\">[PubMed 9433655]</a></p>\n<p>19. Toon S, Hopkins KJ, Garstang FM, Aarons L, Sedman A, Rowland M. Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects. <i>Clin Pharmacol Ther</i>. 1987;42(1):33-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3474093\">[PubMed 3474093]</a></p>\n<p>20. Rocci ML Jr, Vlasses PH, Distlerath LM, et al. Norfloxacin does not alter warfarin's disposition or anticoagulant effect. <i>J Clin Pharmacol</i>. 1990;30(8):728-732. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2401751\">[PubMed 2401751]</a></p>\n<p>21. Sellers EM, Koch-Weser J. Displacement of warfarin from human albumin by diazoxide and ethacrynic, mefenamic, and nalidixic acids. <i>Clin Pharmacol Ther</i>. 1970;11(4):524-529. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5429179\">[PubMed 5429179]</a></p>\n<p>22. Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. <i>Clin Pharmacol Ther</i>. 2009;85(4):434-438. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19212314\">[PubMed 19212314]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2967":"<p><b>Title</b> Cisapride / Macrolide Antibiotics</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Macrolide Antibiotics may enhance the QTc-prolonging effect of Cisapride. Macrolide Antibiotics may decrease the metabolism of Cisapride. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The concomitant use of cisapride and clarithromycin, erythromycin, telithromycin or troleandomycin is contraindicated. Concomitant azithromycin should likely also be avoided when possible.</p>\n<div>\n <p><b>Macrolide Antibiotics Interacting Members</b> Azithromycin (Systemic), Clarithromycin*, Erythromycin (Systemic), Roxithromycin, Telithromycin<br><b>Exceptions</b> Fidaxomicin, Spiramycin</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Peak and trough serum cisapride concentrations (10 mg 4 times/day) were nearly tripled in 12 normal subjects following 5 days of concurrent therapy with clarithromycin (500 mg twice daily). The QT interval was increased 25-27 msec over preclarithromycin values.<sup>1</sup> The AUC of cisapride was increased 70% during concomitant administration of telithromycin, a ketolide antibiotic.<sup>2</sup> Case reports of patients who developed torsade de pointes when receiving concomitant therapy with cisapride and clarithromycin or erythromycin have been published.<sup>3,4,5,6</sup> The manufacturer of cisapride has issued a warning that the concomitant use of cisapride with clarithromycin, erythromycin, or troleandomycin is contraindicated.<sup>6</sup> These agents appear to inhibit the CYP3A4-mediated metabolism of cisapride. The increased cisapride concentrations lead to the cardiac conduction abnormalities. Azithromycin and spiramycin are unlikely to cause a similar pharmacokinetic interaction with cisapride, but evidence suggests azithromycin does likely have a moderate risk for significant QTc prolongation, so azithromycin should be similarly avoided.</p> \n<p><b>Footnotes</b> </p>\n<p>1. van Haarst AD, van’t Klooster GA, van Gerven JM, et al. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. <i>Clin Pharmacol Ther</i>. 1998;64(5):542-546. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9834046\">[PubMed 9834046]</a></p>\n<p>2. Ketec (telithromycin) [product monograph]. Laval, Quebec, Canada: Aventis Pharma Inc; 2003.</p>\n<p>3. Sekkarie MA. Torsade de Pointes in two chronic renal failure patients treated with cisapride and clarithromycin. <i>Am J Kidney Dis</i>. 1997;30(3):437-439. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9292575\">[PubMed 9292575]</a></p>\n<p>4. Gray VS. Syncopal episodes associated With cisapride and concurrent drugs. <i>Ann Pharmacother</i>. 1998;32(6):648-651. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9640482\">[PubMed 9640482]</a></p>\n<p>5. Jenkins IR, Gibson J. Cisapride, erythromycin and arrhythmia. <i>Anaesth Intensive Care</i>. 1996;24(6):728. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8971331\">[PubMed 8971331]</a></p>\n<p>6. Propulsid (cisapride) [prescribing information]. Titusville, NJ: Janssen Pharmaceutica; 1998.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2968":"<p><b>Title</b> Cisapride / Protease Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Protease Inhibitors may increase the serum concentration of Cisapride. This may result in QTc prolongation and malignant cardiac arrhythmias. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of cisapride and protease inhibitors is contraindicated and should be avoided.</p>\n<div>\n <p><b>Protease Inhibitors Interacting Members</b> Atazanavir*, Darunavir, Fosamprenavir, Indinavir*, Lopinavir, Nelfinavir*, Ritonavir*, Saquinavir*, Tipranavir</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The manufacturer of cisapride states that indinavir and ritonavir are contraindicated in patients receiving cisapride due to the potential for such concomitant therapy to cause serious cardiac arrhythmias (e.g., torsade de pointes).<sup>1</sup> Similarly, all protease inhibitors contraindicate use with cisapride due to the risk for adverse cardiovascular effects.<sup>2,3,4,5,6,7,8,9,10</sup> These agents likely inhibit the CYP3A-mediated metabolism of cisapride, and thus increase cisapride serum concentrations. Increased cisapride serum concentrations have been associated with QTc prolongation and malignant arrhythmias.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Propulsid (cisapride). Titusville, NJ: Janssen Pharmaceutica, 1998.</p>\n<p>2. Prescribing information. Reyataz (atazanavir). Princeton, NJ: Bristol-Myers Squibb, 03/2012.</p>\n<p>3. Prescribing information. Prezista (darunavir). Raritan, NJ: Centocor Biotech Products, L.P., 02/2012.</p>\n<p>4. Prescribing information. Lexiva (fosamprenavir). Research Triangle Park, NC: GlaxoSmithKline, September 2009.</p>\n<p>5. Prescribing information. Crixivan (indinavir). Whitehouse Station, NJ: Merck &amp; Co., Inc., April 2012.</p>\n<p>6. Prescribing information. Kaletra (lopinavir/ritonavir). North Chicago, IL: Abbott Laboratories, 02/2012.</p>\n<p>7. Prescribing information. Viracept (nelfinavir). La Jolla, CA: Agouron Pharmaceuticals, Inc., April 2012.</p>\n<p>8. Prescribing information. Norvir (ritonavir). North Chicago, IL: Abbott Laboratories, 03/2012.</p>\n<p>9. Prescribing information. Invirase (saquinavir). Nutley, NJ: Roche Laboratories Inc., 02/2012.</p>\n<p>10. Prescribing information. Aptivus (tipranavir). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., 04/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2969":"<p><b>Title</b> Cisapride / Nefazodone</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Nefazodone may increase the serum concentration of Cisapride. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of cisapride and nefazodone.</p> \n<p><b>Discussion</b> The manufacturer of cisapride states that nefazodone is contraindicated in patients receiving cisapride due to the potential for concomitant therapy to cause serious cardiac arrhythmias (eg, torsades de pointes).<sup>1</sup> <br><br>Nefazodone inhibition of cisapride metabolism via CYP3A4 is the likely mechanism of this interaction. Nefazodone inhibition of cisapride metabolism via other cytochrome pathways such as CYP1A2, 2B6, or 2D6 may also play a minor role.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Propulsid (cisapride). Titusville, NJ: Janssen Pharmaceutica, 1998.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2970":"<p><b>Title</b> CISplatin / Loop Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Loop Diuretics may enhance the nephrotoxic effect of CISplatin. Loop Diuretics may enhance the ototoxic effect of CISplatin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for possible enhanced ototoxicity and nephrotoxicity if cisplatin is given concomitantly with a loop diuretic. Ensuring adequate fluid balance and limiting loop diuretic doses may limit toxicity.</p>\n<div>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid*, Furosemide*, Torsemide</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Prescribing information for furosemide warns and that nephrotoxic effects of cisplatin may be enhanced when furosemide is given to achieve forced diuresis, unless furosemide is given in lower doses and positive fluid balance is maintained.<sup>1</sup> Additionally, although data are sparse there is a possible risk of additive ototoxicity with combination therapy.<sup>1,2</sup> Ototoxicity is a known adverse effect of both cisplatin and loop diuretics. A study in guinea pigs demonstrated that concomitant therapy with cisplatin and ethacrynic acid resulted in a greater degree of ototoxicity than either agent alone, and that the physiological damage may have been permanent.<sup>2</sup><br><br>Enhanced nephrotoxicity or ototoxicity may result from combination therapy due to additive adverse pharmacologic effects of the individual agents. Ensuring adequate fluid balance and limiting loop diuretic doses may limit toxicity.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Lasix (furosemide). Bridgewater, NJ: sanofi-aventis U.S. LLC, September 2008.</p>\n<p>2. Komune S and Snow JB, “Potentiating Effects of Cisplatin and Ethacrynic Acid in Ototoxicity,” <i>Arch Otolaryngol</i>, 1981, 107:594-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7197152\">[PubMed 7197152]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2971":"<p><b>Title</b> Selective Serotonin Reuptake Inhibitors / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. While methylene blue and linezolid are expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors. Refer to monographs specific to those agents for details. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of selective serotonin reuptake inhibitors (SSRI) and monoamine oxidase inhibitors (MAOI), both selective and nonselective, should be avoided. In addition, a significant washout period should be employed between discontinuing one agent and initiating the other (i.e., changing from SSRI to MAOI or vice-versa). The washout period should probably be at least 1-2 weeks (2 weeks for vilazodone, 3 weeks for vortioxetine, 5 weeks for fluoxetine), depending on the half-life of the agent being discontinued. In general, furazolidone, linezolid, and procarbazine will pose less risk than isocarboxazid, phenelzine, or tranylcypromine. Caution is still advised. Selegiline administered in high oral dosages (e.g., more than 10 mg/day of tablet/capsule; more than 2.5 mg/day of orally disintegrating tablet) or transdermally will exhibit nonselective MAOI activity.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Moclobemide*, Phenelzine*, Procarbazine, Rasagiline, Safinamide, Selegiline*, Syrian Rue, Tranylcypromine*<br><b>Exceptions</b> Linezolid, Methylene Blue, Tedizolid</p>\n <p><b>Selective Serotonin Reuptake Inhibitors Interacting Members</b> Citalopram*, Dapoxetine, Escitalopram, FLUoxetine*, FluvoxaMINE, PARoxetine, Sertraline*, Vilazodone, Vortioxetine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A patient developed anxiety, confusion, double vision, shivering, and nausea on day 4 of tranylcypromine therapy (10 mg/day on days 1-3, 20 mg on day 4).<sup>1</sup> Tranylcypromine was started 2 days after discontinuing fluoxetine therapy. All symptoms resolved within 24 hours of discontinuing tranylcypromine. A fatality was associated with the combination of phenelzine and sertraline.<sup>2</sup> Three other fatalities have been attributed to concomitant citalopram and moclobemide, both taken in overdose proportions.<sup>3</sup> Additional case reports implicate the combination of oral selegiline and fluoxetine in causing mania, and hypertension and vasoconstriction.<sup>4</sup> Serotonin is metabolized by monoamine oxidase (MAO)-A. Nonselective MAO inhibitors (A and B), as well as moclobemide (a selective MAO-A inhibitor), would be expected to decrease the metabolism of serotonin, and increase the risk of serotonin syndrome. Moclobemide has been noted to cause problems with citalopram only in overdose situations. Selegiline administered in high oral dosages (e.g., more than 10 mg/day of tablet/capsule; more than 2.5 mg/day of orally disintegrating tablet) or transdermally will exhibit nonselective MAOI activity.<br><br>No cases of serotonin syndrome were noted in a retrospective cohort study of patients with Parkinson's disease treated with the relatively selective MAO-B inhibitor rasagiline and/or an antidepressant (n=1504 total, n=471 receiving rasagiline and an antidepressant). More than 75% of the antidepressants used were SSRIs, and the average antidepressant dose was relatively low to moderate for most agents.<sup>5</sup> Similarly, the rasagiline prescribing information describes data with 141 patients receiving both rasagiline and an SSRI indicating no adverse reaction, though it is noted that the small numbers of patients and the SSRI doses do not allow the ruling out of any adverse reaction associated with the combination.<sup>6</sup> Rasagiline prescribing information does specifically warn that concomitant use with an SSRI is not recommended.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sternbach H. Danger of MAOI therapy after fluoxetine withdrawal. <i>Lancet</i>. 1988;2:850. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2902292\">[PubMed 2902292]</a></p>\n<p>2. Graber MA, Hoehns TB, Perry PJ. Sertraline-phenelzine drug interaction: a serotonin syndrome reaction. <i>Ann Pharmacother</i>. 1994;28:732-735. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7919561\">[PubMed 7919561]</a></p>\n<p>3. Neuvonen PH, Pohjola-Sintonen S, Tacke U, et al. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. <i>Lancet</i>. 1993;342:1419. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7901695\">[PubMed 7901695]</a></p>\n<p>4. Suchowersky O, deVries JD. Interaction of fluoxetine and selegiline. <i>Can J Psychiatry</i>. 1990;35:571-572. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2119876\">[PubMed 2119876]</a></p>\n<p>5. Panisset M, Chen JJ, Rhyee SH, Conner J, Mathena J; STACCATO study investigators. Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO). <i>Pharmacotherapy</i>. 2014;34(12):1250-1258. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25314256\">[PubMed 25314256]</a></p>\n<p>6. Azilect (rasagiline) [prescribing information]. North Wales, PA: TEVA Pharmaceuticals, Inc.; May 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2973":"<p><b>Title</b> Ergot Derivatives / Macrolide Antibiotics</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Macrolide Antibiotics may increase the serum concentration of Ergot Derivatives. Cabergoline and Clarithromycin may interact, see specific monograph for full details. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for toxic effects of ergot derivatives (specifically the signs and symptoms of ergotism: cramping, pain, and ischemia in the extremities) if used concomitant with a macrolide antibiotic. The concomitant use of telithromycin and ergot derivatives is contraindicated by the manufacturer.<sup>1</sup> Azithromycin is not expected to negatively affect ergot derivatives, and therefore may be a safer alternative.</p>\n<div>\n <p><b>Ergot Derivatives Interacting Members</b> Bromocriptine, Dihydroergotamine*, Ergoloid Mesylates, Ergonovine, Ergotamine*, Methylergonovine<br><b>Exceptions</b> Cabergoline, Nicergoline, Pergolide</p>\n <p><b>Macrolide Antibiotics Interacting Members</b> Clarithromycin*, Erythromycin (Systemic)*, Roxithromycin, Telithromycin*<br><b>Exceptions</b> Azithromycin (Systemic), Fidaxomicin, Spiramycin</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A number of case reports describe the development of ergotism (characterized by cramping, pain, and ischemia in the extremities) in patients who were receiving either macrolide antibiotics or ergot derivatives, without incident, and subsequently started on the opposite agent.<sup>2,3,4,5</sup> Symptoms were often evident within a few hours of concomitant therapy, and emergency hospitalization could become necessary within a few days. The clearance of a single oral dose of bromocriptine (5 mg) was reduced by 70% in 5 normal subjects when administered following 4 days of erythromycin administration (250 mg 4 times/day).<sup>6</sup> The AUC of alpha-dihydroergocryptine (10 mg single dose) was increased up to 16.5-fold when administered halfway through a 4-day course of erythromycin (500 mg 3 times/day).<sup>7</sup> The mechanism of these interactions are likely related to inhibition of CYP isoenzymes by the antibiotic, and reduced metabolism of the ergot derivative. Azithromycin and spiramycin would not be expected to affect the ergot derivative like the other macrolides due to their lack of CYP inhibiting properties.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ketec [package insert]. Laval, Quebec: Aventis Pharma Inc, 2003.</p>\n<p>2. Francis H, Tyndall A, and Webb J, “Severe Vascular Spasm Due to Erythromycin-Ergotamine Interaction,” <i>Clin Rheumatol</i>, 1984, 3(2):243-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6236021\">[PubMed 6236021]</a></p>\n<p>3. Leroy F, Asseman P, Pruvost P, et al, “Dihydroergotamine-Erythromycin-Induced Ergotism,” <i>Ann Intern Med</i>, 1988, 109(3):249. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3389610\">[PubMed 3389610]</a></p>\n<p>4. Ghali R, De Lean J, Douville Y, et al, “Erythromycin-Associated Ergotamine Intoxication: Arteriographic and Electrophysiologic Analysis of a Rare Cause of Severe Ischemia of the Lower Extremities and Associated Ischemic Neuropathy,” <i>Ann Vasc Surg</i>, 1993, 7(3):291-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8391300\">[PubMed 8391300]</a></p>\n<p>5. Horowitz RS, Dart RC, and Gomez HF, “Clinical Ergotism With Lingual Ischemia Induced by Clarithromycin-Ergotamine Interaction,” <i>Arch Intern Med</i>, 1996, 156(4):456-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8607732\">[PubMed 8607732]</a></p>\n<p>6. Nelson MV, Berchou RC, Kareti D, et al, “Pharmacokinetic Evaluation of Erythromycin and Caffeine Administered With Bromocriptine,” <i>Clin Pharmacol Ther</i>, 1990, 47(6):694-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2357864\">[PubMed 2357864]</a></p>\n<p>7. de May C, Althaus M, Ezan E, et al, “Erythromycin Increases Plasma Concentrations of Alpha-Dihydroergocryptine in Humans,” <i>Clin Pharmacol Ther</i>, 2001, 70(2):142-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11503008\">[PubMed 11503008]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2974":"<p><b>Title</b> Pimozide / Macrolide Antibiotics</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Macrolide Antibiotics may enhance the QTc-prolonging effect of Pimozide. Macrolide Antibiotics may decrease the metabolism of Pimozide. This mechanism may not apply to azithromycin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Use of pimozide with macrolide antibiotics is contraindicated.</p>\n<div>\n <p><b>Macrolide Antibiotics Interacting Members</b> Azithromycin (Systemic), Clarithromycin*, Erythromycin (Systemic), Roxithromycin, Telithromycin<br><b>Exceptions</b> Fidaxomicin, Spiramycin</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of a single oral dose of pimozide (6 mg) was increased by more than 100%, and the maximum serum concentration increased by approximately 50%, in 12 healthy volunteers when administered following a 5-day course of clarithromycin (500 mg twice daily).<sup>1</sup> The QTc<sub>max</sub> increased from 19-28 msec. According to pimozide prescribing information, 2 sudden deaths have been reported following the addition of clarithromycin to patients receiving pimozide.<sup>2</sup> <br><br>Interactions between pimozide and the macrolide antibiotics included in this monograph may occur via at least two mechanisms. First, all included macrolides may prolong the QTc interval, thus potentially adding to or potentiating QTc prolonging effects of pimozide and increasing the risk of arrhythmia. Second, most included macrolides (with the likely exception of azithromycin) may inhibit CYP3A4 mediated pimozide metabolism and thereby elevate systemic pimozide concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Desta Z, Kerbusch T, and Flockhart DA, “Effect of Clarithromycin on the Pharmacokinetics and Pharmacodynamics of Pimozide in Healthy, Poor, and Extensive Metabolizers of Cytochrome P450 2D6 (CYP2D6),” <i>Clin Pharmacol Ther</i>, 1999, 65(1):10-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9951426\">[PubMed 9951426]</a></p>\n<p>2. Prescribing information. Orap (pimozide). Sellersville, PA: Teva Pharmaceuticals USA, 1/2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2976":"<p><b>Title</b> Phenytoin / Benzodiazepines</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for toxic effects of phenytoin if a benzodiazepine is initiated/dose increased, or decreased effects if a benzodiazepine is discontinued/dose decreased.</p>\n<div>\n <p><b>Benzodiazepines Interacting Members</b> Bromazepam, ChlordiazePOXIDE*, CloBAZam, ClonazePAM*, Clorazepate, DiazePAM*, Estazolam, Ethyl Loflazepate, Etizolam, Flunitrazepam, Flurazepam, Loprazolam, LORazepam, Lormetazepam, Midazolam, Nitrazepam, Nordazepam, Oxazepam, Prazepam, Quazepam, Temazepam, Tofisopam, Triazolam<br><b>Exception</b> ALPRAZolam</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Data are inconsistent regarding any interactions that may exist between phenytoin and various benzodiazepines. A study in 25 phenytoin-stable patients (300-400 mg/day) showed a nearly twofold increase in serum phenytoin concentrations when patients also received either chlordiazepoxide or diazepam.<sup>1</sup> Several other reports described increased serum phenytoin concentrations when receiving concomitant benzodiazepines (including chlordiazepoxide, clonazepam, and diazepam).<sup>2,3,4,5</sup> In contrast, multipatient, multidose studies have demonstrated decreased serum phenytoin concentrations when such was administered with these same benzodiazepines.<sup>6,7,8,9</sup> Alprazolam has been reported to not interact with phenytoin.<sup>10</sup> The varied reported effects do not allow for clarity in understanding potential mechanisms of interaction. The ability for agents to inhibit and/or induce CYP isoenzymes is a potential explanation. Monitoring for potential changes in serum phenytoin concentrations, given the large changes reported in some studies, is warranted.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Vajda FJ E, Prineas RJ, and Lovell RRH, “Interaction Between Phenytoin and the Benzodiazepines,” <i>Lancet</i>, 1971, i:346. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5541733\">[PubMed 5541733]</a></p>\n<p>2. Shuttleworth E, Wise G, and Paulson G, “Choreoathetosis and Diphenylhydantoin Intoxication,” <i>JAMA</i>, 1974, 230:1170. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4479423\">[PubMed 4479423]</a></p>\n<p>3. Windorfer P, “Drug Interactions During Anticonvulsive Therapy,” <i>Int J Clin Pharmacol</i>, 1976, 14:236.</p>\n<p>4. Kutt H and McDowell FJ, “Management of Epilepsy With Diphenylhydantoin Sodium,” <i>JAMA</i>, 1968, 203:969. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5694319\">[PubMed 5694319]</a></p>\n<p>5. Murphy A and Wilbur K, “Phenytoin-Diazepam Interaction,” <i>Ann Pharmacother</i>, 2003, 37(5):659-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12708941\">[PubMed 12708941]</a></p>\n<p>6. Saavedra IN, Aguilera LI, Faure E, et al, “Case Report. Phenytoin/Clonazepam Interaction,” <i>Ther Drug Monit</i>, 1985, 7:481. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4082246\">[PubMed 4082246]</a></p>\n<p>7. Siris JH, Pippenger CE, Werner WL, et al, “Anticonvulsive Drug Serum Levels in Psychiatric Patients With Seizure Disorders,” <i>NY State J Med</i>, 1974, 74:1554-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4527066\">[PubMed 4527066]</a></p>\n<p>8. Houghton GW and Richens A, “The Effects of Benzodiazepines and Pheneturide on Phenytoin Metabolism in Man,” <i>Br J Clin Pharmacol</i>, 1974, 1:P344.</p>\n<p>9. Edwards VE and Eadie MJ, “Clonazepam - A Clinical Study of its Effectiveness as an Anticonvulsant,” <i>Proc Aus Assoc Neurol</i>, 1973, 10:61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4600355\">[PubMed 4600355]</a></p>\n<p>10. Patrias JM, DiPiro JT, Cheung RP, et al, “Effect of Alprazolam on Phenytoin Pharmacokinetics,” <i>Drug Intell Clin Pharm</i>, 1987, 21:2A.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2977":"<p><b>Title</b> Vitamin K Antagonists / Fibric Acid Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fibric Acid Derivatives may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> The significance of this interaction may warrant a 25% to 33% reduction in the dosage of the oral anticoagulant if a fibric acid derivative is to be started. Monitor for toxic effects of oral anticoagulants if a fibric acid derivative is initiated/dose increased, or decreased effects if a fibric acid derivative is discontinued/dose decreased.</p>\n<div>\n <p><b>Fibric Acid Derivatives Interacting Members</b> Bezafibrate, Ciprofibrate, Fenofibrate and Derivatives, Gemfibrozil*</p>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The majority of 42 patients in a multicenter study required dosage reductions in their anticoagulant (warfarin or phenindione) following the addition of clofibrate to their regimens.<sup>1</sup> Bleeding occurred in several patients, and up to 33% anticoagulant dosage reductions were reported necessary to maintain appropriate anticoagulation parameters. Similar reports have been published with clofibrate with both warfarin and dicumarol,<sup>2,3,4</sup> with death having been reported as a clinical consequence.<sup>3</sup> Fenofibrate<sup>5,6,7,8</sup> and gemfibrozil<sup>9,10</sup> have been similarly implicated in causing problems with oral anticoagulants. Product labeling for ciprofibrate also warns of this interaction and recommends anticoagulant dose reduction along with close INR monitoring.<sup>11</sup> The mechanism(s) of these interactions is uncertain. Suggested mechanisms include: displacement of warfarin from protein binding sites; increased affinity of anticoagulant for binding sites; and altered anticoagulant metabolism (fenofibrate is noted to be a mild-moderate inhibitor of CYP2C9 by the manufacturer); and drug-induced reductions in coagulation factor synthesis.<sup>4,7,12,13,14,15</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Oliver MF, Roberts SD, Hayes D, et al, “Effect of Atromid and Ethyl Chlorophenoxy-Isobutyrate on Anticoagulant Requirements,” <i>Lancet</i>, 1963, i:143. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13940003\">[PubMed 13940003]</a></p>\n<p>2. Eastham RD, “Warfarin Dosage, Clofibrate and Age of Patient,” <i>Br Med J</i>, 1973, ii:554. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4714500\">[PubMed 4714500]</a></p>\n<p>3. Solomon RB and Rosner F, “Massive Haemorrhage and Death During Treatment With Clofibrate and Warfarin,” <i>NY State J Med</i>, 1973, 73:2002-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4517462\">[PubMed 4517462]</a></p>\n<p>4. Schrogie JJ and Solomon HM, “The Anticoagulant Response to Bishydroxycoumarin. II. The Effect of D-Thyroxine, Clofibrate and Norethandrolone,” <i>Clin Pharmacol Ther</i>, 1967, 8:70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4163172\">[PubMed 4163172]</a></p>\n<p>5. Lauwers PL, “Effect of Procetofene on Blood Lipids of Subjects With Essential Hyperlipidaemia,” <i>Curr Ther Res Clin Exp</i>, 1979, 26:30-8.</p>\n<p>6. Aldridge MA and Ito MK, “Fenofibrate and Warfarin Interaction,” <i>Pharmacotherapy</i>, 2001, 21(7):886-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11444587\">[PubMed 11444587]</a></p>\n<p>7. Ascah KJ, Rock GA, and Wells PS, “Interaction Between Fenofibrate and Warfarin,” <i>Ann Pharmacother</i>, 1998, 32(7-8):765-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9681093\">[PubMed 9681093]</a></p>\n<p>8. Kim KY and Mancano MA, “Fenofibrate Potentiates Warfarin Effects,” <i>Ann Pharmacother</i>, 2003, 37:212-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12549950\">[PubMed 12549950]</a></p>\n<p>9. Ahmad S, “Gemfibrozil Interaction With Warfarin Sodium (Coumadin),” <i>Chest</i>, 1990, 98:1041-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2209118\">[PubMed 2209118]</a></p>\n<p>10. Dixon DL, Williams VG, “Interaction Between Gemfibrozil and Warfarin: Case Report and Review of the Literature,” <i>Pharmacotherapy</i>, 2009, 29(6):744-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19476425\">[PubMed 19476425]</a></p>\n<p>11. Ciprofibrate [summary of product characteristics]. Harlington Road, Hillingdon, United Kingdom: NRIM Limited; November 2014.</p>\n<p>12. Solomon HM, Schrogie JJ, and Williams D, “The Displacement of Phenylbutazone-C14 and Warfarin-C14 From Human Albumin by Various Drugs and Fatty Acids,” <i>Biochem Pharmacol</i>, 1968, 17:143. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5638549\">[PubMed 5638549]</a></p>\n<p>13. Solomon HM and Schrogie JJ, “The Effect of Various Drugs on the Binding of Warfarin-C14 to Human Albumin,” <i>Biochem Pharmacol</i>, 1967, 16:1219. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6053595\">[PubMed 6053595]</a></p>\n<p>14. Zimmermann R, Ehlers W, Walter E, et al, “The Effect of Bezafibrate on the Fibrinolytic System and the Drug Interaction With Phenprocoumon,” <i>Atherosclerosis</i>, 1978, 29:477-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=666891\">[PubMed 666891]</a></p>\n<p>15. Prescribing information. Tricor (fenofibrate). North Chicago, IL: Abbott Laboratories, 12/2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2978":"<p><b>Title</b> Tricyclic Antidepressants / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome. While methylene blue and linezolid are expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors. Refer to monographs specific to those agents for details. <b>Severity</b> Major <b>Onset</b> Rapid <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> This combination should usually be avoided. Diligently monitor for evidence of hypertensive crisis and/or serotonin syndrome if a monoamine oxidase inhibitor (MAOI) and a tricyclic antidepressant (TCA) are concomitantly administered. Allow for an adequate washout period if a MAOI is discontinued and a TCA is to be started. A 2-week washout period is generally required. In general, furazolidone, linezolid, and procarbazine will pose less risk than isocarboxazid, phenelzine, or tranylcypromine. Caution is still advised. Selegiline administered in high oral dosages (eg, &gt;10 mg daily of tablet/capsule; &gt; 2.5 mg daily of orally disintegrating tablet) or transdermally will exhibit nonselective MAOI activity.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid*, Moclobemide*, Phenelzine*, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tranylcypromine*<br><b>Exceptions</b> Linezolid, Methylene Blue, Tedizolid</p>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline*, Amoxapine, ClomiPRAMINE*, Desipramine*, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine*, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The literature contains many reports of symptoms resembling the serotonin syndrome that have occurred in patients receiving concomitant monoamine oxidase inhibitor (MAOI) and tricyclic antidepressant (TCA) therapy. At times, the therapies were not concomitant, but one may have been started subsequent to discontinuing the other without an adequate washout period.<sup>1,2,3,4,5,6,7,8,9,10,11</sup> Symptoms in these cases included hyperpyrexia, muscle spasms and rigidity, seizure, coma, and even death. Implicated drug combinations included: Isocarboxazid with imipramine; tranylcypromine with imipramine and clomipramine; phenelzine with imipramine, desipramine, and clomipramine; moclobemide with imipramine, and clomipramine. The mechanism of these interactions is unclear. It is, therefore, difficult to identify safe combinations of these agents. However, the safe and beneficial use of MAOI/TCA combinations has been described.<sup>12,13,14</sup> Prudence in monitoring appears warranted.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Brachfeld J, Wirtschafter A, and Wolfe S, “Imipramine-Tranylcypromine Incompatibility. Near Fatal Toxic Reaction,” <i>JAMA</i>, 1963, 186:1172. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14063404\">[PubMed 14063404]</a></p>\n<p>2. Graham PM, Potter JM, and Paterson JW, “Combination Monoamine Oxidase Inhibitor/Tricyclic Antidepressant Interaction,” <i>Lancet</i>, 1982, ii:440. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6124828\">[PubMed 6124828]</a></p>\n<p>3. Bowen LW, “Fatal Hyperpyrexia With Antidepressant Drugs,” <i>Br Med J</i>, 1964, 2:1465. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14209383\">[PubMed 14209383]</a></p>\n<p>4. Nierenberg DW and Semprebon M, “The Central Nervous System Serotonin Syndrome,” <i>Clin Pharmacol Ther</i>, 1993, 53:84-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8257462\">[PubMed 8257462]</a></p>\n<p>5. Stern TA, Schwartz JH, and Shuster JL, “Catastrophic Illness Associated With the Combination of Clomipramine, Phenelzine and Chlorpromazine,” <i>Ann Clin Psychiatry</i>, 1992, 4:81-5.</p>\n<p>6. Tackley RM and Tregaskis B, “Fatal Disseminated Intravascular Coagulation Following a Monoamine Oxidase Inhibitor/Tricyclic Interaction,” <i>Anaesthesia</i>, 1987, 42:760-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3631476\">[PubMed 3631476]</a></p>\n<p>7. Brodribb TR, Downey M, and Gilbar PJ, “Efficacy and Adverse Effects of Moclobemide,” <i>Lancet</i>, 1994, 343:475-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7905962\">[PubMed 7905962]</a></p>\n<p>8. Spigset O, Mjorndal T, and Lovheim O, “Serotonin Syndrome Caused by a Moclobemide-Clomipramine Interaction,” <i>Br Med J</i>, 1993, 306:248. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8443525\">[PubMed 8443525]</a></p>\n<p>9. Francois B, Marquet P, Desachy A, et al, “Serotonin Syndrome Due to an Overdose of Moclobemide and Clomipramine. A Potentially Life-Threatening Association,” <i>Intensive Care Med</i>, 1997, 23:122-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9037653\">[PubMed 9037653]</a></p>\n<p>10. Ferrer-Dufol A, Perez-Aradros C, and Murillo EC, “Fatal Serotonin Syndrome Caused by Moclobemide-Clomipramine Overdose,” <i>Clin Toxicol</i>, 1998, 36:31-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9541038\">[PubMed 9541038]</a></p>\n<p>11. Kane FJ and Freeman D, “Nonfatal Reaction to Imipramine-MAOI Inhibitor Combination,” <i>Am J Psychiatry</i>, 1963, 120:79. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14030577\">[PubMed 14030577]</a></p>\n<p>12. Ponto LB, Perry PJ, Liskow BI, et al, “Drug Therapy Reviews: Tricyclic Antidepressant and Monoamine Oxidase Inhibitor Combination Therapy,” <i>Am J Hosp Pharm</i>, 1977, 34:954. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=333909\">[PubMed 333909]</a></p>\n<p>13. White K, Pistole T, and Boyd JL, “Combined Monoamine Oxidase Inhibitor-Tricyclic Antidepressant Treatment: A Pilot Study,” <i>Am J Psychiatry</i>, 1980, 137:1422-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7435677\">[PubMed 7435677]</a></p>\n<p>14. Berlanga C and Ortego-Soto HA, “A 3-Year Follow-up of a Group of Treatment-Resistant Depressed Patients With a MAOI/Tricyclic Combination,” <i>J Affect Disord</i>, 1995, 34:187-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7560546\">[PubMed 7560546]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2980":"<p><b>Title</b> CloZAPine / Benzodiazepines</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Benzodiazepines may enhance the adverse/toxic effect of CloZAPine. <b>Severity</b> Major <b>Onset</b> Rapid <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine. Monitor for respiratory depression and hypotension in patients who are receiving benzodiazepines and start clozapine. Increase monitoring of response to therapy in all patients who use this combination.</p>\n<div>\n <p><b>Benzodiazepines Interacting Members</b> ALPRAZolam, Bromazepam, ChlordiazePOXIDE, CloBAZam, ClonazePAM*, Clorazepate, DiazePAM*, Estazolam, Ethyl Loflazepate, Etizolam, Flunitrazepam, Flurazepam*, Loprazolam, LORazepam*, Lormetazepam, Midazolam, Nitrazepam, Nordazepam, Oxazepam, Prazepam, Quazepam, Temazepam, Tofisopam, Triazolam</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Several case reports describe the development of hypersalivation, severe respiratory depression/arrest, hypotension, unconsciousness, or delirium with concurrent use of clozapine and various benzodiazepines.<sup>1,2,3,4</sup> Some of these effects were apparent within a few hours of initiating clozapine in benzodiazepine-stable patients.<sup>1,2</sup> Though similar events have been reported with clozapine alone, the clozapine prescribing information recommends caution when initiating clozapine therapy in a patient who is taking a benzodiazepine or any other psychotropic medication.<sup>5</sup><br><br>In one retrospective chart review of 152 patients taking both clozapine and a benzodiazepine, there were no reported fatalities associated with the combination, and the authors concluded that this combination could be used safely, though the study was limited by a relatively small number of available outcome measures.<sup>6</sup><br><br>The specific mechanism for this reported interaction is uncertain. Data from an animal study in which benzodiazepines augmented the cataleptic effects of clozapine and other antipsychotic medications suggests that benzodiazepines may block the activation of normal feedback pathways that usually occurs during antipsychotic therapy.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Grohmann R, Ruuther E, Sassim N, et al, “Adverse Effects of Clozapine,” <i>Psychopharmacology</i>, 1989, 99:S101-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2813662\">[PubMed 2813662]</a></p>\n<p>2. Friedman LJ, Tabb SE, Worthington JJ, et al, “Clozapine - A Novel Antipsychotic Agent,” <i>N Engl J Med</i>, 1991, 325:518. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1852187\">[PubMed 1852187]</a></p>\n<p>3. Cobb CD, Anderson CB, Seidel DR, “Possible Interaction Between Clozapine and Lorazepam,” <i>Am J Psychiatry</i>, 1991, 148(11):1606-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1928489\">[PubMed 1928489]</a></p>\n<p>4. Jackson CW, Markowitz JS, Brewerton TD, “Delirium Associated with Clozapine and Benzodiazepine Combinations,” <i>Ann Clin Psychiatry</i>, 1995, 7(3):139-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8646274\">[PubMed 8646274]</a></p>\n<p>5. Prescribing information. Clozaril (clozapine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, December 2010.</p>\n<p>6. Bitter R, Demler TL, Opler L, “Safety Evaluation of the Concomitant Use of Clozapine and Benzodiazepines: A Retrospective, Cross-Sectional Chart Review,” <i>J Psychiatr Pract</i>, 2008, 14(5):265-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18832957\">[PubMed 18832957]</a></p>\n<p>7. Keller HH, Schaffner R, Haefely W, “Interaction of Benzodiazepines with Neuroleptics at Central Dopamine Neurons,” <i>Naunyn Schmiedebergs Arch Pharmacol</i>, 1976, 294(1):1-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12477\">[PubMed 12477]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2984":"<p><b>Title</b> Fibric Acid Derivatives / Bile Acid Sequestrants</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Bile Acid Sequestrants may decrease the absorption of Fibric Acid Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of fibric acid derivatives if administered concurrently with a bile acid sequestrant. If concomitant therapy is used, separate doses by at least 2 hours to minimize this interaction. Fenofibric acid labeling recommends administration one hour prior to or 4-6 hours after a bile acid sequestrant.</p>\n<div>\n <p><b>Bile Acid Sequestrants Interacting Members</b> Cholestyramine Resin, Colestipol*<br><b>Exception</b> Colesevelam</p>\n <p><b>Fibric Acid Derivatives Interacting Members</b> Bezafibrate, Ciprofibrate, Fenofibrate and Derivatives, Gemfibrozil*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of gemfibrozil (600 mg) was decreased approximately 30% in 10 patients when administered at the same time as a dose of colestipol (5 g).<sup>1</sup> No change in absorption was noted when the gemfibrozil was administered 2 hours before or after the colestipol. The clinical significance of this event is unknown. The mechanism is presumed to be related to the potential for colestipol to bind gemfibrozil in the GI tract. Colesevelam does not significantly affect the bioavailability of fenofibrate.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Forland SC, Feng Y, and Cutler RE, “Apparent Reduced Absorption of Gemfibrozil When Given With Colestipol,” <i>J Clin Pharmacol</i>, 1990, 30:29-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2303577\">[PubMed 2303577]</a></p>\n<p>2. Welchol [package insert]. Parsippany, NJ: Daiichi Sankyo, Inc, 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2985":"<p><b>Title</b> Tetracyclines / Bile Acid Sequestrants</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of tetracycline antibiotics are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Bile Acid Sequestrants may decrease the absorption of Tetracyclines. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of tetracycline derivatives if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. The manufacturer of colesevelam suggests that drugs should be administered at least 1 hour before or 4 hours after colesevelam.<sup>1</sup></p>\n<div>\n <p><b>Bile Acid Sequestrants Interacting Members</b> Cholestyramine Resin, Colesevelam, Colestipol*</p>\n <p><b>Tetracyclines Interacting Members</b> Demeclocycline, Doxycycline, Lymecycline, Minocycline, Oxytetracycline, Tetracycline (Systemic)*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The absorption of tetracycline (500 mg) was decreased by &gt;50% in 9 normal subjects when coadministered with colestipol (30 g).<sup>2</sup> The clinical significance of this effect is unknown. The mechanism is presumed to be related to the ability of colestipol to bind tetracycline in the GI tract. The impact of separating the administration of drug doses by 2 or more hours is unknown, but is presumed to be of value in minimizing the effect. The effect of other bile acid sequestrants is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Welchol [package insert]. Parsippany, NJ: Daiichi Sankyo, Inc, 2006.</p>\n<p>2. Friedman H, Greenblatt DJ, and LeDuc BW, “Impaired Absorption of Tetracycline By Colestipol Is Not Reversed By Orange Juice,” <i>J Clin Pharmacol</i>, 1989, 29:748-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2778097\">[PubMed 2778097]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2986":"<p><b>Title</b> Thiazide and Thiazide-Like Diuretics / Bile Acid Sequestrants</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of thiazide diuretics are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Bile Acid Sequestrants may decrease the absorption of Thiazide and Thiazide-Like Diuretics. The diuretic response is likewise decreased. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of thiazide diuretics if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.</p>\n<div>\n <p><b>Bile Acid Sequestrants Interacting Members</b> Cholestyramine Resin*, Colesevelam, Colestipol*</p>\n <p><b>Thiazide and Thiazide-Like Diuretics Interacting Members</b> Bendroflumethiazide, Chlorothiazide*, Chlorthalidone, Cyclopenthiazide, HydroCHLOROthiazide*, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone, Xipamide</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The serum concentrations of hydrochlorothiazide were reduced by &gt;50% in subjects when coadministered with either cholestyramine or colestipol. The diuretic response was similarly (or at times more significantly) reduced.<sup>1</sup> Administering cholestyramine 4 hours after the dose of hydrochlorothiazide lessened, but did not eliminate, the effect.<sup>2</sup> A similar interaction has been reported between colestipol and chlorothiazide.<sup>3</sup> The mechanism of this interaction is related to the ability of bile acid sequestrants to bind drug products in the GI tract, thus limiting their absorption. The effect of colesevelam is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hunninghake DB, King S, and La Croix K, “The Effect of Cholestyramine and Colestipol on the Absorption of Hydrochlorothiazide,” <i>Int J Clin Pharmacol Ther Toxicol</i>, 1982, 20(4):151-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7076343\">[PubMed 7076343]</a></p>\n<p>2. Hunninghake DB and Hibbard DM, “Influence of Time Intervals for Cholestyramine Dosing on the Absorption of Hydrochlorothiazide,” <i>Clin Pharmacol Ther</i>, 1986, 39:329-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3948472\">[PubMed 3948472]</a></p>\n<p>3. Kauffmann RE and Azarnoff DL, “Effect of Colestipol on Gastrointestinal Absorption of Chlorothiazide in Man,” <i>Clin Pharmacol Ther</i>, 1973, 14:886. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4729904\">[PubMed 4729904]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2987":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / Penicillins</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Penicillins may diminish the therapeutic effect of Estrogen Derivatives (Contraceptive). Concerns generated by anecdotal reports have been refuted by more rigorous scientific and clinical data. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required. Exception: Nafcillin - see related monograph.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol, Mestranol</p>\n <p><b>Penicillins Interacting Members</b> Amdinocillin, Amoxicillin, Ampicillin*, Bacampicillin, Cloxacillin, Dicloxacillin, Flucloxacillin, Oxacillin, Penicillin G (Parenteral/Aqueous), Penicillin G Benzathine, Penicillin G Procaine, Penicillin V Benzathine, Penicillin V Potassium, Piperacillin, Temocillin, Ticarcillin<br><b>Exception</b> Nafcillin</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Anecdotal data indicate the possibility that penicillin antibiotics might inhibit the efficacy of hormonal contraceptives. These are almost exclusively related to estrogen-containing products.<sup>1,2</sup> A 2-month study in 11 subjects taking an oral contraceptive (containing 50 mcg estrogen) and ampicillin showed no effect of the ampicillin on the ovulation suppression effect of the contraceptive.<sup>3</sup> A paucity of epidemiologic data suggests that the incidence of pregnancy that occurs with concomitant antibiotic and hormonal contraception is no greater than the incidence during the use of hormonal contraception alone without concomitant antibiotics.<sup>4,5,6</sup> A thorough review of this topic was conducted by Archer et al.<sup>7</sup> They concluded that “available scientific and pharmacokinetic data do not support the hypothesis that antibiotics (with the exception of rifampin) lower the contraceptive efficacy of oral contraceptives.” A year 2000 Practice Bulletin of the American College of Obstetrics and Gynecology recommends the use of nonhormonal contraceptives only (due to interaction concern) with the concomitant use of rifampin or griseofulvin.<sup>8</sup> A proposed (yet otherwise unproven) mechanism for this potential interaction is based on the antibiotic's ability to reduce gut bacteria which are important for hydrolysis of conjugated estrogen, which subsequently permits the reabsorption of the estrogen (ie, enterohepatic circulation is interrupted, resulting in lower serum concentrations of the estrogen). No supporting evidence is available. Two penicillin antibiotics, nafcillin and dicloxacillin, may offer additional potential mechanisms for interaction with estrogen-containing contraceptives. Both agents appear to induce CYP3A4 isoenzymes and, therefore, may reduce serum estrogen concentrations. No reports confirming these effects or associated problems have been identified.<br><br>Of note, ethinyl estradiol patches and vaginal rings introduce substantial circulating drug concentrations. It is also not clear to what extent efficacy of vaginal ring products is dependent on local versus systemic effects. Therefore, caution with coadministration of interacting drugs is warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Back DJ, Breckenridge AM, MacIver M, et al, “The Effect of Ampicillin on Oral Contraceptive Steroids in Women,” <i>Br J Clin Pharmacol</i>, 1982, 14:43-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6809025\">[PubMed 6809025]</a></p>\n<p>2. Back DJ, Grimmer FM, Orme ML, et al, “Evaluation of Committee on Safety of Medicines Yellow Card Reports on Oral Contraceptive-Drug Interactions With Anticonvulsants and Antibiotics,” <i>Br J Clin Pharmacol</i>, 1988, 25:527-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3408633\">[PubMed 3408633]</a></p>\n<p>3. Friedman CI, Huneke AL, Kim MH, et al, “The Effect of Ampicillin on Oral Contraceptive Effectiveness,” <i>Obstet Gynecol</i>, 1980, 55:33-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7188714\">[PubMed 7188714]</a></p>\n<p>4. Sparrow MJ, “Pill Method Failures,” <i>N Z Med J</i>, 1987, 100:102-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3470667\">[PubMed 3470667]</a></p>\n<p>5. Back DJ, Grimmer SF, Orme ML, et al, “Evaluation of Committee on Safety of Medicines Yellow Card Reports on Oral Contraceptive-Drug Interactions With Anticonvulsants and Antibiotics,” <i>Br J Clin Pharmacol</i>, 1988, 25(5):527-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3408633\">[PubMed 3408633]</a></p>\n<p>6. Helms SE, Bredle DL, Zajic J, et al, “Oral Contraceptive Failure Rates and Oral Antibiotics,” <i>J Am Acad Dermatol</i>, 1997, 36:705-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9146531\">[PubMed 9146531]</a></p>\n<p>7. Archer JS and Archer DF, “Oral Contraceptive Efficacy and Antibiotic Interaction: A Myth Debunked,” <i>J Am Acad Dermatol</i>, 2002, 46:917-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12063491\">[PubMed 12063491]</a></p>\n<p>8. ACOG Practice Bulletin, The Use of Hormonal Contraception in Women With Coexisting Medical Conditions, July, 2000, The American College of Obstetricians and Gynecologists, Washington DC.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2988":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CarBAMazepine may diminish the therapeutic effect of Estrogen Derivatives (Contraceptive). Contraceptive failure is possible. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Contraceptive failure is possible. If carbamazepine must be used in a patient desiring effective birth control, hormonal contraceptives may not provide adequate protection against conception. Patients must be instructed to use alternative, nonhormonal contraceptives. It is important to note that breakthrough bleeding, though an important sign regarding the diminished effect of oral contraceptives, might not be present in spite of the occurrence of an interaction.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol*, Mestranol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A number of case reports describe women on oral contraceptives who became pregnant following the initiation of carbamazepine.<sup>1,2,3,4</sup> Pharmacokinetics of single doses of ethinyl estradiol and levonorgestrel were studied in 4 women both before, and 8-12 weeks after, the initiation of carbamazepine therapy.<sup>5</sup> The serum concentrations of ethinyl estradiol and levonorgestrel were reduced 42% and 40%, respectively, in the presence of the carbamazepine. Other data support these results.<sup>6</sup> Unplanned pregnancies associated with carbamazepine and contraceptives have also been reported with norgestrel subdermal capsule use.<sup>7</sup> The mechanism of this pharmacokinetic effect is unknown, but might be due to enhanced metabolism. Whether the use of lower dose products carries greater risk than higher dose products is unclear. Note that ethinyl estradiol patches and vaginal rings introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rapport DJ and Calabrese JR, “Interactions Between Carbamazepine and Birth Control Pills,” <i>Psychosomatics</i>, 1989, 30(4):462-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2798744\">[PubMed 2798744]</a></p>\n<p>2. Kenyon IE, “Unplanned Pregnancy in an Epileptic,” <i>Br Med J</i>, 1972, 1(801):686-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5015305\">[PubMed 5015305]</a></p>\n<p>3. Janz D and Schmidt D, “Antiepileptic Drugs and Failure of Oral Contraceptives,” <i>Lancet</i>, 1974, 1(7866):1113 (letter). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4135275\">[PubMed 4135275]</a></p>\n<p>4. Laengner H and Detering K, “Antiepileptic Drugs and Failure of Oral Contraceptives,” <i>Lancet</i>, 1974, 2(7880):600 (letter). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4140317\">[PubMed 4140317]</a></p>\n<p>5. Crawford P, Chadwick DJ, Martin C, et al, “The Interaction of Phenytoin and Carbamazepine With Combined Oral Contraceptive Steroids,” <i>Br J Clin Pharmacol</i>, 1990, 30(6):892-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2126946\">[PubMed 2126946]</a></p>\n<p>6. Doose DR, Wang SS, Padmanabhan M, et al, “Effect of Topiramate or Carbamazepine on the Pharmacokinetics of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol in Healthy Obese and Nonobese Female Subjects,” <i>Epilepsia</i>, 2003, 44(4):540-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12681003\">[PubMed 12681003]</a></p>\n<p>7. Haukkamaa M, “Contraception by Norplant Subdermal Capsules is Not Reliable in Epileptic Patients on Anticonvulsant Treatment,” <i>Contraception</i>, 1986, 33(6):559-65. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3095023\">[PubMed 3095023]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2989":"<p><b>Title</b> Progestins (Contraceptive) / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CarBAMazepine may diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Contraceptive failure is possible. If carbamazepine must be used in a patient desiring effective birth control, hormonal contraceptives may provide adequate protection against conception. Patients must be instructed to use alternative, nonhormonal contraceptives. It is important to note that breakthrough bleeding, though an important sign regarding the diminished effect of hormonal contraceptives, might not be present in spite of the occurrence of an interaction. When using levonorgestrel as an emergency contraceptive, recommendations outside of the United States suggest doubling the dose of levonorgestrel to 3 mg in women who have used enzyme inducing drugs in the previous 4 weeks.<sup>1</sup></p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A number of case reports describe women on oral contraceptives who became pregnant following the initiation of carbamazepine.<sup>2,3,4,5</sup> Pharmacokinetics of single doses of ethinyl estradiol and levonorgestrel were studied in 4 women both before, and 8-12 weeks after, the initiation of carbamazepine therapy.<sup>6</sup> The serum concentrations of ethinyl estradiol and levonorgestrel were reduced 42% and 40%, respectively in the presence of the carbamazepine. Unplanned pregnancies associated with carbamazepine and contraceptives have also been reported with norgestrel subdermal capsule use.<sup>7</sup> The mechanism of this pharmacokinetic effect is unknown, but might be due to enhanced metabolism. Whether the use of lower dose products carries greater risk than higher dose products is unclear. Note that many non-oral progestin-containing products (gels, vaginal rings, injectables, etc) introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. The Medicines and Healthcare products Regulatory Agency (MHRA). Levonorgestrel-containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers and contraceptive efficacy. <i>Drug Safety Update</i>. 2016;10(2):1-8. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/553274/Sept_2016_DSU.pdf. Accessed September 28, 2016.</p>\n<p>2. Rapport DJ and Calabrese JR, “Interactions Between Carbamazepine and Birth Control Pills,” <i>Psychosomatics</i>, 1989, 30:462-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2798744\">[PubMed 2798744]</a></p>\n<p>3. Kenyon IE, “Unplanned Pregnancy in an Epileptic,” <i>Br Med J</i>, 1972, 1:686-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5015305\">[PubMed 5015305]</a></p>\n<p>4. Janz D and Schmidt D, “Antiepileptic Drugs and Failure of Oral Contraceptives,” <i>Lancet</i>, 1974, 1:1113 (letter). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4135275\">[PubMed 4135275]</a></p>\n<p>5. Laengner H and Detering K, “Antiepileptic Drugs and Failure of Oral Contraceptives,” <i>Lancet</i>, 1974, 2:600 (letter). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4140317\">[PubMed 4140317]</a></p>\n<p>6. Crawford P, Chadwick DJ, Martin C, et al, “The Interaction of Phenytoin and Carbamazepine With Combined Oral Contraceptive Steroids,” <i>Br J Clin Pharmacol</i>, 1990, 30(6):892-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2126946\">[PubMed 2126946]</a></p>\n<p>7. Haukkamaa M, “Contraception by Norplant Subdermal Capsules is Not Reliable in Epileptic Patients on Anticonvulsant Treatment,” <i>Contraception</i>, 1986, 33:559. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3095023\">[PubMed 3095023]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2990":"<p><b>Title</b> Progestins (Contraceptive) / Acitretin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Acitretin may diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Given the potential for progestin-only preparations to fail to prevent pregnancy during acitretin therapy, such products should not be relied upon. Alternative, nonhormonal forms of contraception must be employed during acitretin therapy.</p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> The manufacturer of acitretin states “it has been established that acitretin interferes with the contraceptive effect of microdosed progestin minipill preparations. It is not known whether other progestational contraceptives, such as implants and injectables, may be inadequate methods of contraception during acitretin therapy.”<sup>1</sup> Of note, many such non-oral progestin-containing products (gels, vaginal rings, injectables, etc) do introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs seems warranted. The specific mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Soriatane (acitretin). Coral Gables, FL: Stiefel Laboratories, Inc., 01/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2991":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / Felbamate</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Felbamate may decrease the serum concentration of Estrogen Derivatives (Contraceptive). Contraceptive failure is possible. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Contraceptive failure is possible. Patients must be instructed to use alternative, nonhormonal forms of contraception during felbamate therapy. It may be possible to use higher doses of the hormonal contraceptive to ensure adequate concentrations of circulating hormones. Careful monitoring of serum hormone concentrations may be the only way to ensure adequate dosing. If agents are used concomitantly, monitor for signs of reduced hormone concentrations (eg, breakthrough bleeding) noting that the absence of such signs does not indicate therapeutic success.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol*, Mestranol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of ethinyl estradiol (received via an oral contraceptive containing 30 mcg + gestodene 75 mcg) was decreased an average of 13% in 31 normal women following the addition of felbamate (2400 mg/day from day 15 of month 1 to day 14 of month 2 of ovulation cycle) to their regimens.<sup>1,2</sup> No subjects showed any evidence of ovulation during the placebo-controlled study, however breakthrough bleeding was noted in one subject. Gestodene concentrations were decreased by 42%. The mechanism of these interactions is unknown, but may be related to the ability of felbamate to increase the metabolism of some chemical entities. The effect of this interaction on the reliability of hormonal contraceptives is unknown. Note that ethinyl estradiol patches and vaginal rings introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Banfield C, Saano V, Glue P, et al, “Effects of Felbamate on Oral Contraceptive Pharmacokinetics,” <i>Clin Pharmacol Ther</i>, 1995, 57:207.</p>\n<p>2. Saano V, Glue P, Banfield CR, et al, “Effects of Felbamate on the Pharmacokinetics of a Low-Dose Combination Oral Contraceptive,” <i>Clin Pharmacol Ther</i>, 1995, 58(5):523-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7586946\">[PubMed 7586946]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2992":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / OXcarbazepine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> OXcarbazepine may decrease the serum concentration of Estrogen Derivatives (Contraceptive). Contraceptive failure is possible. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Contraceptive failure is possible. If oxcarbazepine must be used in a patient desiring effective birth control, hormonal contraceptives may not provide adequate protection against conception. Patients must be instructed to use alternative, nonhormonal contraceptives. It is important to note that breakthrough bleeding, though an important sign regarding the diminished effect of hormonal contraceptives, might not be present in spite of the occurrence of an interaction.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol*, Mestranol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of ethinyl estradiol (as an oral contraceptive combined with levonorgestrel) was decreased approximately 47% in 16 normal women when oxcarbazepine was added to their regimens.<sup>1</sup> The progestin was decreased to a similar extent. Breakthrough bleeding was noted in some subjects. Earlier studies yielded similar results.<sup>2,3</sup> In spite of the menstrual changes, no cases of failed contraception have been identified. <br><br>The prescribing information for oxcarbazepine states that concurrent use of oxcarbazepine with hormonal contraceptives may render these contraceptives less effective.<sup>4</sup><br><br>The mechanism of these interactions may be related to the ability of oxcarbazepine to increase hepatic metabolism of the hormones (i.e., increase first-pass effect). Note that ethinyl estradiol patches and vaginal rings introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Fattore C, Cipolla G, Gatti G, et al, “Induction of Ethinylestradiol and Levonorgestrel Metabolism by Oxycarbazepine in Healthy Women,” <i>Epilepsia</i>, 1999, 40(6):783-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10368079\">[PubMed 10368079]</a></p>\n<p>2. Klosterskov-Jensen P, Saano V, Haring P, et al, “Possible Interaction Between Oxcarbazepine and an Oral Contraceptive,” <i>Epilepsia</i>, 1992, 33:1149-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1464278\">[PubMed 1464278]</a></p>\n<p>3. Sonnen AE, “Oxcarbazepine and Oral Contraceptives,” <i>Acta Neurol Scand</i>, 1990, 82(Suppl 133):37.</p>\n<p>4. Trileptal (oxcarbazepine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2993":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / Barbiturates</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Barbiturates may diminish the therapeutic effect of Estrogen Derivatives (Contraceptive). Contraceptive failure is possible. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> If barbiturates must be used in a patient desiring effective birth control, hormone-containing contraceptives (including non-oral products) may not provide adequate protection against conception. Contraceptive failure is possible. Patients must be instructed to use alternative, nonhormonal contraceptives. It is important to note that breakthrough bleeding, though an important sign regarding the diminished effect of oral contraceptives, might not be present in spite of the occurrence of an interaction.</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital, Butabarbital, Butalbital, Methohexital, PENTobarbital, PHENobarbital*, Primidone, Secobarbital, Thiopental</p>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol, Mestranol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case reports describe women on oral contraceptives who became pregnant during concomitant therapy with oral contraceptives and phenobarbital.<sup>1,2</sup> The mechanism of this interaction is unknown, but might be a pharmacokinetic effect related to phenobarbital-enhanced metabolism of estrogens and/or progestins. Whether the use of lower dose products carries greater risk of therapeutic failure than higher dose products is unclear. Note that ethinyl estradiol patches and vaginal rings introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Janz D and Schmidt D, “Antiepileptic Drugs and Failure of Oral Contraceptives,” <i>Lancet</i>, 1974, i:1113. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4135275\">[PubMed 4135275]</a></p>\n<p>2. Hempel E and Klinger W, “Drug Stimulated Biotransformation of Hormonal Contraceptive Steroids. Clinical Implications,” <i>Drugs</i>, 1976, 12:442. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1001220\">[PubMed 1001220]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2994":"<p><b>Title</b> Progestins (Contraceptive) / Barbiturates</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Barbiturates may diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Contraceptive failure is possible. If barbiturates must be used in a patient desiring effective birth control, hormonal contraceptives may not provide adequate protection against conception. Patients must be instructed to use alternative, nonhormonal contraceptives. It is important to note that breakthrough bleeding, though an important sign regarding the diminished effect of hormonal contraceptives, might not be present in spite of the occurrence of an interaction. When using levonorgestrel as an emergency contraceptive, recommendations outside of the United States suggest doubling the dose of levonorgestrel to 3 mg in women who have used enzyme inducing drugs in the previous 4 weeks.<sup>1</sup></p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital, Butabarbital, Butalbital, Methohexital, PENTobarbital, PHENobarbital*, Primidone, Secobarbital, Thiopental</p>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case reports describe women on oral contraceptives who became pregnant during concomitant therapy with oral contraceptives and phenobarbital.<sup>2,3</sup> The mechanism of this interaction is unknown, but might be a pharmacokinetic effect related to phenobarbital-enhanced metabolism of estrogens and/or progestins. Whether the use of lower dose products carries greater risk of therapeutic failure than higher dose products is unclear. Note that many non-oral progestin-containing products (gels, vaginal rings, injectables, etc) introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. The Medicines and Healthcare products Regulatory Agency (MHRA). Levonorgestrel-containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers and contraceptive efficacy. <i>Drug Safety Update</i>. 2016;10(2):1-8. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/553274/Sept_2016_DSU.pdf. Accessed September 28, 2016.</p>\n<p>2. Janz D, Schmidt D. Letter: Anti-epileptic drugs and failure of oral contraceptives. <i>Lancet</i>. 1974;1(7866):1113. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4135275\">[PubMed 4135275]</a></p>\n<p>3. Hempel E, Klinger W. Drug stimulated biotransformation of hormonal steroid contraceptives: clinical implications. <i>Drugs</i>. 1976;12(6):442-448. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1001220\">[PubMed 1001220]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2995":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Phenytoin may diminish the therapeutic effect of Estrogen Derivatives (Contraceptive). Contraceptive failure is possible. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Contraceptive failure is possible. If phenytoin must be used in a patient desiring effective birth control, oral contraceptives (and possibly nonoral contraceptives) may not provide adequate protection against conception. Patients must be instructed to use alternative, nonhormonal forms of contraceptives. It is important to note that breakthrough bleeding, though an important sign regarding the diminished effect of oral contraceptives, might not be present in spite of the occurrence of an interaction.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol, Mestranol</p>\n</div> \n<p><b>Discussion</b> Case reports describe women on oral contraceptives who became pregnant during concomitant therapy with oral contraceptives and phenytoin.<sup>1,2</sup> The mechanism of this interaction is unknown, but might be a pharmacokinetic effect related to phenytoin-enhanced metabolism of estrogens and/or progestins. Whether the use of lower dose products carries greater risk of therapeutic failure than higher dose products is unclear. Note that ethinyl estradiol patches and vaginal rings introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kenyon IE, “Unplanned Pregnancy in an Epileptic,” <i>Br Med J</i>, 1972, 1:686. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5015305\">[PubMed 5015305]</a></p>\n<p>2. Janz D and Schmidt D, “Antiepileptic Drugs and Failure of Oral Contraceptives,” <i>Lancet</i>, 1974, i:1113. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4135275\">[PubMed 4135275]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2996":"<p><b>Title</b> Progestins (Contraceptive) / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Phenytoin may diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Contraceptive failure is possible. If phenytoin must be used in a patient desiring effective birth control, hormonal contraceptives may not provide adequate protection against conception. Patients must be instructed to use alternative, nonhormonal contraceptives. It is important to note that breakthrough bleeding, though an important sign regarding the diminished effect of hormonal contraceptives, might not be present in spite of the occurrence of an interaction. When using levonorgestrel as an emergency contraceptive, recommendations outside of the United States suggest doubling the dose of levonorgestrel to 3 mg in women who have used enzyme inducing drugs in the previous 4 weeks.<sup>1</sup></p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> Case reports describe women on oral contraceptives who became pregnant during concomitant therapy with phenytoin.<sup>2,3</sup> Contraceptive failure has also been reported when phenytoin was combined with levonorgestrel subdermal capsules.<sup>4,5</sup> The mechanism of this interaction is unknown, but might be a pharmacokinetic effect related to phenytoin-enhanced metabolism of estrogens and/or progestins. Whether the use of lower dose products carries greater risk of therapeutic failure than higher dose products is unclear. Note that many non-oral progestin-containing products (gels, vaginal rings, injectables, etc) introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. The Medicines and Healthcare products Regulatory Agency (MHRA). Levonorgestrel-containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers and contraceptive efficacy. <i>Drug Safety Update</i>. 2016;10(2):1-8. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/553274/Sept_2016_DSU.pdf. Accessed September 28, 2016.</p>\n<p>2. Kenyon IE, “Unplanned Pregnancy in an Epileptic,” <i>Br Med J</i>, 1972, 1:686. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5015305\">[PubMed 5015305]</a></p>\n<p>3. Janz D and Schmidt D, “Antiepileptic Drugs and Failure of Oral Contraceptives,” <i>Lancet</i>, 1974, i:1113. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4135275\">[PubMed 4135275]</a></p>\n<p>4. Odlind V and Olsson SE, “Enhanced Metabolism of Levonorgestrel During Phenytoin Treatment in a Woman With <i>Norplant</i> Implants,” <i>Contraception</i>, 1986, 33:257-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3087695\">[PubMed 3087695]</a></p>\n<p>5. Haukkamaa M, “Contraception by <i>Norplant</i> Subdermal Capsules is Not Reliable in Epileptic Patients on Anticonvulsant Treatment,” <i>Contraception</i>, 1986, 33:559-65. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3095023\">[PubMed 3095023]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2997":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / Rifamycin Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Rifamycin Derivatives may decrease the serum concentration of Estrogen Derivatives (Contraceptive). Contraceptive failure is possible. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Contraceptive failure is possible. If a rifamycin derivative must be used in a patient desiring effective birth control, hormonal contraceptives may not provide adequate protection against conception. Patients must be instructed to use alternative, nonhormonal contraceptives. It is important to note that breakthrough bleeding, though an important sign regarding the diminished effect of many hormonal contraceptives, might not be present in spite of the occurrence of an interaction.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol*, Mestranol</p>\n <p><b>Rifamycin Derivatives Interacting Members</b> Rifabutin*, RifAMPin*, Rifapentine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Many reports describe continued ovulation, breakthrough bleeding/spotting, and contraceptive failure in patients receiving concomitant oral contraceptives (combined estrogens and progestins) and rifampin.<sup>1,2,3,4,5,6</sup> The AUC of ethinyl estradiol was decreased by 62.5% in 12 females taking a combination oral contraceptive (including norethindrone) when coadministered with rifampin on cycle days 7-21.<sup>7</sup> Progestin concentrations were also decreased. Ovulation did not occur in any of these subjects as a result of the apparent interaction. Similar results were demonstrated in 22 subjects receiving ethinyl estradiol/norethindrone and rifampin or rifabutin, with the rifabutin subjects experiencing lesser changes in hormone concentrations and incidence of breakthrough bleeding.<sup>8</sup> The rifabutin results have been confirmed in another study.<sup>7</sup> The mechanism of these interactions is likely related to rifamycin-induced increases in hormone metabolism. The American College of Obstetricians and Gynecologists recommends the use of nonhormonal contraception during concomitant therapy.<sup>9</sup> Note that ethinyl estradiol patches and vaginal rings introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Reimers D, Nocke-Finck L, and Breuer H, “Rifampicin Causes a Lowering in Efficacy of Oral Contraceptives by Influencing Oestrogen Excretion,” <i>Reports on Rifampicin: XXII International Tuberculosis Conference</i>, Tokyo, September 1973, 87-9.</p>\n<p>2. Reimers D, Nocke-Finck L, and Breuer H, “Rifampicin, Pill Do Not Go Well Together,” <i>JAMA</i>, 1974, 227:608. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12276861\">[PubMed 12276861]</a></p>\n<p>3. Skolnik JL, Stoler BS, Katz DB, et al, “Rifampicin, Oral Contraceptives and Pregnancy,” <i>JAMA</i>, 1976, 236:1382. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=989097\">[PubMed 989097]</a></p>\n<p>4. Meyer BH, Muller FO, and Wessels P, “Lack of Interaction Between Roxithromycin and an Oral Contraceptive,” <i>Eur J Pharmacol</i>, 1990, 183:1031-2.</p>\n<p>5. Meyer BH, Muller FO, Wessels P, et al, “A Model to Detect Interactions Between Roxithromycin and Oral Contraceptives,” <i>Clin Pharmacol Ther</i>, 1990, 47:671-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2113449\">[PubMed 2113449]</a></p>\n<p>6. Joshi JV, Joshi UM, Sankolli GM, et al, “A Study of Interaction of Low-Dose Combination Oral Contraceptive With Antitubercular Drugs,” <i>Contraception</i>, 1980, 21:617-29. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7428368\">[PubMed 7428368]</a></p>\n<p>7. Barditch-Crovo P, Trapnell CB, Ette E, et al, “The Effects of Rifampin and Rifabutin on the Pharmacokinetics and Pharmacodynamics of a Combination Oral Contraceptive,” <i>Clin Pharmacol Ther</i>, 1999, 65(4):428-38. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10223781\">[PubMed 10223781]</a></p>\n<p>8. LeBel M, Masson E, Guilbert E, et al, “Drug Interaction With Oral Contraceptive (OC) Rifabutin (FAB) Versus Rifampicin (FAM),” <i>American Society for Clinical Pharmacology and Therapeutics</i>, 1997, (abstract).</p>\n<p>9. ACOG Practice Bulletin, The Use of Hormonal Contraception in Women With Coexisting Medical Conditions, July, 2000, The American College of Obstetricians and Gynecologists, Washington DC.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2998":"<p><b>Title</b> Progestins (Contraceptive) / Rifamycin Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Rifamycin Derivatives may decrease the serum concentration of Progestins (Contraceptive). Contraceptive failure is possible. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Contraceptive failure is possible. If a rifamycin derivative must be used in a patient desiring effective birth control, hormonal contraceptives may not provide adequate protection against conception. Patients must be instructed to use alternative, nonhormonal contraceptives. It is important to note that breakthrough bleeding, though an important sign regarding the diminished effect of hormonal contraceptives, might not be present in spite of the occurrence of an interaction. When using levonorgestrel as an emergency contraceptive, recommendations outside of the US suggest doubling the dose of levonorgestrel to 3 mg in women who have used enzyme inducing drugs in the previous 4 weeks.<sup>1</sup></p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone*, Norgestimate, Norgestrel</p>\n <p><b>Rifamycin Derivatives Interacting Members</b> Rifabutin*, RifAMPin*, Rifapentine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Many reports describe continued ovulation, breakthrough bleeding/spotting, and contraceptive failure in patients receiving concomitant oral contraceptives (combined estrogens and progestins).<sup>2,3,4,5,6,7</sup> The AUC of norethindrone was decreased by 49.4% in 12 females taking a combination oral contraceptive (including ethinyl estradiol) when coadministered with rifampin on cycle days 7-21.<sup>8</sup> Estrogen concentrations were also decreased. Ovulation did not occur in any of these subjects as a result of the apparent interaction. Similar results were demonstrated in 22 subjects receiving ethinyl estradiol/norethindrone and rifampin or rifabutin, with the rifabutin subjects experiencing lesser changes in hormone concentrations and incidence of breakthrough bleeding.<sup>9</sup> The rifabutin results have been confirmed in another study.<sup>8</sup> The mechanism of these interactions is likely related to rifamycin-induced increases in hormone metabolism. The American College of Obstetricians and Gynecologists recommend the use of nonhormonal contraception during concomitant therapy of griseofulvin and hormonal contraceptives.<sup>10</sup> Note that many non-oral progestin-containing products (gels, vaginal rings, injectables, etc) introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. The Medicines and Healthcare products Regulatory Agency (MHRA). Levonorgestrel-containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers and contraceptive efficacy. <i>Drug Safety Update</i>. 2016;10(2):1-8. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/553274/Sept_2016_DSU.pdf. Accessed September 28, 2016.</p>\n<p>2. Reimers D, Nocke-Finck L, and Breuer H, “Rifampicin Causes a Lowering in Efficacy of Oral Contraceptives by Influencing Oestrogen Excretion,” <i>Reports on Rifampicin: XXII International Tuberculosis Conference</i>, Tokyo, September 1973, 87-9.</p>\n<p>3. Reimers D, Nocke-Finck L, and Breuer H, “Rifampicin, Pill Do Not Go Well Together,” <i>JAMA</i>, 1974, 227:608.</p>\n<p>4. Skolnik JL, Stoler BS, Katz DB, et al, “Rifampicin, Oral Contraceptives and Pregnancy,” <i>JAMA</i>, 1976, 236:1382. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=989097\">[PubMed 989097]</a></p>\n<p>5. Meyer BH, Muller FO, and Wessels P, “Lack of Interaction Between Roxithromycin and an Oral Contraceptive,” <i>Eur J Pharmacol</i>, 1990, 183:1031-2.</p>\n<p>6. Meyer BH, Muller FO, Wessels P, et al, “A Model to Detect Interactions Between Roxithromycin and Oral Contraceptives,” <i>Clin Pharmacol Ther</i>, 1990, 47:671-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2113449\">[PubMed 2113449]</a></p>\n<p>7. Joshi JV, Joshi UM, Sankolli GM, et al, “A Study of Interaction of Low-Dose Combination Oral Contraceptive With Antitubercular Drugs,” <i>Contraception</i>, 1980, 21:617-29. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7428368\">[PubMed 7428368]</a></p>\n<p>8. Barditch-Crovo P, Trapnell CB, Ette E, et al, “A Pharmacokinetic and Pharmacodynamic Evaluation of the Effect of Rifampin and Rifabutin on Combination Oral Contraceptives,” <i>Clin Pharmacol Ther</i>, 1998, 63:180. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10223781\">[PubMed 10223781]</a></p>\n<p>9. LeBel M, Masson E, Guilbert E, et al, “Drug Interaction With Oral Contraceptive (OC) Rifabutin (FAB) Versus Rifampicin (FAM),” <i>American Society for Clinical Pharmacology and Therapeutics</i>, 1997 (abstract).</p>\n<p>10. ACOG Practice Bulletin, The Use of Hormonal Contraception in Women With Coexisting Medical Conditions, July, 2000, The American College of Obstetricians and Gynecologists, Washington DC.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2999":"<p><b>Title</b> Selegiline / Estrogen Derivatives (Contraceptive)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Estrogen Derivatives (Contraceptive) may increase the serum concentration of Selegiline. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for toxic effects of selegiline if a hormonal contraceptive is initiated or the dose is increased. The increased selegiline serum concentrations may result in a loss of MAOI-A selectivity, and potentially cause a host of additional problems related to nonselective MAOI activity.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol, Mestranol</p>\n</div> \n<p><b>Discussion</b> The serum concentrations of oral selegiline were increased in 4 women by approximately 20-fold while concomitantly receiving oral contraceptives.<sup>1</sup> The potential for increased incidence of side effects, and drug interactions due to loss of monoamine oxidase-B selectivity, is enhanced. The mechanism of this interaction is unknown. It has been postulated that hormonal contraceptives may diminish N-demethylation metabolism of selegiline. Note that ethinyl estradiol patches and vaginal rings introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Laine K, Antilla M, Helminen A, et al, “Dose Linerity Study of Selegiline Pharmacokinetics After Oral Administration: Evidence for Strong Drug Interaction With Female Sex Steroids,” <i>Br J Clin Pharmacol</i>, 1999, 47:249-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10215747\">[PubMed 10215747]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}